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1. Introduction
About one person in five, living in the western world, dies of cancer. Other health
problems such as heart diseases cause more deaths in the world as a whole (Alberts et
al., 1994). However, cancer has a unique importance since one has to study
fundamental functions of a cell in order to understand cancer. Furthermore, one has to
investigate both the inner workings of cells such as their social interactions in the
tissues of the body to ultimately understand the disease and to devise rational ways to
treat it.
1.1 Neurofibromatosis
The term neurofibromatosis describes the two major human genetic disorders,
neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). Both NF1 and
NF2 display autosomal dominant inheritance and are tumors associated with the
nervous system; however, they are distinct clinical and genetic entities (Mulvihill et al.,
1990). NF1, also know as von Recklinghausen neurofibromatosis or peripheral
neurofibromatosis, is more common than NF2 with an incidence of 1 in 4,000.
Neurofibromas, café-au lait macules, Lisch nodules of the iris, and a predisposition to
certain malignant tumors are characteristics of neurofibromatosis 1 (Riccardi, 1981).
The gene NF1 has been mapped to chromosome 17 and has subsequently been isolated
and characterized (Cawthon et al., 1990; Viskochil et al., 1990; Wallace et al., 1990).
The large protein product of the NF1 gene has been named neurofibromin. It has a
strong homology to the family of GTPase-activating proteins (GAP) and is involved in
regulating Ras. The absence of neurofibromin leads to elevated basal levels of Ras-GTP
in NF1-derived schwannomas and is thought to play a causal role in the etiology of
these tumors (Ballester et al., 1990; Basu et al., 1992; Buchberg et al., 1990; DeClue et
al., 1992; Xu et al., 1990).
By contrast, neurofibromatosis 2 affects approximately 1 in 40,000 individuals
and is characterized by bilateral vestibular schwannomas, which are benign, slow-
growing tumors on the vestibular branch of the 8th cranial nerve. The exerting pressure
of these tumors often results in deafness and balance disorders in early adulthood. In
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few cases, onset occurs in childhood or in late adulthood. Although these tumors are
benign, they are difficult to manage due to their anatomic location. Other brain-tumors
such as meningiomas, gliomas, spinal schwannomas, and ependymomas are also
common and are generally present in the affected young adult. In addition, the
development of posterior capsular opacities has been observed in many patients.
(Evans et al., 1992; Martuza et al., 1988; Kaiser-Kupfer et al., 1989).
My “Dissertation” (PhD thesis) will focus on the characterization of
Neurofibromatosis 2 (NF2) tumor suppressor binding proteins, and NF2 will be
discussed in greater detail. The introduction will be subdivided into the following three
sections:
• NF2, the genetic disease, including the definition and neuropathology.
• NF2, the gene, including the identification of the gene, the gene structure and
mutations in NF2.
• NF2, the protein, including merlin and its family members; possible functions of
merlin and ERM proteins and merlin/ERM interacting proteins
1.2 NF2, the Genetic Disease
1.2.1 Definition
Neurofibromatosis 2 is an uncommon disorder, and is also known as central
neurofibromatosis or bilateral acoustic neurofibromatosis. The condition is inherited in
an autosomal dominant manner with high penetrance. However, one half of the cases
has no family history and therefore most likely represents new mutations. Patients
with NF2 are genetically predisposed to a number of characteristic tumors, although
some non-neoplastic conditions occur. Currently, diagnostic criteria for NF2 includes at
least one of the following (Evans et al., 1992; Huson et al., 1994; Short et al., 1994):
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• Bilateral vestibular schwannomas.
• A first-degree relative with NF2, and either (A) a unilateral vestibular schwannoma
or (B) two of the following: meningioma, schwannoma, glioma, neurofibroma,
posterior subcapsular lens opacity, or cerebral calcification.
• Two of the following: (A) unilateral vestibular schwannoma or (B) multiple
meningiomas or (C) either schwannoma, glioma, neurofibroma, posterior
subcapsular lens opacity, or cerebral calcification.
1.2.2 Neuropathology
Both sporadic and familial NF2 can result in a number of different tumors. Following is
a list of the most common tumors and abnormal cell proliferations:
• Vestibular schwannomas (primary hallmark of NF2)
• Peripheral (non-vestibular) schwannomas
• Cutaneous schwannomas
• Meningiomas (secondary hallmark of NF2)
• Meningioangiomatosis
• Gliomas
• Glial Hamartomas
Bilateral, vestibular schwannomas (Figure 1A+B) occur both in sporadic and in familial
cases on the vestibular branch of the eighth cranial nerve and show the same preference
for the internal acoustic meatus (Louis et al., 1995). In sporadic schwannomas, the
primary motor nerves are typically not affected as often as sensory nerves and roots
(Evans et al., 1992; Halliday et al., 1991). In familial schwannomas (NF2), the tumors
occur earlier in life, are multiple and may occur on any of the cranial and peripheral
nerves. Also, three different variants of cutaneous schwannomas have been described in
about half of NF2 patients (Evans et al., 1992; Martuza et al., 1988; Short et al., 1994).
The multiple peripheral (non-vestibular) schwannomas are currently studied in greater
detail, and it remains to be determined whether these symptoms are variants of NF2 or
a distinct disease. Therefore, the occurrence of peripheral schwannomas currently only
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Figure 1. MRI Scans of Bilateral Vestibular
Schwannomas and Multiple Meningiomas
of Patients with NF2. A 14 year old boy has
small tumors (arrows) on his eighth cranial
nerves (A). The 50 year old uncle of the
teenager in (A) has large tumors at the junction
of the pons and the lobes of the cerebellum (B).
These tumors are pressing on the base of the
brain and could only be removed with damage
to the eighth cranial nerve resulting in deafness.
The goal of current NF2 management is to
detect tumors while they are the size seen in (A)
and amenable to treatment. Older patients with
NF2 may develop meningiomas (arrows)
throughout the brain (C). (Modified from
http://neurosurgery.mgh.harvard.edu/NF2.htm  ).
defines a patient with a family history as having NF2. Schwannomas of NF2 patients
are histologically very similar to their sporadic counterparts (Louis et al., 1995).
Multiple meningiomas, the second hallmark of NF2, occur in the majority of
NF2 patients, and they tend to occur earlier in life in these patients than in their
sporadic counterparts (Figure 1C). However, multiple meningiomas alone do not
characterize a patient as having NF2. Meningiomas that do occur in NF2 are usually
histologically benign and of the fibroblastic type (Russell et al., 1989; Schiffer et al.,
1993). A molecular genetic study of a family with cases that were diagnosed with
multiple meningiomas, but no vestibular schwannomas, did not show linkage to the
NF2 locus, suggesting a distinct gene responsible for these meningiomas (Pulst, et al.,
C
A B
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NF2 locus, suggesting a distinct gene responsible for these meningiomas (Pulst, et al.,
1993). Furthermore, there is evidence from this family that the potential non-NF2
meningioma locus is responsible for meningothelial meningiomas, as opposed to the
fibroblastic type (Sieb et al., 1992). This view is supported by sporadic meningiomas,
where both chromosome 22q allelic loss and NF2 gene mutations are more common in
fibroblastic and transitional subtypes than in meningothelial forms (Wellenreuther et al.,
1995). Together, these kinds of studies have lead to the estimate that approximately
40% of all meningiomas have neither NF2 gene mutations nor allelic loss of chromosome
22q, which implies that a gene other than the NF2 gene is involved in the formation of
some meningiomas. It is likely that this second gene is not on chromosome 22q, since
NF2 gene mutations in meningiomas correlate closely with chromosome 22q loss (Louis
et al., 1995).
1.3 NF2, the Gene
1.3.1 Identification of the Gene
Genetic linkage studies and analysis of both sporadic and familial tumors led to the
prediction that the NF2 gene was located on chromosome 22 (Narod et al., 1992;
Rouleau et al., 1987; Rouleau et al., 1990; Wertelecki et al., 1988). It was expected that
the NF2 gene functions as a tumor suppressor gene (Knudson, 1971) whose
inactivation leads to tumor formation (Seizinger et al., 1986, 1987a, 1987b). The
evidence for this hypothesis was obtained from a family study of a single, extremely
large, extended NF2 pedigree. In this family, irregularities on chromosome 22 could be
tracked through multiple generations. The pattern of inheritance of the disorder was
correlated with the inheritance of multiple polymorphic DNA markers on chromosome
22q12. Subsequent investigations of this and additional NF2 families gradually refined
the localization of the genetic defect and underlined the single occurrence of the
observed genetic defect for all cases of the disorder (Bijlsma et al., 1992; Couturier et
al., 1990; Fiedler et al., 1991; Fontaine et al., 1991a, 1991b; Rouleau et al., 1990; Wolff
et al., 1992). Finally, in 1993, the NF2 tumor suppressor gene was identified by
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Trofatter et al. (1993) using a positional cloning approach, and later that year it was
confirmed by Rouleau et al. (1993). The isolation of this disease gene, based on its
chromosomal location, was fundamental to then analyze the normal and defective
versions of this culprit gene.
1.3.2 The Gene Structure
The NF2 gene shows strong homology to a family of genes encoding proteins known as
ERM (Ezrin, Radixin and Moesin), and it spans a region of 110kb, producing mRNAs
of ~7kb, ~4.4kb, and ~2.6kb. These mRNAs encode at least two major alternative
isoforms consisting of exons 1 through 15 and 17 or constitutive exons 1 through 16
(Bianchi et al., 1994; Haase et al., 1994; Pykett et al., 1994; Trofatter et al., 1993).
Thus, the NF2 gene products of these two isoforms differ from each other at the
extreme carboxy-terminus. Alternative splicing of other exons in the NF2 gene has been
reported, but its physiological significance remains unclear (Arakawa et al., 1994;
Pykett et al., 1994; Schmucker et al., 1999). The NF2 gene is expressed in most human
tissues, including heart, lung, skeletal muscle, kidney, breast, ovary, placenta, brain,
pancreas and liver (Rouleau et al., 1993; Trofatter et al., 1993). Once the gene was
identified, it became possible to analyze germline and somatic mutations that are
predicted to affect protein expression and thus lead to tumorigenesis.
1.3.3 Mutations in NF2
A large number of germline and somatic mutations have been found in NF2 patients.
Mainly inactivating genetic alterations, such as frameshift and nonsense mutations, have
been identified, although rare missense mutations have also been discovered.
Interestingly, germline mutations have been found to be different from those that occur
on a somatic basis (Table 1). The most frequent type of germline mutations is point
mutations that either alter splice junctions or create new stop codons. Small deletions or
occasional insertions have mainly been found in somatic mutations. These alterations
produce either a frameshift with a subsequent, premature stop codon, or alternatively
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disrupt proper splicing. The current data proposes that mutations in schwannomas are
observed throughout most of the coding sequence although no mutations have been
found in the isoform defining exons 16 and 17 (Gusella et al., 1999). Mutations in
meningiomas have been mainly found in the first half of the gene, and one large study
suggests that germline mutations preferentially occur in exons 1 through 8 (Louis et al.,
1995). Thus, the wide variety of inactivating mutations, most of which truncate the
protein, supports the tumor suppressor model. Since no mutations have been reported
in the isoform 1 and 2 defining exons 16 or 17, both merlin isoforms may be capable of
fulfilling its tumor suppressor function (Gusella et al., 1996).
Mutation Types of mutation Sites of mutation
NF2 patients Germline Point mutations > deletions Hot spots at Arg residues?
Schwannomas Somatic Deletions > Point mutations None
Meningiomas Somatic Deletions > Point mutations First half of coding sequence?
Table 1. Trend in Mutational Spectra of the NF2 gene. (Modified from Louis et al., 1995)
Non-NF2 related tumors including colorectal tumors, melanomas and breast
carcinomas were screened for mutations in the NF2 gene. These studies suggest that the
NF2 gene is involved in few colorectal tumors although it is not critical in colon
tumorigenesis (Rustgi et al., 1995). Mutations in the NF2 gene were also found in
melanomas and breast carcinomas, and the importance of these findings with respect to
tumorigenesis needs to be further addressed (Bianchi et al., 1994). However,
inactivating mutations of the NF2 gene are frequent in malignant mesotheliomas
(Bianchi et al., 1995; Sekido et al., 1995). Somatic mutations inactivating the NF2
encoded protein in mesotheliomas appear to be a progression, rather than an initiation
event, since NF2 patients do not show a predisposition to this tumor type.
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1.4 NF2, the Protein (Merlin)
1.4.1 Merlin and its Family Members
As mentioned above, the NF2 gene has been isolated by a positional cloning strategy,
and the identity of this novel tumor suppressor, which belongs to the 4.1 protein
superfamily, has been discovered. The NF2 gene encodes a 595 (isoform 1) or a 590
(isoform 2) amino acid protein named merlin. This protein was named merlin (moesin,
ezrin and radixin like protein) because of its striking similarity to ezrin, radixin and
moesin (ERM) (Trofatter et al., 1993). It has also been named schwannomin for its role
in preventing schwannoma formation (Rouleau et al., 1993). Members of the protein
4.1 superfamily include protein 4.1, talin, ezrin, radixin, moesin, merlin and DAL-1
(differentially expressed in adenocarcinoma of the lung 1). Furthermore, several protein
tyrosine phosphatases such as PTPH1 (protein-tyrosine phosphatase-related cDNAs
from a HeLa cell library), PTPMEG (protein-tyrosine phosphatase of the human
megakaryoblastic cell line MEG-01) and pez (phosphatase with ezrin domain) are
members of the protein 4.1 superfamily (Gu et al., 1991; Gusella et al., 1996; Smith et
al., 1995; Tran et al., 1999; Yang et al., 1991). A homologous domain defines the
members of this family with ~270 amino acids (FERM-domain) near the amino-
terminus, which is followed by a long α-helical domain and a charged carboxy-terminal
domain. Overall, merlin is 45 to 47% identical to the ERM proteins and the amino-
terminus is 63% identical to these family members (Figure 2) (Gusella et al., 1999).
The strong similarity of merlin and the ERM proteins (MERM) has resulted in
analogous research of these proteins and indeed many common features have been
found. However, there is increasing evidence that merlin has unique functions. Merlin is
detected with an apparent size of 66kD by Western blot analysis, close to that
predicted from its actual sequence (Gonzalez-Agosti et al., 1996), whereas, the ERM
proteins migrate with an apparent molecular mass greater than predicted from their
sequence. The anomalous migration has been ascribed to the structure of the carboxy-
terminus and these observations suggest that merlin differs from its family members in
the properties of this region (Gonzalez-Agosti et al., 1996).
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Figure 2. Merlin and its Related ERM Proteins. See text for details.
(Modified from Gusella et al., 1996).
1.4.2 Possible Functions of Merlin and ERM Proteins
Localization studies demonstrate that merlin and the ERM proteins have not only
common structural patterns but also share common cell distribution patterns. Using
indirect immunofluorescence, endogenous merlin has been localized to the motile regions
such as leading or ruffling edges in meningioma cells and human fibroblast. Furthermore,
merlin co-localizes with F-actin in these motile regions in a serum or PDGF-dependent
manner. However, unlike ezrin and moesin, merlin does not co-localize with F-actin at
the stress fibers in human meningioma cells (Gonzalez-Agosti et al., 1996; Ramesh V.,
pers. commun.). All three ERM proteins localize similarly to cortical actin structures
near the plasma membrane such as microvilli, membrane ruffles and lamellipodia
(Amieve et al., 1994; Berryman et al., 1993; den Bakker et al., 1999; Franck et al., 1993;
Gonzalez-Agosti et al., 1996; Goslin et al., 1989; Henry et al., 1995; Huynh et al.,
1996; Sato et al., 1992; Stemmer-Rachamimov et al., 1997a; Sainio et al., 1997; Winckler
et al., 1994; Xu L. et al., 1998). Thus, merlin and the ERM proteins have overlapping
subcellular distributions.
  FERM-Domain    ∝- helix
charged
C-terminus
100 % merlin
band 4.129 %
moesin64 % 25 %
ezrin62 % 27 %
radixin64 % 22 %
15 %
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Biochemical and structural investigations have unveiled similar conformational
regulation of all MERM proteins. The amino-terminal ~300-amino acids of any ERM
member can form an association with the carboxy-terminal ~100 residues of any
member causing intra- and/or intermolecular head-to-tail associations. The regions that
lead to these associations have been dubbed amino- and carboxy- ERM association
domains respectively (N- and C-ERMADs) (Gary et al., 1995; Magendantz et al.,
1995; Pearson et al., 2000). Additionally, intermolecular head-to-tail association of
ERM proteins have been detected in vivo such as ezrin-ezrin, ezrin-moesin and moesin-
moesin dimers and oligomers (Berryman et al., 1995; Bretscher et al., 1995). How the
different intermolecular and intramolecular associations of the ERM proteins contribute
their activation in vivo remains to be determined. These studies lead to a model in which
the inactive (closed) protein cannot associate with its binding partners including
membrane- associated proteins and F-actin (Gary et al., 1995; Pestonjamasp et al.,
1995; Reczek et al., 1998; Takahashi et al., 1997; Turunen et al., 1994).
Phosphorylation of a carboxy-terminal threonine in conjunction with binding of specific
phosphatidylinositides has been implicated in conformational regulation of the ERM
proteins (Figure 3) (Matsui et al., 1998; Matsui et al., 1999; Nakamura et al., 1995;
Nakamura et al., 1999; Pietromonaco et al., 1998; Simons et al., 1998). Testing this
mode of regulation for merlin has been the subject of intensive research, and predictions
were ambiguous since the carboxy-terminus of merlin shares only ~24% sequence
identity with the ERM proteins over the critical region at the carboxy-terminus.
Moreover, the sequence surrounding the threonine mentioned above, T558 in moesin, is
well conserved in all three ERM proteins but it is quite distinct in merlin. This would
suggests that phosphorylation of this particular threonine has no effect on merlin
conformation.
Interestingly, merlin isoform 1 is regulated in a fashion similar to the ERM
proteins; the carboxy-terminus of isoform 1 binds to the amino-terminus of merlin and
moesin with comparable affinities. In contrast, merlin isoform 2 lacks the ability to
form inter- and/or intramolecular head-to-tail associations (Gonzalez-Agosti et al.,
1999; Gronholm et al., 1999; Huang et al., 1998; Sherman et al., 1997).
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Figure 3. An Intramolecular Head-to-Tail Association Model for the Activation of ERM
Proteins. The amino- and carboxy-terminal halves of native ERM proteins may mutually
suppress their functions such as membrane- and actin binding respectively, through
intramolecular head-to-tail association.
As mentioned above, mutational analysis of the NF2 gene supports the
hypothesis that both merlin isoforms may be capable of fulfilling its tumor suppressor
function. In contrast, the ERM proteins are expressed in the NF2 related tumors and
have not been linked to tumor suppressor syndromes like NF2 (Stemmer-Rachamimov
et al., 1997b). This argues that the critical signaling pathway disrupted by merlin
deficiency is specific and not common to the ERM proteins. Overexpression of merlin
isoform 1 in NF2-positive and NF2-negative primary human meningioma cells inhibits
cell proliferation (Ikeda et al., 1999). Introduction of merlin into cultured rat
schwannoma cells suggests that merlin isoform 1 is the more potent tumor suppressor
(Sherman et al., 1997). However, this assay involves significant overexpression of
merlin, and as the tumors involved did not arise due to merlin deficiency, it is possible
that this growth suppression involves a different mechanism than in vivo tumor
suppression. In fact, the growth of non-NF2 tumor target cell types such as fibroblasts
CD44, CD43,
ICAM-1, ICAM-2
ERM
Rho-Kinase, PIP2
Actin
C
NC
N
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can be altered by merlin overexpression (Lutchman et al., 1995), illustrating the
difficulty of directly equating growth suppression in cell culture with tumor
suppression in vivo.
MacKay et al. (1997) have shown that the ERM proteins are essential
participants in Rho- and Rac-mediated stress fiber assembly, cortical actin
polymerization and focal complex formation. While some of these functions may be
unique to the ERM proteins, there is increasing evidence that merlin also participates in
a Rac-mediated pathway (MacKay et al., 1997; Ramesh V., pers. commun.; Shaw et al.,
2001).
1.4.3 Merlin and ERM Interacting Proteins
Various avenues have been taken to study the function of merlin and to further compare
merlin and the ERM proteins. These studies include the previously mentioned research
on the conformation of MERM proteins, as well as studies involving fly and mouse
models, cell culture investigations and the identification of MERM binding proteins.
The ERM proteins have been demonstrated to bind to the integral membrane protein
CD44, which is a receptor for hyaluronan (Tsukita et al., 1994). However, full-length
ERM proteins have very low affinity to the cytoplasmic domain of CD44 in vitro,
whereas truncated amino-terminal halves of ERM proteins bind to CD44 with high
affinity (Hirao et al., 1996). In addition, significant amounts of monomeric ezrin can be
detected as a soluble form in the cytoplasm (Berryman et al., 1995; Bretscher et al.,
1995). These findings support the hypothesis of the intramolecular head-to-tail
association model for ERM protein activation and inactivation (Figure 3) and show that
the ERM proteins are connected directly to the plasma membrane through integral
membrane proteins. Subsequent studies have shown that the ERM proteins can also
bind through their FERM-domain to other membrane proteins including CD43,
intercellular adhesion molecules 1 and 2 (ICAM1 and ICAM2) and layilin (Borowsky
et al., 1998; Heiska et al., 1998; Legg et al., 1998; Serrador et al., 1998; Tsukita et al.,
1994; Yonemura et al., 1999).
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ERM proteins have a common carboxy-terminal actin binding side that is not
present in either isoform of merlin. However, the association of merlin to actin has been
characterized in detail, and this interaction is mediated through a different binding
domain, which is also present in ezrin (James et al., 2001; Xu H. et al., 1998). CD44,
NHE-RF and RhoGDI have also been shown to associate with the MERM proteins
(Maeda et al., 1999; Morrison et al., 2001; Murthy et al., 1998). Merlin binding
proteins include schwannomin interacting protein (SCHIP-1), syntenin, β-fodrin, β1-
integrin, βII-spectrin and hepatocyte growth factor-regulated tyrosine kinase substrate
(HRS) (Goutebroze et al., 2000; Jannatipour et al., 2001; Neill et al., 2001; Obremski et
al., 1998; Scoles et al., 1998, 2000). However not all of these proteins may have been
tested for a possible interaction with the ERM proteins. It is of interest to note that
merlin has been shown to bind to ERM family members in vitro and in vivo (Gonzalez-
Agosti et al., 1999; Gronholm et al., 1999; Huang et al., 1998). A recent study suggests
furthermore that these interactions contribute to the regulation of these proteins
(Morrison et al., 2001). Thus, investigating MERM interacting proteins demonstrated
further biochemical and cell biological mimicry between merlin and the ERM proteins.
The yeast two-hybrid system was employed in the Molecular Neurogenetics
Unit at Massachusetts General Hospital and Harvard Medical School, Boston, to
identify components that bind to merlin and the regulatory cofactor for Na+-H+
exchanger (NHE-RF) was found to be a common interactor for the MERM proteins
(Murthy et al., 1998). Independently, a group of 50-55kD polypeptides that were
specifically retained on beads containing immobilized amino-terminal domains of ezrin
and moesin were also identified as NHE-RF (a.k.a. EBP50). These polypeptides were
shown to be constitutively phosphorylated (Reczek et al., 1997). Human NHE-RF is a
358 amino acid protein containing two PSD-95/DlgA/ZO-1 (PDZ-) domains that are
known to mediate protein-protein interactions. It also possesses a MERM binding
domain that encompasses the 30 most carboxy-terminal residues (Figure 4).
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Figure 4. Simplified Structure of NHE-RF containing PDZ-Domains. Boxes show
the coding region of NHE-RF. The orange areas represent PDZ-domains 1 and 2. The
green area represents the MERM binding domain (Modified after Murthy et al., 1998).
NHE-RF was originally identified in rabbit as a protein kinase A dependent
regulator of the Na+-H+ exchanger NHE3 to which it binds though the second PDZ-
domain (Weinman et al., 1995). The cytoplasmic protein, NHE-RF, has a family
member called NHE-RF2 (a.k.a. E3KARP, SIP-1 and TKA-1) which also has two
PDZ-domains, is 55% identical to NHE-RF and has been shown to bind to ezrin and
merlin. NHE-RF2 was originally isolated through a yeast two-hybrid screen searching
for proteins that interact with the cytoplasmic domain (aa 375-832) of the NHE3 (Hall
et al., 1998a; Nguyen et al., 2001; Yun et al., 1998). These studies provided evidence
for the molecular linkage between MERM proteins and the cytoplasmic domain of
NHE3 thus connecting the MERM proteins indirectly to the plasma membrane.
A number of studies have led to the identification of various proteins (mainly
membrane proteins) that bind NHE-RF and NHE-RF2. In particular, mutagenesis
studies of the cytoplasmic tail of the β2-adrenergic receptor have revealed that the
optimal binding motif to the first PDZ-domain of NHE-RF is DS/TXL (Hall et al.,
1998a). These authors further showed that co-expression of the β2-adrenergic receptor
with NHE3 resulted in inadequate regulation of exchanger activity by cAMP. However,
normal regulation of NHE3 occurred when a mutant receptor with an additional alanine
at the carboxy-terminus was co-transfected along with the exchanger (Hall et al., 1998a;
Hall et al., 1998b). Searching databases for proteins with this binding cassette reveals
many proteins with the PDZ-1 binding motif at the extreme carboxy-terminus. The
identification of NHE-RF binding proteins is of great interest to further define the role
of this adaptor protein, and various proteins that bind NHE-RF and/or NHE-RF2 have
emerged out of a field of intensive study.
PDZ-1 PDZ-2 MERM
aa: 11 97 149 236 330 358
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1.5 Specific Aims
Although progress was made over recent years, the physiological function of merlin is
still the subject of many ongoing studies. Insights into possible roles of merlin have
come in part from animal models (fly and mouse), and at the time this work began,
limited information on merlin binding proteins was available. Several cellular proteins
had been shown to interact with merlin in vitro; however, the identities of these
proteins had not been revealed (Takeshima et al., 1994). NHE-RF was one of the first
merlin binding proteins that was also found binding to the ERM proteins (Murthy et
al., 1998; Rezcek et al., 1997). Therefore, it was and still remains of great interest to
characterize further the interaction between merlin and NHE-RF.
Despite the existing similarities of the MERM proteins, merlin is predicted to
have unique functions since only mutations in the NF2 gene have been found in the
tumor suppressor syndrome NF2. In contrast to merlin the ERM proteins are
functionally expressed in these tumors. This observation suggests that the critical
signaling pathway disrupted by the absence of merlin is unique and specific to this
tumor suppressor protein and is not shared with the ERM proteins. To decipher this
function, critical cellular target proteins that interact with merlin but not with the ERM
proteins need to be discovered. The specific aims of this “Dissertation” (PhD thesis)
were as follows:
• Characterization of the interaction of NHE-RF with merlin isoform 1 and 2
Merlin isoform 1, but not isoform 2, has been shown to form intramolecular head-
to-tail associations (Gonzalez-Agosti et al., 1999; Gronholm et al., 1999; Huang et
al., 1998; Sherman et al., 1997). In this context, the relationship of NHE-RF to the
isoforms of merlin and the influence of phospholipids was examined through in
vitro binding studies.
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• Isolation and characterization of NHE-RF binding proteins
During the course of this work, mutagenesis studies revealed that the optimal
binding motif of the first PDZ-domain of NHE-RF is DS/TXL (Hall et al., 1998a).
The 56kD subunit of the H+ ATPase has the carboxy-terminal motif DTAL. Thus,
localization and binding studies (in vitro and in vivo) between NHE-RF and the H+
ATPase were employed to test a possible interaction as well as the relevance of a
possible interaction.
• Examination of NHE-RF in human cancer
The fact that NF2 mutations are found in only approximately 60% of meningiomas
implies that a gene other than the NF2 gene is involved in the formation of some of
these tumors (Louis et al., 1995). Thus, a possible inactivation of the NHE-RF gene
in meningiomas where no NF2 mutations have been found was tested by molecular
genetic analyses. Furthermore, the expression and localization of NHE-RF was
investigated in meningiomas and tumors derived from other organs including colon,
ovary and breast.
• Characterization of novel merlin binding proteins
To determine other functions of merlin, identifying additional merlin binding
proteins is of great interest. Particular functions of merlin that are not shared with
the ERM proteins may illuminate its role as a tumor suppressor protein. Two
candidates, named merintA and merintB, were isolated in a yeast two-hybrid screen
together with NHE-RF. Here, the significance of this interaction was analyzed in
vitro and in vivo through binding studies, expression analysis and localization
studies to address the functional importance of these potential interactions.
These experiments were designed to study functions of merlin and possibly to
link this tumor suppressor protein to distinct signal transduction pathways in order to
elucidate ultimately how merlin contributes to tumorgenesis.
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2. Materials and Methods
2.1 Materials
Animals
• Female BALB/c mice for monoclonal antibody production (Massachusetts General
Hospital animal facility)
• Male Harlan Sprague-Dawley rats for kidney lysates and NHE-RF/ H+ ATPase
staining (Massachusetts General Hospital animal facility)
Antibodies and Solutions for Immunofluorescence Analysis
Primary Antibodies
Commercial and Other Antibodies
• α-FLAG (M2, monoclonal antibody; Sigma)
• α-Grb2-C23 (sc-255, polyclonal rabbit IgG; Santa Cruz)
• α-GST-B14 (sc-138,  monoclonal mouse IgG1; Santa Cruz)
• α-HA (hybridoma supernatant; kindly provided by Dr. Ed Harlow,
Massachusetts General Hospital, Boston)
• α-HA (12CA5, monoclonal antibody; Roche)
• α-His-RGS (34610, monoclonal antibody, Qiagen)
• α-Merlin-A19 (sc-331, polyclonal rabbit IgG; Santa Cruz)
• α-phospho-tyrosine (4G10, monoclonal antibody; Upstate Biotechnology)
• α-phospho-tyrosine (pY20, monoclonal antibody; TaKaRa)
Merlin
• N21 (polyclonal rabbit serum; antigen: thrombin cleaved GST-merlin aa 1-
332; Gonzalez-Agosti et al., 1996)
• 1C4 (monoclonal mouse IgG1; antigen: thrombin cleaved GST-merlin aa 308-
590; Gonzalez-Agosti et al., 1996)
MerintA
• Tim3 (polyclonal anti-peptide serum; antigen: aa 165-178)
• 7E1 (monoclonal mouse IgG2b, antigen: GST-merintA aa 13-178)
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H+ ATPase
• B1-Subunit (polyclonal, affinity-purified rabbit antibody; Breton et al.,
2000)
• E-Subunit (polyclonal, affinity-purified chicken antibody; Breton et al.,
2000)
• E-Subunit E11 (monoclonal antibody; kindly provided by Dr. Steven
Gluck, University of Florida, Gainesville)
NHE-RF
• IC270 (polyclonal rabbit serum; antigen: GST-NHE-RF aa 270-358;
Gonzalez-Agosti et al., 1999)
• 1D12 (monoclonal mouse IgG2a; antigen: GST-NHE-RF aa 270-358)
 
Secondary Antibodies and Immunodetection Reagents
• Donkey α-chicken-FITC (Jackson ImmunoResearch Laboratories)
• Goat α-mouse-FITC (BioSource International)
• Goat α-mouse-HRP (Amersham Pharmacia Biotech)
• Goat α-mouse-Rhodamine (BioSource International)
• Goat α-rabbit-biotin (Vector Laboratories)
• Goat α-rabbit-FITC (BioSource International)
• Goat α-rabbit-HRP (Amersham Pharmacia Biotech)
• Goat α-rabbit-Rhodamine (BioSource International)
• Goat α-rabbit-CY3 (Jackson ImmunoResearch Laboratories)
• Rabbit α-chicken-HRP (Sigma)
• Streptavidin-HRP (Amersham Pharmacia Biotech)
Solutions for Immunofluorescence Analysis
• Hoechst 33342, stains nuclei (B2261; Sigma)
• Mounting media (ProLong antifade kit, P-7481; Molecular Probes)
• Rhodamine phalloidin, stains F-actin specifically (R-415; Molecular Probes)
Bacterial Strains
• BL21 (B F- dcm ompT hsdS(rB- mB-) gal; Stratagene)
• DH5α (F-, hsdR17(rk-,mk-), lambda-, supE44, endA1, thi1, gyrA96.relA1;
Hanahan, 1993)
• M15 (K12-mutant with ∆(prolac)thi, Φ80d, ara-rspL, strr, lacZdel; Qiagen)
• NM522 (supE thi-1 ∆ (lac-proAB), ∆ (mcrB-hsdSM)5, (rK- mK+), F'proAB lacI
q∆DM15; Stratagene)
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 Commercial Grb2 GST-Fusion Proteins
• Full length protein (aa 1-217, sc-4015, Santa Cruz)
Oligonucleotides
 Oligonucleotides were obtained from GibcoBRL.
• Cloning of A4: aa 1-178 of merintA with 5’ HA-tag in pcDNA3
15S-BamHI: GAT GGA TCC ATG TAC CCA TAC GAT GTT CCA GAT
TAC GCT CTT ATG GCG GCT CCA CTA GGG GGT
9AS-NotI: GGG GCG GCC GCT CAC GTT GGC TTC AG
• Cloning of C35: aa 340-590 (isoform 2) of merlin in pGEX-2T
340S-BamHI: GAT GGA TCC GCT CGA GAG AAG CAG ATG AGG
5114-EcoRI: CCC GAA TTC TCA AAT GCA GAT AGG TCT TCT
• Cloning of C36: aa 340-579 (common to both isoforms) of merlin in pGEX-2T
340S-BamHI: GAT GGA TCC GCT CGA GAG AAG CAG ATG AGG
579AS-EcoRI: CCC GAA TTC CTT TTT AAT GGT ATT GTG CTT
• Cloning of GST-MerintA: aa 13-178 of merintA in pGEX-4T1
1S-BamHI: GAT GGA TCC ACG AGG CGG CCA CCC
9AS-NotI: GGG GCG GCC GCT CAC GTT GGC TTC AG
• Cloning of His-MerintA: aa 13-178 of merintA in pQE30
1S-BamHI: GAT GGA TCC ACG AGG CGG CCA CCC
2AS-PstI: GGG CTG CAG TCA CGT TGG CTT CAG
• pcDNA3 primers: Vector primers to PCR inserts and sequence
3418: GCA GAG CTC TCT GGC TAA CT
3419: TGG CAA CTA GAA GGC ACA GT
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• pGEX primers: Vector primers to PCR inserts and sequence
5’ pGEX: GGG CTG GCA AGC CAC GTT TGG TG
 3’ pGEX: CCG GGA GCT GCA TGT GTC AGA GG
Plasmids and Expression Vectors
• pcDNA3 (Invitrogen)
• pcDNA3/5’F (Xu L. et al., 1998)
• pEG202 (Gyuris et al., 1993)
• pEGFP-N1 (Clontech)
• pGEX-2T and pGEX-4T1 (Amersham Pharmacia Biotech)
• pLexA (Gyuris et al., 1993)
• pQE30 (Qiagen)
List of Selected Materials
• Antibiotics
Ampicillin (50-100µg/ml final concentration)
Kanamycin (25µg/ml final concentration)
• Blot Buffer for Immunoblots
192mM Glycine
25mM Tris
• DNA Loading Dye
3mM EDTA
50% Glycerol saturated with bromophenol blue
0.1% SDS
0.01M Tris pH 8.0
• LB Broth
10 g/l Bacto-tryptone
5 g/l Bacto-yeast extract
5 g/l NaCl
• LB Agar
LB broth (as described above)
15 g/l Agar
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• Phosphate-Buffered Saline; PBS (pH 7.4)
1mM KH2PO4
155mM NaCl
3mM Na2HPO4 7-H2O
 
• Polyacrylamide Gels:
Separating Gels: 7.5% 10% 12%
1.5M Tris-HCl (pH 8.8) 7.5ml 7.5ml 7.5ml
Distilled water 14.5ml 12ml 10ml
30% Acrylamide/bis (30:0.8) 7.5ml 10ml 12ml
10% SDS 300µl 300µl 300µl
10% Ammonium persulfate 100µl 100µl 100µl
TEMED 15µl 15µl 15µl
Stacking Gel:
0.5M Tris-HCl (pH 6.8) 2.5ml
Distilled water 6.1ml
30% Acrylamide/bis (30:0.8) 1.3ml
10% SDS 100µl
10% Ammonium persulfate 50µl
TEMED 10µl
• Running Buffer for Polyacrylamide Gels
250mM Glycine
0.1% SDS
25mM Tris
 
• Sample Buffer (3x GSD)
300mM DTT
33% Glycerol saturated with bromophenol blue
6% SDS
• SSC (20x)
3M NaCl
0.3M Sodium citrate 2-H2O
Adjust to pH 7.0 with NaOH
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• TBE Buffer
0.089M Boric acid
2mM EDTA
0.1M Tris
• TBS Buffer
 150mM NaCl
 50mM Tris-HCl (pH 8.0)
 
• TBST
 TBS + 0.05% Tween-20
 
• TE Buffer
1mM EDTA
10mM Tris-HCl (pH 8.0)
• TE/RNase
TE buffer (as described above)
0.05mg/ml RNase
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2.2 Molecular Biological Methods
DNA Mini- and Maxipreparation
Purification of plasmids from a culture of bacteria involves the following general
strategy:
• Grow and harvest a culture of bacteria hosting the plasmid DNA of interest.
• Break cells to gain access to the plasmid DNA.
• Remove all components of the cell extract from the plasmid DNA.
• Concentrate the resulting plasmid DNA solution.
A single colony was chosen and grown under antibiotic selection in 5ml LB with the
appropriate antibiotic (e.g. 50µg/ml ampicillin) at 37°C overnight to obtain a culture of
cells containing the plasmid. Cells were pelleted by spinning them at room temperature
for five minutes. In turn, cells were lysed by incubating them in ice-cold Solution 1
(10mM EDTA, 50mM Glucose, 25mM Tris) at room temperature for five minutes,
and subsequently by incubating them in freshly prepared Solution 2 (200mM NaOH,
1% SDS) on ice for five minutes. Finally, ice-cold solution 3 (11.5% glacial acetic acid,
3M KAc) was added to the cell lysates and kept on ice for an additional five minutes.
For minipreparations, cell debris and chromosomal DNA were pelleted by
centrifugation at 14,000x g and 4°C for five minutes. The supernatant, containing the
plasmid DNA, RNA and proteins, was extracted once with phenol-chloroform and once
with chloroform alone. These organic solvents precipitate proteins but leave nucleic
acids (DNA and RNA) in aqueaous solution. The nucleic acids were precipitated in
100% ethanol before being pelleted by spinning at 14,000x g and room temperature for
15 minutes. Pellets were washed with 70% ethanol, air-dried and resuspended in
TE/RNase. For maxipreparations, the plasmid DNA was purified in a cesium chloride
column.
Polymerase Chain Reaction
Polymerase chain reaction (PCR) is a technique that allows selective amplification of a
chosen region of a DNA molecule. Two short oligonucleotides anneal to the DNA
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molecule, one to each strand of the double helix, in order to carry out DNA
amplification by PCR.
A basic protocol was performed for DNA amplification. The first step of this
protocol is to denature the DNA at 94°C for four minutes followed by a second step
consisting of 30 cycles with 3 substeps: denaturation, 94°C for 1 minute; annealing, 58-
62°C for 1 to 2 minutes; and elongation, 72°C for 1 to 3 minutes. The third and final
step allows completion of partial extended products at 72°C for 10 minutes. Primer
stocks were diluted to 2ng of each primer per PCR reaction. A PCR-kit (Roche or
GibcoBRL) supplied Taq polymerase, Taq polymerase buffer and dNTPs. Materials
were adjusted to concentrations recommended by the manufacturer for each reaction.
The annealing temperature was increased for more stringent conditions.
DNA Digest with Restriction Enzymes
Purified restriction endonucleases (type II) cut DNA molecules in a precise manner.
The enzyme EcoR I, for example, recognizes the hexanucleotide GAATTC. Some
endonucleases (e.g. Pvu II or Alu I) make a simple double-stranded cut in the middle of
the recognition site, resulting in a blunt-end, while others, cleavage is staggered, resulting
in DNA fragments with short single-stranded overhangs at each end (so-called “sticky
ends”). These “sticky ends” allow pairing between the bases with the result that the
DNA molecules can “stick” back together. Typically, DNA was cut with 1 unit of
restriction enzyme per µg DNA and incubated at 37°C for 1 to 16 hours. All restriction
enzymes were obtained from New England Biolabs.
Dephosphorylation of Vector DNA
Linearized vector DNA was dephosphorylated at its 5’ ends to prevent religation. Calf
intestine phosphatase (New England Biolabs) was used at 2 unit of enzyme per µg of
DNA at 37°C for 1 to 2 hours. Adding 5mM EDTA and heat inactivating at 65°C for
15 minutes stopped the reaction. DNA was then purified by phenol-chloroform and
chloroform extractions.
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Agarose Gel Electrophoresis and Gel Extraction
DNA can be separated according to size in an electrical field due to its negative charge.
Agarose gels (1 or 1.2%) were poured and electrophoresis was performed at 100V in 1x
TBE buffer for approximately 1 hour. Ethidium bromide was added to the gel at a
concentration of 1µg/ml to visualize DNA under UV light.
A small DNA-gel piece was cut out of the gel if DNA was used for subcloning.
Separation of the DNA from the gel and purification of the DNA was performed
according to recommendations of the gel extraction kit, QiaexII (Qiagen).
 
Ligation
T4 DNA ligase (GibcoBRL) catalyzes the formation of phosphodiester bonds in the
presence of ATP between double-stranded DNAs with 3´ hydroxyl- and 5´ phosphate
termini. A molar ratio of 3:1 to 10:1 of insert:vector was ligated in a total volume of
20µl. The ligation reaction was carried out at 20°C for 4 to 16 hours and subsequently
transformed into bacteria.
Transformation
Transformation is the introduction of DNA into living cells and antibiotic resistance
monitors the uptake of plasmid DNA. Typically, the entire ligation reaction (20µl) was
used to transform 100µl competent cells. The cell-DNA mixture was incubated on ice
for 30 minutes and subsequently heat shocked at 37°C for five minutes to enable
uptake of the recombinant vector by bacterial cells. Subsequently, cells were grown in
LB at 37°C for one hour to allow expression of the resistance gene before being spun at
14,000x g and room temperature for five minutes. Cell pellets were resuspended in
100µl LB and plated on LB plates with the appropriate antibiotic. The plated cells
were then incubated at 37°C overnight and the resulting colonies were screened for the
presence of recombinant DNA by PCR.
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Double-Stranded DNA Sequencing
DNA sequencing enables to determine the precise order of nucleotides in a piece of
DNA. The chain termination method (Sanger et al., 1977) involves the synthesis of a
DNA strand by elongating it from a primer that is annealed to the DNA template.
Elongation is stopped by the four different ddNTPs.
An aliquot of 2-4µg of DNA to sequence, obtained by plasmid mini- or
maxipreparation, was denatured by incubating in 0.2M NaOH and 0.2M EDTA at
room temperature for five minutes. Subsequently, DNA was precipitated with 100%
ethanol in the presence of 0.3M ammonium acetate (pH 4.5). The plasmid DNA was
spun at
14,000x g and 4°C for 10 minutes, pellets were washed once with 70% ethanol and air-
dried. The sequencing reactions were performed with a sequencing kit from United
States Biochemical (USB). Briefly, plasmid DNA was resuspended in water and
incubated at 37°C for 30 minutes with 0.02µg of the appropriate primer and
recommended concentrations of reaction buffer (200mM Tris-HCl, pH 7.5, 100mM
MgCl2, 250mM NaCl). In turn, 5.5µl of a master mix, prepared according to
recommendations of the manufacture, was added to each sequencing reaction and
incubated at room temperature for five minutes to allow incorporation of dNTPs and
33P αATP by DNA polymerase (sequenase). Incubating this reaction mix with dideoxy
nucleotide at 37°C for five minutes terminated the sequencing reaction. Finally, stop
solution (USB) was added and the terminated sequencing reaction was denatured at
95°C before loaded on a polyacrylamide gel.
Ammonium Persulfate (0.1%) was added to the SequaGel-6 monomer solution
(National Diagnostics) to pour 6% polyacrylamide gels. Electrophoresis was performed
at 80W for one to three hours, and the gel was dried for one to two hours on a gel-dryer
(BioRad) and exposed to X-Omat AR film (Kodak, Eastman Co.).
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GenBank Analysis
DNA and protein databases including GenBank, SwissProt and European Molecular
Biology Laboratory databases were searched at the National Center of Biotechnology
Information (http://www.ncbi.nlm.nih.gov/BLAST).
Northern Blot Analysis of Breast Cancer Cell Lines
Isolation of total cellular RNA, electrophoresis, transfer and hybridization were
performed as previously described (Ramesh et al., 1986). Total RNA from breast
cancer cell lines and normal mammary controls were isolated using the lithium-
chloride/urea method. Thirty-five micrograms of the total RNA were separated on a 1%
agarose-formaldehyde gel and blotted to nitrocellulose (Schleicher & Schuell). The DNA
was labeled (α 32P dATP; 3,000 Ci/mmol, DuPont NEN; dCTP; dGTP; dTTP;
Klenow, Roche) at 37°C for five hours and ultra-purified. For the purification, an
Eppendorf tube with a hole in the bottom was packed with glass wool to the 50µl mark
and filled 3/4 with Sepharose CL6b beads. The beads were washed three times with
TNE (10mM Tris, 100mM NaCl, and 1mM EDTA, pH 8.0) and the probe was spun
through. Membranes were probed with the 32P-labeled NHE-RF cDNA in
hybridization solution (1x Denhardt’s solution, 10% dextran sulfate, 45% formamide,
1M NaCl, 0.1% PyroPO4, 100µg/ml ssDNA, 50mM Tris) at 42°C for up to 48 hours.
Next, the membranes were washed extensively: 1x with 2x SSC, 0.5% SDS, room
temperature, 10 minutes; 5x with 2x SSC, 0.1% SDS, room temperature, 10 minutes; 1x
with 1x SSC, 0.1% SDS, 52°C, 45 minutes; and 1x with 0.5x SSC, 0.1% SDS, 52°C, 45
minutes. Filters were then air-dried to dampness, wrapped in Saran-Wrap and exposed
at -80°C to X-Omat AR film (Kodak Eastman Co.). Equal loading was confirmed by
probing the stripped membranes with the GAPDH cDNA.  Signal intensity was
quantified by densitometric scanning of autoradiographs using transmittance analysis
(Fluor-S, Multiimager, BioRad). Densitometric scanning was performed on bands that
were not saturated. Thus, values obtained are in a linear range and reflect a true
assessment.
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Northern Blot Analysis of Multiple Tissue
Commercially available human multiple tissue blots (Clontech) were obtained and
probed with 32P-labeled DNA probes. The human multiple tissue blots were
prehybridized in ExpressHyb solution (Clontech) at 42°C for five hours. The solution
was replaced with fresh ExpressHyp solution containing the 32P labeled and ultra-
purified –DNA. Blots were hybridized at 42°C for 16 hours, washed and exposed to X-
Omat AR film (Kodak Eastman Co.).
cDNA Synthesis
The SuperScript preamplification system (GibcoBRL) was used to synthesize first-
strand cDNAs according to the recommendations of the manufacture. In summary, 2µg
of total RNA were primed with oligo(dT) (0.5µg) and random hexamers (50ng), and
denatured at 70°C for 10 minutes. SuperScriptII Reverse Transciptase (GibcoBRL)
synthesized the cDNA in the presence of dNTPs and reaction buffer (see GibcoBRL)
at 42°C for 50 minutes.
The Marathon cDNA Amplification Kit (Clontech) was used to generate
second-strand cDNA. Towards this end, the total amount of first-strand cDNA was
incubated with dNTPs, second strand reaction buffer (see Clontech) and second-strand
enzyme cocktail (Clontech) at 16°C for 90 minutes. Adding T4 DNA polymerase
(Clontech) at 16°C for an additional 45 minutes completed the reaction. The second-
strand cDNA was extracted once with phenol-chloroform and once with chloroform
alone. The DNA was then precipitated in 100% ethanol before being pelleted by
spinning at 14,000x g and room temperature for 20 minutes. Pellets were washed with
70% ethanol, air-dried and resuspended in H2O.
Rapid Amplification of cDNA Ends (5’ RACE)
The Marathon cDNA Amplification Kit (Clontech) provides a PCR-based method for
selectively constructing cDNAs from specific RNAs. Specially designed adaptors
(Marathon) that significantly reduce background were employed. After second-strand
cDNA synthesis from placenta and peripheral blood mononuclear cells (PBMC) RNA,
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blunt ends were created and the Marathon adaptor was ligated to both ends of the
double-stranded cDNA. Rapid amplification of cDNA ends was performed with the
Marathon (sense) and gene specific primer (antisense) according to manufacture
recommendations. Advantage 2 Taq polymerase (Clontech) was used for the PCR
reaction and the products were subjected to sequence analysis.
Direct PCR Sequence Analysis
5’ RACE products were sequenced as previously described (Beauchamp et al., 1998).
In summary, PCR products (5µl) were incubated with 1U Exonuclease I (USB) and 2U
shrimp alkaline phosphatase (SAP) (Amersham Pharmacia Biotech) at 37°C for 15
minutes, followed by 85°C for 15 minutes. Using the AmpliCycle Sequencing Kit
(Perkin Elmer), 2µl of the Exonuclease I/SAP prepared PCR samples were sequenced
with 33P-dATP according to recommendations of the manufacturer. The sequencing
reactions were performed for 26 PCR cycles (see Polymerase chain reaction) and the
reactions were terminated with stop solution (95% formamide, 20mM EDTA, 0.05%
bromophenol blue, and 0.05% xylene cyanol). Samples were analyzed on a 6%
denaturing polyacrylamide gel, electrophoresed at 80W, which was dried and exposed
to X-Omat AR film (Kodak, Eastman Co.).
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2.3 Biochemical and Cell Biological Methods
Expression and Purification of GST-Fusion Proteins from Bacteria
The glutathione S-transferase (GST) expression system in bacteria allows expression of
a foreign protein, and, thus, large amounts of the recombinant fusion protein can be
purified with glutathione Sepharose beads. Full-length isoform 1 (F39: aa 1-595), full-
length isoform 2 (F40: aa 1-590), amino-terminal (N21: aa 1-332), carboxy-terminal
common to both isoforms (C26: aa 308-579) and carboxy-terminal isoform 1 (C34: aa
340-595) portions of merlin were cloned into pGEX-2T (Amersham Pharmacia
Biotech). The bacterial host cells, BL21, transformed individually with the fusion
constructs, were available in the laboratory. The carboxy-terminal isoform 2 (C35: aa
340-590) was PCR amplified, digested, ligated into pGEX-2T and transformed into
BL21. The integrity of the entire sequence, including the junction region between the
GST-epitope and the merlin coding sequence, was confirmed by DNA sequencing. The
integrity of the protein was verified by Western blot analysis (see below) using GST-
tag and merlin specific antibodies, and the expression of GST fusion proteins were
analyzed by Coomassie staining (see below).
 Expression and purification of GST-merlin fusion proteins was essentially
performed as previously described (Gonzalez-Agosti et al., 1996). In summary, 5ml of
the appropriate BL21 clone was grown to mid-logarithm at 30°C and induced with
0.05M isopropyl β-D-thiogalactopyranoside (IPTG) at room temperature for 16 hours.
The formation of inclusion bodies could be reduced significantly by inducing the fusion
proteins at room temperature. The cells were pelleted, resuspended and incubated in
PBS containing pefabloc (0.5mg/ml) and lysozyme (1.5mg/ml) at 4°C for 15 minutes.
After freeze/thaw cycles (3x) and sonication (3x 30 seconds), debris was removed by
centrifugation at 16,000x g and 4°C for 30 minutes. The soluble supernatant was
collected and incubated with equilibrated glutathione Sepharose 4B beads (Amersham
Pharmacia Biotech) at room temperature for 30 minutes. GST-merlin bound to beads
was washed extensively with PBS containing pefabloc (0.5mg/ml), and eluted in either
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sample buffer (1x GSD: 11% Glycerol, 2% SDS, 100mM DTT, 0.5% bromophenol
blue) or glutathione buffer (20mM glutathione, 150mM NaCl, 50mM Tris, pH 8.0).
Full-length moesin (MFL: aa 1-577), amino-terminal (M5: aa 1-332) and
carboxy-terminal (M3: aa 307-577) portions of moesin were expressed as GST fusion
proteins in pGEX-4T1. Similarly, full-length NHE-RF (IFL: aa 1-358) was expressed
as a GST fusion protein. Expression and purification of the GST-moesin and GST-
NHE-RF were performed as previously described (Gonzalez-Agosti et al., 1999) using
standard methods.
MerintA (GST-merintA: aa 13-178) was PCR amplified, digested, ligated into
pGEX-4T1 and transformed into BL21. The integrity of the entire sequence, including
the junction region between the GST epitope and the merintA coding sequence, was
confirmed by DNA sequencing. Expression and purification of the GST-merintA fusion
protein was performed as described for merlin (see above). The integrity of the protein
was verified by Western blot analysis (see below) using GST-tag and merintA specific
antibodies, and the expression of GST fusion proteins were analyzed by Coomassie
staining (see below).
Expression and Purification of 6xHis-Fusion Proteins from Bacteria
The His-tag expression system in bacteria allows expression of a foreign protein
similarly to the GST expression system. Large amounts of the recombinant fusion
protein can be extracted under native or denaturing conditions and purified using nickel
Sepharose beads. MerintA (His-merintA: aa 13-178) was cloned into pQE30 (Qiagen)
and transformed into the bacterial host, M15. The His-tagged merintA construct was
expressed and purified as recommended by the manufacture. Denaturing conditions
were used since native conditions resulted in a very low yield. To produce the protein,
a saturated culture was diluted 1:40 in 500ml of LB with 100µg/ml ampicillin and
25µg/ml kanamycin and grown at 37°C to mid-logarithm. The protein expression was
induced by isopropyl-β-D-thiogalactopyranoside (IPTG) at a final concentration of
2mM and grown at 37°C for an additional 3 hours. Cells were collected by
centrifugation, resuspended and lysed by stirring in buffer B (100mM NaH2PO4,
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10mM Tris, 8M urea, pH 8.0) at room temperature for 1 hour. The supernatant was
collected after high-speed centrifugation and incubated with equilibrated Ni-NTA
Sepharose CL 6B resin (Qiagen) at room temperature for 45 minutes. Next, the beads
were loaded into a 5ml column next and washed extensively with buffer C (100mM
NaH2PO4, 10mM Tris and 8M urea, pH 6.3). His-merintA was eluted from the beads
with buffer E (100mM NaH2PO4, 10mM Tris, 8M urea, pH 4.5) and the integrity of
the protein was verified by Western blot analysis (see below) using His-tag and
merintA specific antibodies, and the expression of His-merintA was analyzed by
Coomassie staining (see below).
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
The SDS-polyacrylamide gel electrophoresis separates proteins under denaturing
conditions, and according to an electric field, proteins will migrate at a rate dependent
upon their size (Laemmli et al, 1970). The negatively charged detergent sodium dodecyl
sulfate (SDS) is added to proteins, giving the solution and every individual protein a
negative charge. The detergent binds to hydrophobic regions of the protein molecules,
causing them to unfold into extended polypeptide chains. The proteins run through a
stacking gel, which staggers the proteins in a tight band. In turn, the proteins are
separated in a highly cross-linked resolving or separating gel. The electrophoresis was
performed at 7mA overnight or 40mA during the day.
Coomassie Staining
Large amounts of protein (>0.1µg) are stained and detected non-specifically with the
dye Coomassie Brilliant Blue R-250. After separation of proteins by SDS-PAGE, gels
were incubated in Coomassie blue staining solution (0.1% Coomassie Brilliant Blue
R250, 25% methanol and 10% glacial acetic acid) at 20°C for 1 hour. Then, gels were
incubated in destaining solution (25% methanol and 10% glacial acetic acid) to visualize
proteins and dried on a gel-dryer (BioRad) for one hour.
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Western Blot Analysis (Immunoblotting)
Western blot analysis is performed to transfer proteins from a polyacrylamide gel to a
nitrocellulose membrane. Subsequently, the transferred protein can be visualized by
specific antibody binding and detection systems. Electroblotting of proteins to
nitrocelluse (BioRad) was performed at 0.5A and 4°C for 1 to 3 hours. After the
transfer, membranes were stained for total protein with 10% Ponceau-S (Sigma) for one
minute. The membranes were then destained with distilled water until protein bands
were visible. In turn, individual proteins were detected through specific protein-
antibody interactions. To avoid non-specific binding of the used antibodies, the
membranes were blocked in 5% milk/TBST at room temperature for 1 to 16 hours. The
membranes were washed three times with TBST, five minutes each, before they were
probed for one hour with primary antibodies. All polyclonal antibodies were diluted in
TBST containing 1% milk, and monoclonal antibodies were diluted in TBST. Generally,
merlin was detected with 1C4 (1:1,000), NHE-RF with IC270 (serum 1:1,000; affinity-
eluted 1:50) or 1D12 (1:1,000) and merintA with 7E1 (1:500). The following antibodies
were used for Western blot analysis of the H+ ATPase: affinity-purified anti-E subunit
(1:1,000) and affinity-purified anti-B1 subunit (1:1,000). The FLAG-tag antibody, M2,
was diluted 1:2,000 and the HA-tag antibody, 12CA5, was diluted 1:4,000. The
membranes were then washed again, three times, for five minutes with TBST, and
incubated with the secondary antibody for one hour. Horseradish peroxidase conjugated
secondary antibodies were diluted in TBST at the following dilutions: anti-rabbit
(1:20,000), anti-mouse (1:10,000) and anti-chicken (1:4,000). The membranes were
washed a final three times with TBST, incubated one minute in ECL 1 and 2
(Amersham Pharmacia Biotech) and exposed to X-Omat AR film (Kodak, Eastman
Co.). Signal intensities were quantified at times (e.g. Figure 6) by densitometric scanning
of autoradiographs using transmittance analysis (Fluor-S, Multiimager, BioRad).
Densitometric scanning was performed on bands that were not saturated. Thus, values
obtained are in a linear range and reflect a true assessment.
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Blot Overlay Assay
The direct interaction of merintA and Grb2 was confirmed by blot overlay assays.
Purified His-merintA (3µg) or BSA (3µg) as a negative control was subjected to 10%
SDS-gel electrophoresis and transferred to nitrocellulose membranes. After blocking
membranes in 10% non-fat dry milk diluted in TBST, they were incubated with GST-
Grb2 (3µg/ml in TBST) for 16 hours. Membranes were washed three times, incubated
the anti-GST antibody B14 (1:1,000) for 1 hour, washed three more times and
incubated with horseradish peroxidase anti-mouse antibodies (1:10,000) for 1 hour. The
membranes were washed a final three times, incubated one minute in ECL 1 and 2
(Amersham Pharmacia Biotech) and exposed to X-Omat AR film (Kodak, Eastman
Co.).
Generation of Polyclonal and Monoclonal Antibodies Against MerintA
 For polyclonal antibody production of Tim3, Research Genetics, Inc. performed the
peptide synthesis (aa 165-178 of merintA: EQASANIPAPLKPT), coupling with KLH,
immunization and bleeding of rabbits. Bleeds were then tested against merintA
exogenously expressed in mammalian cells.
 For monoclonal antibody production of 7E1, mice were injected six times every
14 days with approximately 50µg of GST purified and eluted protein. After a final
boost the best responder was sacrificed, the spleen was removed and it was fused to
SP2 myeloma cells. Ms. Nicole Smith carried out the fusion and the selection as
previously described (Gonzalez-Agosti et al., 1996). The class and subclass of the
monoclonal, merintA specific antibody 7E1 were determined using an isotyping kit
(Amersham Pharmacia Biotech). For preabsorption experiments, antibodies were
incubated with 1-5µg of specific fusion protein or GST alone as a control.
Affinity Elution of Polyclonal Antibodies
Naturally circulating antibodies in the collected serum of a rabbit produce background
bands during Western blot analysis. To circumvent this problem, the specifically raised
antibody can be purified by an affinity elution protocol. Bacterially expressed and
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purified proteins or cell lysates that overexpress the antigen were run on a single-well
comb polyacrylamide gel, blotted onto nitrocellulose and stained with 10% Ponceau-S
(Sigma) for total protein. The protein band of interest was marked with a needle and the
membrane was blocked with 3% BSA/PBS at room temperature for one hour. In turn,
the membrane was hybridized overnight at room temperature with the anti-serum to be
purified (e.g. Tim3), which was diluted 1:20 in 3% BSA/PBS. Membranes were then
washed three times at room temperature for five minutes each with 3% BSA/PBS, 0.1%
SDS, 0.05% NP40, two times with 3% BSA/PBS and once with PBS only. The part of
the membrane containing the bound antibody of interest was cut into small pieces and
washed twice with distilled water. The antibody was then eluted with 0.2M glycine-
HCl (pH 2.8). Physiological conditions were reobtained by adding Tris-HCl (pH 8.0) to
a final concentration of 0.15M. Membrane debris was removed by spinning the eluted
antibody at 14,000x g and 4o C for 30 minutes before the affinity-eluted antibody was
tested against an appropriate fusion construct or cell lysate by Western blot analysis.
Cell Culture of Mammalian Cells
Mammalian cells were cultured at 37°C with a 10% CO2-concentration. Many cell
lines, including Cos-7 (monkey kidney fibroblast), F293 (adult human fibroblast), G238
(glioma), H237 (glioma), HeLa (adenocarcinoma), Met5A (mesothelioma), RD135
(adult human fibroblast), MRC-5 (fetal human fibroblast) and 293T (embryonic
kidney), were available in the laboratory and maintained in EMEM or DMEM
(GibcoBRL) supplemented with 10% fetal calf serum (FCS) and 1%
penicillin/streptomycin (GibcoBRL) as recommended by the American Type Culture
Collection (ATCC). Breast cancer cell lines were obtained from the Cancer Center,
Massachusetts General Hospital and normal breast epithelial cell lines were obtained
from ATCC. These lines were maintained as described above. For induction
experiments, MCF-7 and MCF-7-ADR cell lines were depleted of estrogen by
maintenance in estrogen-free medium (phenol red deficient DMEM and 10% charcoal
dextran treated fetal calf serum) for 3 days. Cells were then fed with estrogen-free
medium supplemented with 10nM or 100nM β-estradiol (Sigma) and harvested at
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various time points. For experiments with cycloheximide, cells were incubated with
10µg/ml cycloheximide (Calbiochem) for 30 minutes before inducing with β-estradiol.
Human primary meningioma cells were cultured as described (Gonzalez-Agosti
et al., 1996). CAD cells (mouse neural cells) were obtained from Dr. Xandra
Breakefield, Massachusetts General Hospital, and cultured in DMEM-12F as described
(Hewett et al., 2000).
Transfection of Mammalian Cells
To express FLAG-tagged merlin, the FLAG-tag (DYKDDDDK) was engineered into
the expression vector pcDNA3 driven by the CMV promoter (Invitrogen) as
previously described (Xu L. et al., 1998). To generate 5’-tagged merlin expression
constructs, full-length merlin isoforms 1 and 2 were PCR-amplified and ligated into the
BamHI and EcoRI sites of pcDNA3/5’F. The integrity of the entire sequence, including
the junction region between the FLAG-epitope and the merlin coding sequence, was
confirmed by DNA sequencing. Similarly, both isoforms of merlin were cloned into
pEGFP-N1 (Clontech) and expressed as a GFP-fusion protein. All these expression
constructs were available in the laboratory.
To express HA-tagged merintA (A4: aa 1-178), the full-length sequence was
PCR-amplified and ligated into the BamHI and NotI of pcDNA3 (no FLAG). The sense
primer was engineered to have an HA-tag (YPYDVPDYA) between the BamHI
restriction site and the merintA. The integrity of the entire sequence, including the
junction region between the HA-epitope and the merintA coding sequence, was
confirmed by DNA sequencing.
CAD (Cath a-differentiated) cells, Cos-7 cells and 293T cells, were transfected
using LipofectAMINE 2,000 (GibcoBRL) according to manufacture’s
recommendations. Small (immunocytochemistry), medium (e.g. cell fraction assay) and
large scale (e.g. affinity binding assay) transfections were performed and the large-scale
transfection is described here. Amounts of the reagents were adjusted according to scale.
The day before transfection, cells were trypsinized, counted and seeded in a 15cm plate
to obtain approximately 85% confluent cells on the day of transfection (approximately
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40% in serum free media for cells subjected to immunocytochemistry). First, DNA
(<10µg) and LipofectAMINE (<56µl) were diluted separately in 1.4ml media (without
serum or antibiotics). Next, the two dilutions were combined and incubated at room
temperature for 30 minutes to allow the formation of DNA-LipofectAMINE
complexes. Meanwhile, the cells were washed with PBS and new media was added. The
DNA-LipofectAMINE complexes were then slowly added to the cells and incubated
for 12 to 48 hours.
Preparation of Cell Lysates from Mammalian Cells
To make lysates, tissue cultured cells were washed twice in PBS, scraped and pelleted
by centrifucation and cell pellets were resuspended in lysis buffer as indicated. After
samples were lysed at 4°C for 30 minutes they were centifugated at 14,000x g and 4°C
for 30 minutes. Protein concentrations of the supernatants were measured using the DC
protein assay system (BioRad). In this assay, the protein concentration is proportional
to a color reaction that can be quantified by spectrometry.
Preparation of Rat Kidney Cytosol
Inner stripe cytosol preparations of kidneys were performed as described (Breton et al.,
2000). Dr. Vladimir Marshansky anesthetized rats and perfused them with cold PBS for
2 minutes to remove blood. The inner stripe of the kidney was separated under a
dissecting microscope, and pieces (approximately 0.4g) were homogenized in 2ml of
buffer H (1mM EDTA, 0.25M sucrose, 10mM Tris, pH 7.4, protease inhibitor cocktail:
1x Complete, Roche) using a Wheaton glass potter fitted with a Teflon pestle. The
cytosol was obtained by centrifugation of the homogenate at 100,000x g for 1 hour and
total protein concentration was determined with the Pierce BCA protein assay.
Affinity Precipitation Assays and Peptide Competition Assay
This assay was performed under four different aspects: (A) Differential binding of
merlin isoforms to NHE-RF was analyzed. (B) The interaction of NHE-RF, mediated
by the PDZ-binding motif DTAL, to the H+ ATPase was confirmed. (C) The
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interaction of merlin and merintA, identified by the yeast two-hybrid system, was
validated. (D) The predicted interaction of merintA and Grb2 was confirmed.
(A) Differential binding of merlin isoforms to NHE-RF. The breast cancer cells,
ZR-75-B, were lysed in buffer Brij (1% Brij 96, 1mM EDTA, 30% glycerol, 150mM
NaCl, 50mM Tris, pH 8.0 and protease inhibitor cocktail: 1x Complete, Roche). The
cell lysates were incubated with 600pmol of GST-merlin fusion proteins or GST alone
immobilized on glutathione Sepharose 4B beads at 4°C for 16 hours. Subsequently, the
beads were washed extensively with PBS containing pefabloc (0.5mg/ml) to remove
proteins that bind non-specifically. Proteins were eluted with sample buffer (1x GSD),
subjected to 10% SDS-gel electrophoresis and immunoblotted with IC270 serum
(1:1,000). In some experiments, GST-merlin immobilized on beads was preincubated in
buffer Brij with 50µg/ml phosphatidyl serine (Sigma) or in phosphatidylinositol 4,5-
bisphosphate (Sigma) at 4°C for 1 hour. Then, GST-merlin was incubated with cell
lysates including 50µg/ml phosphatidyl serine (Sigma) or in phosphatidylinositol 4,5-
bisphosphate (Sigma) at 4°C for 16 hours. Each phospholipid was dissolved in distilled
water to a final concentration of 1mg/ml and sonicated three times for 10 seconds.
Dr. C. Gonzalez-Agosti performed the reciprocal experiment in the absence of
phospholipids. Cos-7 cells expressing FLAG-tagged merlin isoforms 1 or 2 were lysed
in buffer NP40 (150mM NaCl, 0.5% Nonidet P40, United States Biochmical, 50mM
Tris, pH 8.0, protease inhibitor cocktail: 1x Complete, Roche). These lysates were
incubated with 600pmol of GST-NHE-RF fusion protein or GST alone immobilized on
glutathione Sepharose 4B beads at 4°C for 16 hours. The beads were washed and
proteins were eluted as described above. SDS-gel electrophoresis (7.5%) separated the
proteins that were immunoblotted with the anti-FLAG antibody M2 (1:2,000).
(B) The interaction of NHE-RF, mediated by the PDZ-binding motif DTAL, to the
H+ ATPase. Inner stripe cytosol of rat kidneys (0.4 mg of total protein) was incubated
with 600pmol of GST-NHE-RF or GST alone bound to glutathione Sepharose 4B
beads at 4°C for 16 hours. The beads were washed and proteins were eluted as
described above. SDS-gel electrophoresis (12%) separated the proteins that were
immunoblotted with either the B1 subunit or the E subunit antibodies of the H+
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ATPase as described above (Western blot analysis). For the competition assay,
peptides deriving from the B1 subunit (PQDTEADTAL) or the B2 subunit
(EFYPRDSAKH) were dissolved in distilled water. Either peptide (300mg) was
preincubated with the GST-NHE-RF bound to beads at 4°C for 1 hour. Then, the
cytosol was supplemented with additional 300mg of peptide, added to the beads and
incubated at 4°C for 16 hours. Proteins bound to beads were then handled as described
above.
(C) The interaction of merlin and merintA. Cos-7 cells expressing HA-tagged
merintA (aa 13-178) were lysed in buffer NP40 (150mM NaCl, 0.1% Nonidet P40,
United States Biochmical, 50mM Tris, pH 8.0, protease inhibitor cocktail: 1x
Complete, Roche). These lysates were incubated with 600pmol of GST-merlin fusion
proteins or GST alone immobilized on glutathione Sepharose 4B beads at 4°C for 16
hours. Beads were washed and proteins were eluted as described above. SDS-gel
electrophoresis (10%) separated the proteins that were immunoblotted with an anti-HA
antibody  (1:35) kindly provided by Dr. Ed Harlow, Massachusetts General Hospital.
For the reciprocal experiment, 293T cells expressing FLAG-tagged merlin
isoforms 1 or 2 were lysed in buffer NP40 (150mM NaCl, 0.5% Nonidet P40, United
States Biochmical, 50mM Tris, pH 8.0, protease inhibitor cocktail: 1x Complete,
Roche). These lysates were incubated with 600pmol of GST-merintA or with GST
alone immobilized on glutathione Sepharose 4B beads at 4°C for 16 hours. The beads
were washed and proteins were eluted as described above. SDS-gel electrophoresis
(7.5%) separated the proteins that were immunoblotted with the anti-FLAG antibody
M2 (1:2,000).
(D) The predicted interaction of merintA and Grb2. CAD cells were lysed in
buffer NP40 (150mM NaCl, 0.5% Nonidet P40, United States Biochmical, 50mM Tris,
pH 8.0 with a protease inhibitor cocktail: 1x Complete, Roche). These lysates were
incubated with 600pmol of GST-merintA fusion proteins or GST alone immobilized on
glutathione Sepharose 4B beads at 4°C for 16 hours. Beads were washed and proteins
were eluted as described above. SDS-gel electrophoresis (12%) separated the proteins
that were immunoblotted with the anti-Grb2 antibody sc-255 (1:1,000).
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Immunoprecipitation Assays
This assay was performed under three different aspects: (A) The interaction of NHE-
RF, mediated by the PDZ-binding motif DTAL, to the H+ ATPase was confirmed. (B)
Antibodies against merintA were validated. (C) The interaction of merlin and merintA,
identified by the yeast two-hybrid system, was validated.
(A) The interaction of NHE-RF, mediated by the PDZ-binding motif DTAL, to
the H+ ATPase. Rat kidney cytosol lysates were prepared as for affinity precipitation
assays, except that the entire cortex and outer medulla was taken to obtain cytosol,
which ensured adequate amounts of NHE-RF. To preclear samples, they were
incubating with normal rabbit serum and protein A-agarose beads (Roche). NHE-RF
was immunoprecipitated using IC270 serum and protein A-agarose beads. The samples
were washed extensively with PBS containing pefabloc (0.5mg/ml) and eluted by boiling
in sample buffer (1x GSD). The immunoprecipitates were subjected to SDS-
polyacrylamide gel electrophoresis, blotted and probed with biotinylated IC270 (1:50)
followed by horseradish peroxidase conjucated streptavidin (see biotinylation of
antibodies and immunoblotting using biotinylated primary antibodies). The H+ ATPase
was detected with the monoclonal E subunit antibody (E11) as described above
(Western blot analysis).
(B) Validation of merintA antibodies. CAD cells were lysed in buffer NP40
(150mM NaCl, 0.5% Nonidet P40, United States Biochmical, 50mM Tris, pH 8.0,
protease inhibitor cocktail: 1x Complete, Roche). To preclear lysates, they were
incubating with normal rabbit serum and protein A-agarose beads (Roche). MerintA
was immunoprecipitated using Tim3 serum and protein A-agarose beads. The samples
were washed extensively with PBS containing pefabloc (0.5mg/ml) and eluted by boiling
in sample buffer (1x GSD). The immunoprecipitates were subjected to SDS-
polyacrylamide gel electrophoresis and immunoblotted with the anti-merintA antibody
7E1 (1:500).
(C) The interaction of merlin and merintA. CAD cells overexpressing FLAG-
merlin isoform 2 were lysed in buffer NP40 (150mM NaCl, 0.5% Nonidet P40, United
States Biochmical, 50mM Tris, pH 8.0, protease inhibitor cocktail: 1x Complete,
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Roche). To preclear lysates, they were incubated with normal rabbit serum and protein
A-agarose beads (Roche). Merlin was immunoprecipitated using N21 serum and protein
A-agarose beads. The samples were washed extensively with PBS containing pefabloc
(0.5mg/ml) and eluted by boiling in sample buffer (1x GSD). The immunoprecipitates
were subjected to SDS-polyacrylamide gel electrophoresis and immunoblotted with the
anti-merlin antibody 1C4 (1:500) and the anti-merintA antibody 7E1 (1:500).
Biotinylation of Antibodies
The polyclonal NHE-RF antibody, IC270, was biotinylated to detect the ~50kD protein NHE-
RF in immunoprecipitates. Towards this end, IC270 serum was affinity-eluted as described
above (affinity elution of polyclonal antibodies) and dialyzed against buffer NH (50mM NaCl,
50mM NaHCO3, pH 8.5) to remove free amines. A freshly prepared working stock of NHS-
LC-biotin (Pierce, 10mg/ml in dH2O) was mixed with the dialyzed antibody at a final
concentration of 0.1mg/ml and incubated at 4°C for 60 minutes. The reaction was quenched by
adding 1/20th volume of buffer GT (1M glycine, 1M Tris, pH 6.8) to the sample. In a final
step, the buffer was exchanged into PBS containing 0.02% NaN3 using NAP 10 columns
(Amersham Pharmacia Biotech).
Immunoblotting Using Biotinylated Primary Antibodies
SDS-polyacrylamide gel electrophoresis separated immunoprecipitated antigens, which were
then transferred to nitrocellulose membranes. After blocking membranes in 10% non-fat dry
milk diluted in TBST, they were incubated with biotinylated primary antibody diluted in
TBST containing 1% milk for 2 hours. After the membranes were washed, streptavidin-
horseradish peroxidase (Amersham Pharmacia Biotech) was diluted 1:1,000 in TBST and
applied for 1 hour. The membranes were washed again with TBST, incubated one minute in
ECL 1 and 2 (Amersham Pharmacia Biotech) and exposed to X-Omat AR film (Kodak,
Eastman Co.).
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Soluble and Insoluble Cell Fraction Assay
Cell fractionations were performed as previously described (Hartwig, 1992). Here,
CAD cells were plated (1.75*106/10cm plate), cultured for 16 hours and transfected
with both full-length HA-merintA (A4) and full-length FLAG-merlin isoform 2. After
24 hours, cells were rinsed once with PBS and then incubated in 0.75% Triton X-
100/PHEM buffer (60mM PIPES, 25mM HEPES, 2mM MgCl2, 10mM EGTA, pH
6.9 with 1µM phallacidin and a protease inhibitor cocktail: 1x Complete, Roche) at
37°C for two minutes. Lysed cells were harvested with a rubber policeman and
centrifuged 14,000x g and 4°C for 15 minutes to separate the soluble and insoluble
fractions. The detergent-soluble material was precipitated with 85% acetone at –20°C
for 16 hours and recovered by centrifugation at 14,000x g and 4°C for 15 minutes.
Detergent-insoluble material was scraped in PBS containing protease inhibitors and
centrifuged at 14,000x g and 4°C for 15 minutes. All samples were resuspended in the
same volume of sample buffer (1x GSD), subjected to 12% SDS-polyacrylamide gel
electrophoresis and examined by Western blot analysis.
Immunocytochemistry
Immunofluorescence analysis of tissue culture cells was performed as previously
described (Gonzalez-Agosti et al., 1996). In summary, cells were grown on glass
coverslips, fixed in 4% paraformaldehyde in PBS at 37°C for 15 minutes, washed three
times with PBS and permeabilized with 0.1% NP40/PBS at room temperature for 15
minutes. To reduce background staining, cells were blocked with 10% normal goat
serum (Vector Laboratories) in PBS at 37°C for 45 minutes. Primary antibodies were
incubated at 37°C for 1 hour while secondary antibodies were incubated at 37°C for 30
minutes. All antibodies were diluted in 0.1% BSA/PBS. Coverslips were washed
extensively between antibody incubations and mounted on glass slides using ProLong
(Molecular Probes) as recommended by the manufacturer. Cells were examined on a
Nikon fluorescence microscope using 40x 1.3 N.A. and 60x 1.4 N.A. objectives before
images were recorded on Kodak Tri-X-Pan 400 (Kodak, Eastman Co.). Confocal images
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were obtained with a Nikon TE 300 microscope and the BioRad MRC 100 laser
confocal imaging system.
To stain NHE-RF in the breast cancer cells, MCF-7, the primary antibody
IC270, was affinity-eluted and used at a dilution of 1:2. The secondary goat anti-rabbit
antibody was FITC conjugated. CAD cells were transfected with full-length HA-
merintA (A4) and GFP-merlin isoform 1 or 2, fixed, permeabilized and blocked as
described above. As primary antibodies, 12CA5 (HA-tag, Roche) was used at a dilution
of 1:200 to visualize exogenous merintA followed by the secondary rhodamine
conjugated anti-mouse antibodies. Untransfected CAD cells were stained with the
monoclonal antibody 7E1 at a dilution of 1:10 to visualize endogenous merintA.
Secondary antibodies (rhodamine conjugated to goat anti-mouse antibodies) were used
at dilutions recommended by the manufacturer. To visualize F-actin, rhodamine-
coupled phalloidin (1:1,000) was incubated at 37°C for 30 minutes after the incubation
of primary antibodies. To visualize nuclei, Hoechst 33342 (10µg/ml) was incubated at
37°C for 30 minutes after the incubation of primary antibodies or rhodamine-coupled
phalloidin.
Immunostaining of NHE-RF and H+ ATPase in the Kidney
Rat kidney sections were stained for NHE-RF and the H+ ATPase (Breton et al., 2000).
Male rats were anesthetized and kidneys were fixed by perfusion for 5 minutes through
the abdominal aorta with a fixing solution (4% paraformaldehyde, 10mM sodium
periodate, 70mM lysine (PLP) and 5% sucrose). Kidneys were separated from the
animal, sliced and further fixed by immersion in fixing solution for 6 hours. For the
preparation of 4µm sections, kidneys were washed in PBS and cryoprotected in 30%
sucrose. Tissues were then sectioned with a Reichert Frigocut microtome using
disposable knives. Kidney sections were then picked up on Fisher Superfrost Plus
slides (Fisher Scientific), rinsed in PBS for 10 minutes and treated with 1% SDS for 5
minutes. The latter step augments antigenicity of many proteins as described
previously (Brown et al., 1996). After three additional washes in PBS, 5 minutes each,
sections were incubated in 1% BSA/PBS for 20 minutes to reduce background staining.
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The primary anti-NHE-RF antibody (affinity-eluted IC270; 1:4) was incubated at room
temperature for 2 hours. After washing twice for 5 minutes in high salt PBS (PBS
containing 2.7% NaCl) to reduce nonspecific staining and one further washing in normal
PBS for 5 minutes, CY3 conjugated secondary anti-rabbit antibodies (1:800) were
applied for 60 minutes. For double staining, sections were incubated for 2 hours with an
affinity purified chicken polyclonal antibody against the E subunit of the H+ ATPase
(1:40). Next, samples were washed as before and FITC-coupled secondary anti-chicken
antibodies (1:200) were applied for 60 minutes. Finally, sections were washed three
more times and mounted with Vectashield anti-fading solution (Vector Labs). Control
incubations were performed with IC270 that was preincubated with the GST-NHE-RF
fusion protein (at a final concentration of 0.2 mg/ml) at room temperature for 1 hour.
Samples were examined using a Nikon Eclipse 800 microscope equipped with specific
CY3 and FITC filter combinations and images were captured on Ektachrome 400 Elite
film (Kodak, Eastman Co.). CY3 emission appears yellow using the specific CY3 filter
combination and analog photography (see Figure 9A and C).
Immunostaining of NHE-RF in Breast Carcinomas
Formalin-fixed, paraffin-embedded sections of eighteen invasive breast carcinomas were
retrieved from the files of the Department of Pathology, Massachusetts General
Hospital, Boston. NHE-RF immunohistochemical staining was performed with the
affinity-eluted IC270 antibody. In summary, 8µm thick sections of formalin-fixed,
paraffin-embedded specimens were deparaffinized, rehydrated and immersed in 0.5%
H2O2/methanol for 20 minutes. Sections were then rehydrated in graded ethanols and
microwaved in 0.01M sodium citrate buffer (pH 6.0) for 15 minutes. To reduce non-
specific staining, sections were blocked in 10% normal goat serum and 5% milk in 1%
BSA/PBS solution. Samples were then incubated with the polyclonal antibody IC270
(affinity-eluted 1:100 in 1% BSA/PBS) at 4°C for 16 hours followed by incubation
with biotinylated anti-rabbit secondary antibodies (1:500) at room temperature for 30
minutes. Finally, sections were subjected to standard avidin-biotin complex (ABC)
process (Vectastain Elite ABC kit, Vector Laboratories). Diaminobenzidine (DAB) was
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used as a chromogen, followed by counterstaining with hematoxylin. Formalin fixed,
paraffin-embedded cell pellets from MCF-7 and MCF-7-ADR cell lines were used as
controls. The primary antibody was omitted for negative controls. Ms. Tina Glyptis
determined the status of primary breast for estrogen (ER) and progesterone (PR)
receptors according to standard procedures. In summary, antigen retrieval was achieved
by microwaving the sections in Tris buffer (pH 10) for 10 minutes, blocking with
normal horse serum and incubating with ER antibodies (1:100; DAKO) or with PR
antibodies (1:10; DAKO) at 4°C for 16 hours. Sections were incubated with secondary
antibodies (1:200) at room temperature for 45 minutes followed by ABC reaction,
visualized with DAB and counterstained with hematoxylin.
Electron Microscopy
Immunogold labelling of merlin and merintA was conducted as previously described
(James et al., 2001). CAD cells were plated on coverslips, permeabilized in 0.75%
Triton X-100/PHEM buffer (60mM PIPES, 25mM HEPES, 2mM MgCl2, 10mM
EGTA, pH 6.9 with 1µM phallacidin and a protease inhibitor cocktail: 1x Complete,
Roche) for 2 minutes, and soluble proteins were removed with a PHEM buffer wash.
Samples were fixed with 1% glutaraldehyde in PHEM buffer for 10 minutes and
reactive aldehydes were blocked with 0.1% NaBH4 in PHEM buffer. The coverslips
containing residual, glass-adherent cytoskeletons were washed with PHEM buffer and
treated with 0.1% SDS for 1 minute to augment antigenicity. Cytoskeletons were
incubated with primary antibodies (merlin: A19, 1:10; merintA: 7E1, 1:10) in Tris
buffer containing 1% BSA (150mM NaCl, 20mM Tris, pH 8.2) at 25°C for 1 hour.
After washing three times, coverslips were incubated with goat anti-rabbit IgG-coated
5nm colloidal gold particles (1:20) for merlin staining and with goat anti-mouse IgG-
coated 10nm colloidal gold particles (1:20) for merintA staining. Coverslips were
washed three more times with 1% BSA in Tris buffer and before being fixed with 1%
glutaraldehyde in Tris buffer for 10 minutes. Fixed cytoskeletons were washed
extensively with distilled water, frozen rapidly, freeze-dried and rotary-coated with
1.2nm of tantalum-tungsten at 45° and 3.0mm of carbon at 90° without rotation.
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Coverslips were analyzed and photographed in a Jeol 1200-EX electron microscope
with 100kV accelerating voltage. No gold labelling was found when primary antibodies
were omitted or when preimmune IgG was used as a control.
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3. Results
3.1 Characterization of the Interaction of NHE-RF with Merlin Isoform 1 and 2
The regulatory co-factor for the Na+-H+ exchanger isoform 3 (NHE-RF) was identified
as an interacting protein for merlin in the Molecular Neurogenetics Unit at
Massachusetts General Hospital and Harvard Medical School, Boston. It was
demonstrated that NHE-RF can bind to merlin, moesin and radixin via their conserved
amino-terminal regions (Murthy et al., 1998). Furthermore, a number of reports have
shown that the binding of ERM proteins to their interactors is suppressed in the native
full-length protein (Heiska et al., 1998; Hirao et al., 1996; Matsui et al., 1998). This
phenomenon can be explained by the interdomain interactions of the ERM proteins that
compete with the ligand binding (Reczek et al., 1998). Recent data from the laboratory
of Dr. V. Ramesh demonstrated that merlin isoform 1 can form intra- and intermolecular
head-to-tail associations similar to the ERM proteins. In contrast, merlin isoform 2
lacks this property due to the alternatively spliced carboxy-terminus (Gonzalez-Agosti
et al., 1999). Therefore, it was tested whether these different conformations of merlin
isoforms 1 and 2 correlate with differences in binding with the ligand NHE-RF.
3.1.1 NHE-RF Binds Differentially to Merlin Isoform 1 and 2
Affinity precipitation experiments were performed to investigate the binding of merlin
isoforms to NHE-RF in vitro. Merlin full-length isoforms 1 and 2, the amino-terminal
domain (aa 1-332) and the carboxy-terminal domains of both isoform 1 (aa 340-595)
and 2 (aa 340-590) were expressed as GST fusion proteins. GST alone was included in
these experiments as a negative control. Equal quantities of these proteins were bound
to Sepharose beads and incubated with equal amounts of cell lysates. After extensive
washes, the coupled proteins were removed from the beads by boiling in SDS sample
buffer before being submitted to Western blot analysis. The membrane was incubated
with a specific polyclonal antibody (IC270) to detect NHE-RF that bound to merlin
fusion proteins. The results demonstrate that the amino-terminal domain and full-length
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Figure 5. Binding of NHE-RF to Merlin Isoforms. Lysate from ZR-75-B cells were
incubated with various GST-merlin fusion proteins immobilized on glutathione Sepharose 4B
beads. The beads were extensively washed, bound proteins were separated on 10% SDS-PAGE
and immunoblotted with an anti-NHE-RF antibody (IC270 serum). The arrow indicates NHE-
RF at ~50kD (A). Fl-iso 1, full-length isoform 1; FL-iso 2, full-length isoform 2. Lysates from
ZR-75-B cells incubated with CIP show that NHE-RF migrates faster than from those not
incubated with the phosphatase. Thus, NHE-RF is constitutively phosphorylated (B).
isoform 2 of merlin capture more NHE-RF than full-length isoform 1 of merlin. NHE-
RF did not bind to the carboxy-terminal domain of either isoform of merlin or to the
GST control protein (Figure 5A). Western blots were stained with Ponceau-S for total
proteins before probing with the specific NHE-RF antibody. This staining confirmed
that equal amounts of GST fusion proteins and GST alone were bound to the beads in
the experiments (data not shown). It is known that NHE-RF is a constitutively
phosphorylated protein (Reczek et al., 1997). Treating cell lysates with calf intestinal
alkaline phosphatase (CIP) shows that the multiple NHE-RF species collapse to a
single band that migrates faster than the lowest species of untreated lysates (Figure 5B).
Thus, hypophosphorylated NHE-RF shows no difference in binding to merlin isoforms
in contrast to hyperphosphorylated NHE-RF that binds exclusively to merlin isoform 2
(Figure 5A). These results were confirmed by three independent experiments.
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Figure 6. Binding of Merlin Isoforms 1 and 2 to NHE-RF. Cos-7 cell lysates expressing
either FLAG-tagged merlin isoform 1 or merlin isoform 2 were incubated with GST-NHE-RF
fusion protein or GST protein expressed alone (control) immobilized on glutathione Sepharose
4B beads. The beads were extensively washed, and bound proteins were separated on 7.5%
SDS-PAGE and immunoblotted with the anti-FLAG monoclonal antibody M2. Lysates from
Cos-7 cells expressing merlin isoforms are shown for protein expression level in transfected
cells. The supernatants that were not bound to the beads are shown to point out that NHE-RF
beads capture more merlin isoform 2 than merlin isoform 1 (From Gonzalez-Agosti et al.,
1999).
The reciprocal experiment was conducted in collaboration with Dr. C.
Gonzalez-Agosti, a member of the Ramesh laboratory at the time. Here, merlin
isoforms 1 and 2 were expressed as FLAG-tagged proteins in Cos-7 cells, which were
then utilized in affinity binding assays with GST-NHE-RF fusion protein. The FLAG-
tagged merlin isoform proteins were examined by Western blot analysis with an anti-
FLAG antibody (M2, Sigma) prior to the affinity binding assay to ensure equal
expression. Cell lysates, expressing approximately the same amount of merlin isoform 1
and 2, were then incubated with GST-NHE-RF or GST alone bound to beads. The
proteins that precipitated with the beads were again analyzed by Western blot analysis
for the presence of merlin with the M2 antibody. These experiments demonstrated that
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merlin isoforms expressed in mammalian cells also bind differentially to NHE-RF
(Figure 6). Analysis of the supernatants from the affinity binding assay clearly showed
more depletion of merlin isoform 2 than isoform 1 confirming that more merlin isoform
2 was precipitated along with NHE-RF (Figure 6). A duplicate set of experiments
demonstrated that NHE-RF captured ~4 fold more merlin isoform 2 than isoform 1 as
determined by densitometric scanning of the autorads using transmittance analysis
(Fluor-S, Multiimager, BioRad). Densitometric scanning was performed on bands
deriving from merlin that were not saturated. Thus, values obtained are in a linear range
and reflect true differences. Western blots were stained with Ponceau-S for total
proteins before probing with the FLAG-antibody. This staining confirmed that equal
amounts of GST fusion proteins and GST alone were bound to the beads in the
experiments (data not shown). These data are consistent with the distinct
intramolecular head-to-tail associations of merlin isoforms. The carboxy-terminus of
merlin isoform 1 competes with NHE-RF for the amino-terminal binding site. On the
other hand, merlin isoform 2 exists in a constitutively open conformation that allows
the binding of the MERM binding protein NHE-RF without competition from the
intramolecular association that occurs in merlin isoform 1.
3.1.2 Phospholipids Enhance the Binding of NHE-RF to Merlin Isoform 1
ERM proteins bind to the phospholipids phosphatidylinositol 4-phosphate (PIP) and
phosphatidylinositol 4,5-bisphosphate (PIP2) (Niggli et al., 1995), and it is believed
that this binding evokes conformational changes in these proteins in a manner similar to
the regulation of vinculin activity by PIP2 (Gilmore et al., 1996). Moreover, PIP and
PIP2 enhance the interaction of ERM proteins to their binding partners CD44, ICAM-1
and ICAM-2 while the phospholipids phosphatidyl choline (PC) and phosphatidyl
serine (PS) have no effect (Heiska et al., 1998; Hirao et al., 1996). The affinity
precipitation assay described above was performed to test if PIP2 and PS influence the
binding of NHE-RF to merlin isoforms. The amount of NHE-RF bound to merlin
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Figure 7. PIP2 Enhances Binding of NHE-RF to Merlin Isoform 1. GST-merlin fusion
proteins or GST alone were bound to glutathione Sepharose 4B beads and incubated with ZR-
75-B cell lysates. In addition, 50µg/ml phosphatidyl 4,5-bisphosphate (PIP2) or 50µg/ml
phosphatidyl serine (PS) was added to the beads with the cell lysates. The eluted proteins were
detected by Western blot analysis using IC270 serum (A). Ponceau-S staining of GST-merlin
fusion proteins bound to the beads showing that equal amounts of GST-merlin fusion proteins
bound to the beads (B).
isoform 1 significantly increased in the presence of PIP2 but not in the presence of PS
(Figure 7A). The intensity of the bands was quantified by densitometric scanning of the
autorads using transmittance analysis (Fluor-S, Multiimager, BioRad). A three-fold
increase (3.10 ± 1.04) in binding of NHE-RF to merlin isoform 1 was determined in the
presence of PIP2 compared to binding in the absence of PIP2 (Table 2). In addition,
hyperphosphorylated NHE-RF was captured by merlin isoform 1 in the presence of
PIP2 while this was not seen in the absence of PIP2 (Figure 5A and 7A). The binding of
NHE-RF to either the amino-terminal domain of merlin or merlin isoform 2 (1.07 ±
0.45) was not influenced by PIP2 (Table 2). The control phospholipid, PS, did not
enhance the NHE-RF binding to merlin isoform 1 and did not have an effect on the
binding of hyperphosphorylated NHE-RF and merlin isoform 1 (Figure 7A). Western
blots were stained again with Ponceau-S for total proteins before probing with the
specific antibody and the staining confirmed that equal amounts of GST fusion proteins
and GST alone were bound to the beads in the experiments (Figure 7B). These data are
in agreement with the model worked out for the ERM proteins (Figure 3) and suggest
that merlin isoform 1 may function similarly with respect to intramolecular head-to-tail
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associations, its regulation by PIP2 and the binding to some of its ligands including
NHE-RF.
Isoform 1
1 2 3
Area (OD * mm) without PIP2 0.50 0.07 0.54
with PIP2 0.98 0.30 1.78
Increase of binding (ratio) 1.97 4.01 3.33
Average of increase (ratio) 3.10
Isoform 2
1 2 3
Area (OD * mm) without  PIP2 1.69 2.56 1.63
with  PIP2 1.66 1.74 2.56
Increase of binding (ratio) 0.98 0.68 1.57
Average of increase (ratio) 1.08
Table 2. Merlin Isoform 1 Binding Increases in the Presence of PIP2. NHE-RF was
precipitated with merlin isoform 1 and 2 respectively in three individual experiments. Autorads
obtained by Western blot analysis were examined by densitometric scanning using transmittance
analysis to quantify the amount of NHE-RF that was recovered.
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3.2 Isolation and Characterization of NHE-RF Binding Proteins
Defining functions of NHE-RF is/has been of great interest and NHE-RF binding
proteins have been sought towards this end. Various proteins that bind NHE-RF and
NHE-RF2 have emerged out of a field of intensive study. In particular, mutagenesis
studies of the cytoplasmic tail of the β2-adrenergic receptor have revealed that the
optimal binding motif to the first PDZ-domain of NHE-RF is DS/TXL (Hall et al.,
1998a). Searching databases for proteins with this binding cassette reveals the three
categories receptors, transporters and other proteins, and all of these proteins have the
motif at the extreme carboxy-terminus of these proteins (Table 3).
Potential NHE-RF (PDZ-1) Binding Proteins
Receptors C-terminal motif
β2-adrenergic receptor D-S-L-L
Purinergic P2Y1 receptor D-T-S-L
Platelet-derived growth factor receptor D-S-F-L
Transporters
Cystic fibrosis transmembrane regulator D-T-R-L
Copper transporter (Menke’s disease gene) D-T-A-L
H+ ATPase, B1 subunit D-T-A-L
Other Proteins
Phospholipase C-β1 D-T-P-L
Podocalyxin D-T-H-L
Kunjin virus-specified protein D-T-V-L
Table 3. Potential NHE-RF Binding Proteins. Database searches reveal a number of
proteins that have the PDZ-1 binding cassette of NHE-RF. (Modified from Hall et al.,
1998a)
The B1 (56kD) subunit of the proton-pumping ATPase (H+ ATPase) has the
PDZ-binding motif DTAL, which suggests it is a potential binding partner of NHE-RF.
Most of the PDZ-1 binding proteins of NHE-RF are transmembrane proteins. In
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contrast, the B1 H+ ATPase subunit is part of the V1 portion of the holo-enzyme and
has no membrane-spanning domain. However, it binds to other subunits including those
that span the lipid bilayer of the plasma membrane. In addition, a direct binding
between the E (31kD) and B1 subunit has been established (Figure 8). Multi-subunit
complexes consisting of the V1 portion of the H
+ ATPase can exist as free, cytosolic
entities (Nelson et al., 1999).
The B1 subunit of the H+ ATPase is expressed in several tissues and high levels
are detected in specialized proton-translocating intercalated cells in the kidney. In
contrast, the B2 (56kD) subunit, another isoform of the B1 subunit, is expressed in the
proximal kidney tubules. Significantly, this B2 subunit has a carboxy-terminal
truncation and lacks the terminal DTAL binding motif (Nelson et al., 1992).
Figure 8. Diagram of H+
ATPase. The V1 domain
catalytic/regulatory subunits is
composed of subunits A/B
(red) along with connecting
subunits C, D, E, F, and G
(pink). The Vo domain (blue)
is composed of the H+ cannel
forming subunit M17, along
with subunits M9.7, M40 and
M100. (Modified from
Wieczorek et al., 1999).
In the collecting tubules of the kidney cortex, intercalated cells are known to
actively transport and secrete hydrogen ions against high concentration gradients, thus
modulating the acid-base balance of the body. These intercalated cells show an apical,
basolateral, diffuse, or bipolar H+ ATPase localization that suggests a complex
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regulation of expression and localization at the cell surface (Brown et al., 1988a). A
subpopulation of intercalated cells, the A-cells, secrete protons into the tubule lumen
and always have the H+ ATPase at their apical pole while the antiporter Cl-/HCO3
-
(AE1) is at their basolateral pole (Alper et al., 1989). In other intercalated cells, the B-
cells, the H+ ATPase can be apical, basolateral, or bipolar while AE1 is not detectable in
either plasma membrane domain (Sabolic et al., 1997).
3.2.1 NHE-RF Co-localizes with the H+ ATPase
Previous studies have pinpointed NHE3 and NHE-RF to the proximal tubules in the
kidney: Weinman et al. (1995) showed that NHE-RF inhibits NHE3 in a cAMP-
dependent protein kinase A (PKA) dependent manner in the renal proximal tubule
brush border membrane. Biemesderfer et al. (1997) showed that NHE3 is localized in
proximal tubules by immunohistochemical studies. Thus, one expects NHE-RF to
localize to the proximal tubules, while no information was available of NHE-RF in
intercalated cells.
In this study, NHE-RF localization was examined in the kidney to test if there is an
overlapping pattern with the H+ ATPase. Hence, the specific, polyclonal antibody
(IC270) was employed on fixed cryostat sections. These immunohistochemical studies
were performed in collaboration with Drs. Sylvie Breton and Dennis Brown from the
Renal Unit at Massachusetts General Hospital, Boston. As expected, the greatest
amount of NHE-RF was detected in all proximal tubule segments. Furthermore, NHE-
RF was detected in some cells of the cortical collecting ducts and connecting segments
(Figure 9A and C). Some cells showed distinct basolateral staining (Figure 9A) while
others showed a more diffuse cytoplasmic staining (Figure 9C), and yet others showed
apical staining (Figure 9C). Thus, the extent and intracellular location of NHE-RF was
variable in these cells. Double incubations using a chicken polyclonal antibody against
the E (31kD) subunit of the H+ ATPase identified these cells as intercalated cells of the
collecting tubules in the kidney cortex (Figure 9B and D). Dr. Dennis Brown and
colleagues had previously shown that the three major subunits of the cytoplasmic
Results                                                                                                                                     64
Figure 9. NHE-RF (A and C)
and the E (31kD) Subunit of
the H+ ATPase (B and D)
Colocalize in Double Stained
Sections of Rat Kidney
Cortex. The brush border is
strongly stained in all proximal
tubules. Some cells of the
collecting ducts (CD) and
connecting segments (CNT) are
also stained. Different patterns
of NHE-RF staining are
detected, and the staining
overlaps with that of the H+
ATPase in intercalated cells.
Some cells have basolateral
staining (1), some have diffuse
cytoplasmic staining (2), some
have apical staining (3) and others have little or no NHE-RF staining but show apical H+
ATPase staining (4). In connecting segments (CNT), all cells have strong H+ ATPase staining,
as described previously (Brown et al., 1988b), but only a few of these are clearly NHE-RF
positive. The staining in A and C, which represent single exposures of the NHE-RF staining,
appears yellow because of the use of a highly specific filter combination used for the CY3
fluorophore. CY3 emission is yellow with filter combination  used. Bar, 15µm. (From Breton
et al., 2000).
domain of this enzyme co-localize in intercalated cells. Consequently, the E subunit is a
reliable marker for the entire cytoplasmic domain of the H+ ATPase and contains the B
(56kD) subunit in intercalated cells (Brown et al., 1988b). Here, NHE-RF co-localized
with the H+ ATPase in intercalated cells in these double-stained sections supporting the
idea that these two proteins can interact, possibly through the PDZ-domain binding
motif. However, some intercalated cells contain the H+ ATPase but do not express
detectable levels of NHE-RF (Figure 9A4).
An anti-AE1 antibody that labels only A-cells (Alper et al., 1989) was used in
conjunction with the anti-NHE-RF antibody to distinguish between A- and B-
intercalated cells. All cells with distinct apical, basolateral or diffuse NHE-RF
localization were AE1 negative indicating that these intercalated cells are B-cells (data
not shown, see appendix: Breton et al., 2000, Figure 2). In addition, NHE-RF was not
detected in A-intercalated cells that are only found in the inner stripe of the outer
medulla (data not shown). Thus, NHE-RF is expressed with variable intracellular
localization patterns in B-intercalated cells and overlaps with that of the H+ ATPase in
every individual B-cell in the cortical collecting duct and connecting segment.
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In proximal tubules, the H+ ATPase staining was concentrated in a tight
subapical band at the base of the brush border. This subapical domain did not contain
detectable levels of NHE-RF. As predicted from the location of NHE3 (Biemesderfer et
al., 1997; Weinman et al., 1995) and in contrast to the H+ ATPase, NHE-RF was
detected in the brush border. The basolateral domain of proximal tubules showed no
detectable levels of NHE-RF (data not shown, see appendix: Breton et al., 2000, Figure
3). It is of interest to note that these cells that show no colocalization of NHE-RF are
known to express the carboxy-terminally truncated H+ ATPase B2 isoform, which
lacks the DTAL PDZ-binding motif (Nelson et al., 1992).
The specificity of the obtained staining data was confirmed by preincubating the
NHE-RF antibody with the immunogen (GST-NHE-RF fusion protein). Sections were
stained in parallel with normal and preabsorbed NHE-RF antibodies. The staining in the
proximal tubule as well as in the apical, basolateral and bipolar intercalated cells was
abolished upon incubation with preabsorbed NHE-RF antibodies while staining with
the normal NHE-RF antibody was reproducible (data not shown, see appendix: Breton
et al., 2000, Figure 4). Hence, the staining data obtained of NHE-RF reflect the true
localization of NHE-RF.
3.2.2 Soluble H+ ATPase Complexes bind to NHE-RF In Vitro
The localization of NHE-RF and the H+ ATPase support the hypothesis that these
two proteins can interact through the PDZ-domain binding motif. To test the physical
interaction of these proteins, affinity precipitation experiments were performed in
collaboration with Dr. Vladimir Marshansky, a member of Dr. Dennis Brown’s
laboratory. Equal quantities of GST-NHE-RF and GST alone were bound to Sepharose
beads and incubated with an equal amount of renal medullary cytosol to extract
potential binding proteins. After extensive washes, the coupled proteins were removed
from the beads by boiling and detected by Western blot analysis using specific
antibodies directed against the B1 (56kD) and E (31kD) subunits. The results
demonstrate that both the B1 and the E subunits of the H+ ATPase were present in the
affinity precipitates. Little or no H+ ATPase subunits bound to the negative control
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GST alone demonstrating the specificity of the NHE-RF/H+ ATPase association
(Figure 10A).
Next, competition experiments were performed to investigate the importance of
the B1 subunit PDZ-binding motif for the association with NHE-RF. Carboxy-terminal
peptides deriving from the B1 subunit, which contain the motif DTAL
(PQDTEADTAL) or from the B2 subunit, which lack the motif DTAL
(EFYPRDSAKH) were incubated with the affinity beads (GST-NHE-RF) prior to
adding equal amounts of kidney cytosol. The peptide derived from the B1 subunit
abrogated the interaction of NHE-RF and the H+ ATPase completely while the peptide
derived the B2 subunit had no effect on the association (Figure 10B). These data
suggest that NHE-RF binds directly to the B1 subunit through the PDZ-binding motif.
Furthermore, the E subunit precipitates in concert with the B1 subunit supporting
earlier studies that suggest this subunit is a reliable marker for the entire cytoplasmic
domain of the H+ ATPase (Brown et al., 1988b).
3.2.3 NHE-RF and the H+ ATPase Associate In Vivo
To examine if this association also takes place in vivo, co-immunoprecipitation
experiments were conducted. However, NHE-RF was first immunoprecipitated to test
if the antibody IC270 can be used for these experiments. Once the protocol for
immunoprecipitating NHE-RF was established, co-immunoprecipitations of NHE-RF
and H+ ATPase were attempted.
NHE-RF and the immunoglobulin heavy chain migrate at the same level (~50kD)
and detection of NHE-RF is obscured when polyclonal rabbit antibodies are employed
for immunoprecipitation followed by immunodetection. To overcome this problem a
strategy had to be developed to ensure the integrity of the NHE-RF
immunoprecipitates. Using biotinylated primary antibodies to probe immunoblots of
immunoprecipitates, followed by horseradish peroxidase-conjugated streptavidin
results in little or no background staining caused by the immunoglobulin heavy chain
and yet does not reduce the sensitivity or specificity of the primary antibody
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Figure 10. NHE-RF Binds to the H+ ATPase In Vitro and In Vivo. The B1 and the E
subunits of the H+ ATPase are both captured by GST-NHE-RF beads, but not by beads coupled to
GST alone (A). The ability of the GST-NHE-RF to capture the H+ ATPase (in this case the E
subunit) is completely inhibited by the B1 subunit peptide (which contains the DTAL motif) in
contrast to the B2 subunit peptide (which lacks the DTAL motif) (B). NHE-RF is
immunoprecipitated with the polyclonal antibody IC270. No background staining is detected in
the control lanes normal rabbit serum (NRS) with cell lysate and IC270 without cell lysate (IC270
+ buffer) using biotinylated IC270 for immunoblotting (C). The E subunit of the H+ ATPase is
co-immunoprecipitated by IC270 but not by preimmune serum. In all of these blots, the E
subunit runs slightly higher than the predicted 31kD molecular mass for this subunit. IP,
immunoprecipitate. (Adapted from Breton et al., 2000).
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(Berryman et al., 1998). Thus, a signal seen at ~50kD of immunoprecipitations with the
antibody IC270 is expected to be from the presence of NHE-RF and not from the
immunoglobulin. To test this method, cell lysates were incubated with the NHE-RF
antibody and protein A that is covalently coupled to an agarose matrix. As controls,
lysis buffer alone replaced cell lysate or alternatively, lysate was incubated with a non-
relevant antibody (normal rabbit serum or pre-immune serum). This method was
successfully employed to show that NHE-RF immunoprecipitates with the antibody
IC270 and no background staining is detected in the controls (Figure 10C). Thus, this
antibody can be utilized to study protein-protein interactions by co-
immunoprecipitation experiments.
To test the physical interaction of NHE-RF and the H+ ATPase in vivo, co-
immunoprecipitation experiments were performed in collaboration with Dr. Vladimir
Marshansky. Towards this end, cytosol from the rat kidney was again incubated with
the NHE-RF specific antibody IC270 bound to protein A, which is covalently coupled
to an agarose matrix. Immunoprecipitates were then analyzed with antibodies against
the H+ ATPase. The E subunit of the H+ ATPase was co-immunoprecipitated from
kidney cytosol by the anti-NHE-RF antibody but not in the control where preimmune
serum was employed (Figure 10D). These experiments support that NHE-RF and the
cytoplasmic domain of the H+ ATPase bind to each other and give evidence that this
interaction takes place in vivo.
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3.3 Examination of NHE-RF in Human Cancer
The fact that NF2 mutations are only found in approximately 60% of meningiomas
suggests that a gene other than the NF2 gene is involved in the formation of some of
these tumors (Louis et al., 1995). Candidate genes encode proteins that are in the same
pathway as merlin such as the merlin binding protein NHE-RF. Could NHE-RF,
therefore, be inactivated in meningiomas in which merlin is not mutated? To pursue this
question, a possible inactivation of the NHE-RF gene was tested by molecular genetic
analyses. Moreover, the expression and localization of NHE-RF was investigated in
meningiomas and tumors deriving from other organs including colon, ovary and breast.
3.3.1 Expression of NHE-RF is Upregulated in a Subset of Breast Cancer Cell
Lines
Meningiomas that have no NF2 mutations were selected to determine whether the
merlin binding protein NHE-RF may play a role in the development of these tumors.
Mutations in the NHE-RF gene were sought by single strand conformation
polymorphism (SSCP) in thirty primary meningiomas of which twenty-one express
intact merlin. The status of merlin in the other tumors was not clear. Although four
polymorphisms were found, none of the tumors had any mutations. These observations
imply that mutations in NHE-RF do not play a role in the formation of the tested
tumors (data not shown).
The expression of NHE-RF was studied in ten primary meningioma cell lines
that express intact merlin. Seven meningioma cell lines that do not express merlin were
included in this study for comparison. In addition, a panel of other tumor cell lines
obtained from eleven colon carcinomas, four ovarian cancer and eight breast carcinomas
was examined for NHE-RF protein expression. Western blot analyses performed with
the NHE-RF antibody IC270 did not reveal significant differences between meningioma
cell lines that were positive or negative for merlin. Similarly, none of the examined colon
and ovarian cancer lines exhibited variations in NHE-RF expression (data not shown).
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Figure 11. Western Blot Analysis of Various
Mammary Epithelial and Breast Cancer Cell
Lines. Cells were grown to 85-95% confluency
in DMEM containing 10% fetal calf serum.
Three hundred µg of total cellular protein from
each cell line was subjected to 10% SDS-PAGE
gel electrophoresis, proteins were transferred to
nitrocellulose and probed for NHE-RF with the
polyclonal antibody IC270. The star (*)
indicates normal mammary epithelial breast cell
lines and the arrow indicates NHE-RF at ~50kD.
Therefore, these cell lines were not further analyzed with respect to NHE-RF
mutations or gene expression.
In contrast, three of the eight breast carcinoma cell lines showed an obvious and
dramatic increase in NHE-RF expression. As a control, six normal breast epithelial cell
lines were analyzed and none of these revealed high levels of expression. Ms. Denise
Pinney-Michalowski, a member of the laboratory of Dr. V. Ramesh, conducted Western
blot analyses of these cell lines. The intensity of the bands was further analyzed by
densitometric scanning of the autorads using transmittance analysis (Fluor-S,
Multiimager, BioRad) to compare the expression levels in these cell lines. Results from
three independent experiments revealed that the three cancer cell lines, MCF-7, ZR-75-
B and T-47-D, had 9.50±2.20 fold higher levels of NHE-RF when compared to the
normal mammary lines HBL-100 and MCF-12-F (Figure 11). No expression of NHE-
RF was detected in the breast cancer cell lines DU-447-S while moderate levels of
expression were seen in the breast cancer cell lines MDA-MB-231 and MCF-7-ADR (a
multidrug resistant cell line derived from MCF-7).
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To investigate whether upregulation of NHE-RF is also seen at the level of
transcription, Northern blot analysis was employed using total RNA from all eight
breast cancer lines together with the control breast epithelial cell lines MCF-12-F and
HBL-100. A 4.41±0.88 fold increase in NHE-RF RNA was observed in the cell lines
MCF-7, ZR-75-B, and T-47-D, compared to the controls MCF-12-F and HBL-100
(Figure 12A). Moreover, the detectable levels of NHE-RF RNA were little to none in
the cell lines MDA-MB-231, MCF-7-ADR and DU-447-S. The membranes were re-
probed with GAPDH to confirm that the increase in NHE-RF transcript did not reflect
variations in loading (Figure 12B). Interestingly, no increase of the related NHE-RF2
RNA was observed in any of the breast cancer lines examined (data not shown). Thus,
both mRNA and protein expression of NHE-RF were specifically increased in the three
breast cancer cell lines MCF-7, ZR-75-B and T-47-D.
Figure 12. Northern Blot Analysis of Various Mammary Epithelial and Breast Cancer
Cell Lines. Thirty-five micrograms total RNA from each cell line was subjected to
electrophoresis on a 1% agarose-formaldehyde gel and transferred to nitrocellulose. Membranes
were hybridized with 32P-labeled and ultra-purified full-length NHE-RF cDNA (A). As a control
for total RNA amount, membranes were stripped and rehybridized with 32P-labeled and ultra-
purified GAPDH cDNA (B). The star (*) indicates normal mammary epithelial breast cell lines.
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3.3.2 NHE-RF Expression is Regulated Through the Estrogen Receptor
Next, the mechanism by which NHE-RF expression is upregulated was sought.
Determining this mechanism was facilitated by the observation that the three cell lines
that show a dramatic increase in the expression of NHE-RF have been reported to be
estrogen receptor (ER)- positive (Arteaga et al., 1988). In addition, MDA-MB-231 and
MCF-7-ADR, where no elevated expression of NHE-RF was observed, are known to
be ER- negative (deFazio et al., 1992; Vickers et al., 1989. These findings suggested that
ER could play a regulatory role in NHE-RF expression. To test this hypothesis, both
MCF-7 (ER- positive) and MCF-7-ADR (ER- negative) cell lines were depleted of
estrogen and examined for expression of NHE-RF mRNA and protein compared with
matched, non-estrogen depleted lines. Expression of NHE-RF in estrogen-depleted
MCF-7 cells was found to be significantly reduced relative to the MCF-7 control cells
by Northern and Western blot analyses (Figure 13A, D, control and 0 h respectively).
No difference in the expression of NHE-RF was detected by either Northern blot
analysis in MCF-7-ADR cells grown in the presence and absence of estrogen (Figure
13C).
To further examine the estrogen responsiveness of NHE-RF expression, the
estrogen depleted MCF-7 and MCF-7-ADR cells were treated with the estrogen
analogue β-estradiol, and cells were harvested at various time points. Northern blot
analysis revealed that transcription of NHE-RF in MCF-7 cells is upregulated by about
two-fold as early as 1 hour after hormone treatment and remains above the basal level (0
h) up to at least 24 h after estrogen induction (Figure 13A). These membranes were also
re-probed with GAPDH to confirm that the increase in NHE-RF transcript did not
reflect variation in loading (Figure 13B). This phenomenon was not observed in the cell
line MCF-7-ADR (Figure 13C). To test whether the specific increase in NHE-RF
mRNA is a primary response to β-estradiol, similar experiments were carried out in the
presence of the antibiotic cycloheximide. This antibiotic interferes with the
translocation step by directly interacting with the translocase enzyme, thus inhibiting
protein synthesis in eukaryotes (http://www.calbiochem.com). These experiments
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Figure 13. Expression of NHE-RF is Induced by β-Estradiol in the cell line MCF-7. Cells
were plated and grown under standard conditions (control) or alternatively depleted of estrogen
by growing in estrogen-free medium for 3 days. These cells were then fed with estrogen free
medium supplemented with β-estradiol and harvested after 1h, 2h, 4h, 8h, 24h and 48h.
Northern blot analysis was performed as described in Figure 12 and the membranes were
hybridized with 32P labeled full-length NHE-RF cDNA, stripped and rehybridized with 32P-
labeled GAPDH cDNA (A). Western blot analysis of the same cells was performed and the
membrane was probed with the anti-NHE-RF monoclonal antibody 1D12. Induction of NHE-
RF at 10nM and 100nM estradiol are shown (B).
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showed that cycloheximide does not block the increase in NHE-RF mRNA in the ER-
positive cell line MCF-7 (data not shown). Therefore, the upregulation of NHE-RF is a
primary response to estrogen as opposed to being mediated by other proteins that are
induced by this hormone.
Western blot analysis was performed for the estrogen depleted and β-estradiol
induced cell lines (conducted by Ms. Denise Pinney-Michalowski, a member of the
laboratory of Dr. V. Ramesh). This analysis was aimed to examine the effect of this
estrogen analogue on NHE-RF protein expression at various time points. A 4.45±2.90
fold increase over the estrogen depleted level (0 h) of NHE-RF was seen in MCF-7 cells
treated with 10nM and 100nM β-estradiol for 24 and 48 hours (Figure 13D). Again, no
induction of NHE-RF was observed in the ER-negative cell line MCF-7-ADR by
Western blot analysis (data not shown) confirming the results of the Northern blot
analysis (Figure 13C).
Estrogen is known to increase the number and the length of microvilli at the cell
surface of MCF-7 cells 48 hours after treatment (Vic et al., 1982). Furthermore, NHE-
RF has been localized to microvilli, the finger-like structures at the surface of a cell
(Murthy et al., 1998). Therefore, the localization of NHE-RF was examined by indirect
immunofluorescence analysis in control MCF-7 cells, cells depleted of estrogen (0 h),
and cells stimulated with β-estradiol (48 h) (conducted by Dr. C. Agosti-Gonzalez).
NHE-RF was not detectable in estrogen depleted, non-induced MCF-7 cells (0 h) while
cells grown under regular conditions (control: non-depleted and always in the presence
of estrogen) showed NHE-RF localization in the few microvilli seen. In contrast, a
dramatic increase in NHE-RF was observed in the increased number of microvilli after
48 hours of β-estradiol induction (Figure 14). The ER-negative cell line MCF-7-ADR
did not reveal an increase in microvilli formation nor in NHE-RF staining when
subjected to the same analysis as its parental counterpart MCF-7 (data not shown).
Hence, the localization of NHE-RF to microvilli in MCF-7 cells closely correlates with
the effects of estrogen on cell cytoarchitecture and support the upregulation of NHE-
RF seen by Northern blot and Western blot analysis.
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Figure 14. Visualization of NHE-RF by Immunocytochemistry in β-Estradiol Induced Cells. Cells
were plated and grown under standard conditions (control); depleted of estrogen by growing in estrogen-
free medium for 3 days (0 h) and induced with 100nM β-estradiol (48 h). These cells were stained with
the affinity eluted anti-NHE-RF antibody IC270. Control cells show localization of NHE-RF in some
microvilli (arrows). Localization of NHE-RF is not detected in estrogen depleted and non-induced cells.
Stimulation of depleted cells with β-estradiol for 48 h shows a dramatic increase in NHE-RF in the
microvilli-rich apical surface of the cells. Bar, 5µm.
3.3.3 Expression of NHE-RF in Primary Breast Tumors
To ascertain that estrogen regulation of NHE-RF is also seen in vivo in breast cancer,
the analysis of NHE-RF expression was extended to primary breast tumor samples in
collaboration with Drs. Anat Stemmer-Rachamimov and David Louis from Molecular
Neuro-Oncology at Massachusetts General Hospital, Boston. Examination of sections
from eighteen infiltrating breast adenocarcinomas showed strong correlation between
positive immunostaining for ER and high expression of the NHE-RF protein: over 90%
(10/11) of the ER- positive tumors strongly expressed NHE-RF. On the other hand,
only 30% (2/7) of the ER- negative tumors showed strong expression of NHE-RF. In
ER positive tumors, immunostaining of NHE-RF was observed in most tumor cells,
contrasting the adjacent immunonegative stroma. NHE-RF protein is seen as
membranous staining, especially prominent at the luminal aspect of the cell (Figure
15A) and as diffuse cytoplasmic staining  (Figure 15B). Of the seven ER- negative
cancers, five showed very weak to absent NHE-RF staining (Figure 15C). The control
cells MCF-7 and MCF-7-ADR showed strong and weak expression, respectively, by
immunohistochemistry validating the data obtained in primary breast tumors (Figure
15D1, D2). Controls that included omission of primary antibody were negative (data
Control 0 h 48 h
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Figure 15. Expression of NHE-RF in ER-positive and ER-negative breast carcinomas by
immunohistochemistry. NHE-RF is strongly expressed in ER-positive breast carcinomas of
different patients: linear membranous pattern (A) or in a diffuse cytoplasmic pattern (B). Lack of
expression of NHE-RF in an ER-negative tumor (C). Formalin fixed, paraffin-embedded cell
pellets from MCF-7 and MCF-7-ADR cell lines used as positive controls show strong and
weak expression of NHE-RF respectively (D1 and D2).
not shown). Together, the results obtained from primary breast tumors show a strong
correlation between NHE-RF and ER expression supporting the data obtained in the
cell lines. In addition, these results suggest a role for NHE-RF in ER mediated signaling
in breast tumors.
  D1  D2 C
A   B
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3.4 Isolation and Characterization of Novel Merlin Binding Proteins
Although the NF2 gene was cloned in 1993, limited information about its protein
product merlin is available. Clues come from animal models such as mouse and fly as
well as from the identification of merlin binding proteins. To further define the role of
merlin as a tumor suppressor, additional merlin binding proteins were sought.
3.4.1 Identification of Merlin Binding Proteins by a Yeast Two-Hybrid Screen
A human fetal frontal cortex interaction library was screened with three different
(p)merbaits (merbait, merbait N and merbait C) by Dr. A. Murthy (Figure 16A). About
106 primary transformants were pooled and replated (at a multiplicity of 20) onto
galactose leu 2 selection plates. Thirty-three colonies, which showed galactose-
dependent growth and blue color on leu 2 plates and on 5-bromo-4-chloro-3-indolyl b-
D-galactopyranoside medium, respectively, were identified, and plasmids containing the
cDNA clones were isolated. Restriction mapping and hybridization experiments
revealed that these cDNAs were clustered into three different groups of overlapping
clones, representing three different cDNAs as recurrent, independent interactors. The
first of these cDNAs, merintC, the human homologue of a regulatory co-factor of the
Na+-H+ exchanger (NHE-RF), has been reported (Murthy et al., 1998).
In this study, the other cDNAs were characterized and provided mixed results.
MerintB interacts consistently in the yeast two-hybrid assay with the amino-terminal
and full-length merlin constructs (Figure 16B). The sequence analysis of this cDNA had
revealed that this is a novel gene and no entries in any databases were found at the time
it was isolated. However, recent database searches showed that merintB has been
cloned over the course of this work and entries for the human and mouse genes can be
found at GenBank/EMBL/DDBJ. The human gene for merintB encodes a 125 amino
acid protein and was named “similar to golgi-associated MP1 adapter protein”. The
sequence can be found under the accession number XM_017041. The mouse gene for
merintB is 99% identical to its human orthologue and was named “mitogen activated
protein binding protein interacting protein (Mapbpip)” or p14. This sequence can be
Results                                                                                                                                     78
Bait- MerintA- MerintB- MerintC-
(NHE-RF)
Merlin (Merbait)             +-             +-             +-
Merbait N -             +-             +-
Merbait C             +- - -
APP - - -
Bicoid - - -
CDC2 - - -
IQ GAP - - -
Neurofibromin (NF1) - - -
Figure 16. Isolation of Merlin Binding Proteins Using the Yeast-Two Hybrid
System. Schematic diagram of the merlin baits that were used to seek merlin binding
proteins (A). Table indicating the specificity of interactions. Controls were tested
under the same conditions as merlin baits and do not show any interaction with any of
the candidates (B).
found under the accession number NM_031248. Wunderlich et al. (2001) reported that
merintB/p14 associates with the cytoplasmic face of late endosomes/lysosomes in a
variety of different cell types and that it binds to MP1 (mitogen-activated protein
kinase (MAPK) partner 1. In our study, the interaction between merlin and merintB
was tested beyond the yeast two-hybrid system by other methods such as affinity
N terminal
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domain
Merbait
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aa 1 341 595
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precipitation assays. However, no binding could be detected in these experiments (data
not shown) and therefore merintB was not further characterized.
The final cDNA is a ~500 base pair fragment, which is referred to as merintA.
MerintA had been tested for associations in yeast strains containing either the amino-
(aa 1–341) or the carboxy- (aa 342–595) terminal portion of merlin as bait (conducted
by Dr. A. Murthy). Results of these tests indicated that merintA specifically associates
with full-length and carboxy-terminal merlin constructs but not with controls such as
APP, Bicoid, CDC2, IQ GAP or neurofibromin (NF1) (Figure 16B).
3.4.2 DNA Sequence Analysis and Isolation of a Full-length MerintA cDNA
To determine the identity of merintA and for subsequent analyses, the original cDNA
was cloned into pcDNA3 (Invitrogen). Towards this end, a restriction digest was
performed to release the cDNA out of the vector pJG4-5. This strategy ensures that
the sequence obtained has no errors introduced by Taq polymerase during polymerase
chain reaction (PCR). Furthermore, the hemagglutinin (HA) tag from pJG4-5 could be
carried along in fusion with the cDNA, which allows detecting the protein product of
merintA HA-tag antibodies. However, this strategy resulted in 270 additional base pairs
(or 90 amino acids) of vector sequence from pJG4-5 between the HA-tag and merintA.
Sequence analysis revealed that merintA is a novel gene, which has not been described
so far. The cDNA of merintA did not have a start codon in the reading frame indicating
that the 5’ end of this clone was not complete. The original cDNA did have a stop
codon in the open reading frame although the poly-A signal was missing. Thus, rapid
amplification of cDNA ends (5’ RACE) was performed from placenta and peripheral
blood mononuclear cells (PBMC) cDNAs to obtain the 5’ end of merintA. Clones from
two independent PCRs were analyzed to identify the sequence of the merintA cDNA.
Additional 36bp were obtained with a start codon and surrounding sequence that is
almost completely identical to the Kozak sequence. The combined sequence analysis of
the original cDNA from the yeast two-hybrid screen and the 5’ RACE revealed a novel
gene that encodes a protein of 178 amino acids (Figure 17A). The COILS2 program
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A    1 ggcacagcaaacatggcggctccactagggggtatgttttctgggcagccacccggtccc  60
      1             M  A  A  P  L  G  G  M  F  S  G  Q  P  P  G  P    16
     61 cctcaggccccgccgggccttccgggccaagcttcgcttcttcaggcagctccaggcgct 120
     17 P  Q  A  P  P  G  L  P  G  Q  A  S  L  L  Q  A  A  P  G  A    36
    121 cctagaccttccagcagtactttggtggacgagttggagtcatctttcgaggcttgcttt 180
     37 P  R  P  S  S  S  T  L  V  D  E  L  E  S  S  F  E  A  C  F    56
    181 gcatctctggtgagtcaggactatgtcaatggcaccgatcaggaagaaattcgaaccggt 240
     57 A  S  L  V  S  Q  D  Y  V  N  G  T  D  Q  E  E  I  R  T  G    76
    241 gttgatcagtgtatccagaagtttctggatattgcaagacagacagaatgttttttctta 300
     77 V  D  Q  C  I  Q  K  F  L  D  I  A  R  Q  T  E  C  F  F  L    96
    301 caaaaaagattgcagttatctgtccagaaaccagagcaagttatcaaagaggatgtgtca 360
     97 Q  K  R  L  Q  L  S  V  Q  K  P  E  Q  V  I  K  E  D  V  S   116
    361 gaactaaggaatgaattacagcggaaagatgcactagtccagaagcacttgacaaagctg 420
    117 E  L  R  N  E  L  Q  R  K  D  A  L  V  Q  K  H  L  T  K  L   136
    421 aggcattggcagcaggtgctggaggacatcaacgtgcagcacaaaaagcccgccgacatc 480
    137 R  H  W  Q  Q  V  L  E  D  I  N  V  Q  H  K  K  P  A  D  I   156
    481 cctcagggctccttggcctacctggagcaggcatctgccaacatccctgcacctctgaag 540
    157 P  Q  G  S  L  A  Y  L  E  Q  A  S  A  N  I  P  A  P  L  K   176
    541 ccaacgtgagcaaagggcagaggcagttggcctatgagtgggctgatgcgtgaggttggc 600
    177 P  T  *
        cacacattccttcctgtggacttgacattttggaagaactctttgccagataatgagttc
        attttagttttatgctcccattgaaaaattttccactatttttataagctgttaatttct
        tgagtactttataacatgtctgtagcttggataaaccaagtaagtattttttttttgtct
        ttagcaaagtttagactgtgaatatgatgacacagattcttttttatggtggctttgctt
        gttttaaatttttgcatgacttttcatctttttatgtgtgtttcctgtagtttgatccga
        aggaaaagagtatagtagcctgagaatcaggagatgggagttttagtcgtaggccttatg
        ataattaccccgcggtggtgtgtagaaaagtatgtaaatttgctctgttttaagactttg
        aactacctcaagaagaggaatctaatacaatatttgtaatgttt
B
Figure 17. cDNA Sequence and Genomic Structure of the MerintA Gene. Nucleotide
and derived protein sequences of the human merintA cDNA. The nucleotide sequences of
exons 1 and 3 are depicted in red and the nucleotide sequences of exons 2 and 4 are depicted
in blue. The predicted Grb2 binding motif is boxed (A). Schematic diagram of the predicted
intron and exon segments comprising the merintA gene. Boxes indicate exons and are
numbered sequentially from 5’ to 3’ (B).
1 kb
1 2 3 4
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 (http://tofu.tamu.edu/Pise/5.a/coils2.html) predicted a coiled-coil domain between
amino acids 109 and 145 of the merintA sequence. Moreover, several glycine and
proline residues reside at the amino-terminus of the protein generating a low-complexity
region. When the sequence data was first obtained, no matches were found in the
databases; however, during the course of this study, further database analyses identified
a genomic clone (AC006160) and revealed that the human merintA gene resides at
chromosome locus 4p15.3. Furthermore, a comparison of the transcribed and genomic
sequences predicts that the merintA gene consists of four exons (Figure 17B). At least
eight partial or complete processed pseudogenes at different locations in the human
genome can be found. However, these pseudogenes are all degenerated, containing
interspersed stop codons, and it is questionable that any of these are expressed. No
other expressed genes producing proteins related to merintA have been found to date,
making it a novel protein unassociated with any known functional families. Through the
course of this study three mRNA sequences, which match that of merintA were
deposited at GenBank/EMBL/DDBJ with accession numbers AF317679, AF358829
and AF321617. These entries are 1069bp, 1363bp and 3109bp sequences although the
open reading frames are identical among themselves and to merintA differing only in the
length of the untranslated regions. Information submitted to GenBank/EMBL/DDBJ for
AF317679 suggests that merintA is tumor-related protein while AF358829 indicates
that merintA may play some role as a tumor angiogenesis marker. No other information
has been reported to date.
Further database analyses identified anonymous, predicted orthologues in mouse
(BAB23039), cow (AW357991 and AW (464009), zebrafish (AI942663 and
AI884138) and fly (AAF56470) while no orthologues were immediately evident in
worm or yeast. MerintA is highly conserved in vertebrates with only 10 residue
differences. Six of these are conservative between human and mouse and three of the
four non-conservative changes occur in the low complexity amino-terminal region. The
zebrafish and fly orthologues are 76 and 43 % identical to the human protein (Figure
18). Thus, merintA is a novel gene that is conserved in various species and encodes a
protein of unknown function.
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                1                                                   50
 HUMAN MerintA  MAAPLGGMFS GQ.PPGP.PQ APPGLPGQAS LLQAAPGAPR PSSSTLVDEL
 MOUSE MerintA  MAASLGGMFT GQ.PPGP.PP PPPGLPGQAS LLQAAPGAPR PSNSTLVDEL
 COW   MerintA  MAAPLGGMFS GQ.PPGP.PQ PPPGLLGQAS LLQATPGVPR TSNSTLVDEL
 FISH  MerintA  MASSMGGLFP GQQPPGSLPP SGPGGPGQPG LLTGTPG.NR GANNTLVDEL
 FLY   MerintA  .......... .......... .......... .....MASNE SGGGNLMDEF
                51                                                 100
 HUMAN MerintA  ESSFEACFAS LVSQDYVNGT DQEEIRTGVD QCIQKFLDIA RQTECFFLQK
 MOUSE MerintA  ESSFEACFAS LVSQDYVNGT DQEEIRTGVD QCIQKFLDIA RQTECFFLQK
 COW   MerintA  ESSFEACFAS LVSQDYVNGT DQEEIRTGVD QCIQKFLDIA RQTECFFLQK
 FISH  MerintA  EASFEACFAS LVSQDYVNGT DQEEIRTGVD QCIQKVLDVA RQTECFFLQK
 FLY   MerintA  EEAFQSCLLT LTKQEPNSGT NKEEIDLEVQ KTTNRFIDVA RQMEAFFLQK
                101                                                150
 HUMAN MerintA  RLQLSVQKPE QVIKEDVSEL RNELQRKDAL VQKHLTKLRH WQQVLEDINV
 MOUSE MerintA  RLQLSVQKPD QVIKEDVSEL RSELQRKDAL VQKHLTKLRH WQQVLEDINV
 COW   MerintA  RLQLSVQKPE QVIKEDVSEL RNELQRKDAL VQKHLTKLRH WQQVLEDINM
 FISH  MerintA  RLQLSVQKPE QVEKEDASEL KNELQRKEML IQKHLAKIHH WQQVLEDINV
 FLY   MerintA  RFLVSTLKPY MLIKDENQDL SIEIQRKEAL LQKHYNRLEE WKACLSDIQQ
                151                                                200
 HUMAN MerintA  Q.HKKPAD.. ...IPQGSLA YLEQASANIP APLKPT.... ..........
 MOUSE MerintA  Q.HKKPAD.. ...MPQGSLA FLEQASANIP APLKQT.... ..........
 COW   MerintA  Q.HKKPAD.. ...IPQGSLA YLEQASANIP APMKQT.... ..........
 FISH  MerintA  Q.HKKPTE.. ...LPQGPLA FLEQASANLP APMKPN.... ..........
 FLY   MerintA  GVHSRPTPPI GSGMLQGPGG GMPPMGGTPP RPGMMPGMPP GAMQPGGPMQ
                201                    224
 HUMAN MerintA  .......... .......... ....
 MOUSE MerintA  .......... .......... ....
 COW   MerintA  .......... .......... ....
 FISH  MerintA  .......... .......... ....
 FLY   MerintA  PSPHMLQAQQ MQQLRMISRQ MPPK
Figure 18. Alignment on MerintA Orthologues. The protein sequence of human merintA was
aligned with the predicted sequences of mouse, cow, fish and fly merintA using multalin at
http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_multalin.html . The
complete sequences of the human, mouse, and fly proteins are available at the following
GenBank accesion numbers: Homo sapiens (AAK32724), Mus musculus (BAB23039) and
Drosophila melanogaster (AAF56470). MerintA EST sequences are available for cow and fish:
Bos taurus (AW357991 and AW464009) and Danio rerio (AI942663 and AI884138). A
contiguous sequence was assembled from the cow and fish EST sequences and the open reading
frame was translated into the respective protein sequence. While the (p)YVNG Grb2 binding
motif is conserved in mouse, cow and fish it is of interest to note that it is not present in fly.
3.4.3 MerintA is Widely Expressed in Cells and Tissues
To investigate the merintA protein mono- and polyclonal antibodies were generated.
Mice were immunized with a GST-merintA fusion protein (aa 13-178). Ms. Nicole
Smith, a member of the laboratory of Dr. V. Ramesh fused the spleen of a responding
mouse to SP2 cells and the resulting monoclonal antibody was named 7E1. This
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antibody recognizes a predominant band at ~24kD (Figure 19A), which is slightly larger
than predicted (20kD) from the open reading frame. This 24kD polypeptide
disappeared upon preabsorbing the antibody with purified merintA protein. Polyclonal
anti-merintA antibodies were generated by immunizing rabbits with keyhole limpet
hemocyanin- (KLH) conjugated peptides from the amino-terminal (aa 9-23), central (aa
114-125) and carboxy-terminal (aa 165- 178) regions of merintA. The peptides were
synthesized and injected by Research Genetics Inc, Huntsville. Bleeds collected ten
weeks after immunization from all animals were tested and gave mixed results. While
the bleeds of the animals injected with the amino-terminal and central region of merintA
showed little to no response, the carboxy-terminal bleed responded well resulting in the
polyclonal antiserum Tim3. The specificity of the antibodies 7E1 and Tim3 was further
confirmed by immunoprecipitation experiments. Towards this end, Tim3 was
employed to immunoprecipitate merintA and the monoclonal antibody 7E1 recognized
the same 24kD protein in the following Western blot analysis (Figure 19B, lane 2). Two
important controls ensure specificity of the antibody used to immunoprecipitate and
the signal detected by the antibody used for Western blot analysis. Therefore,
immunoprecipitation experiments were carried out with Tim3 but the cell lysate was
substituted with lysis buffer (Figure 19B, lane 3). No signal was detected in this control
indicating that the band detected in the complete reaction represents merintA as
opposed to the light chain of Tim3 that approximately co-migrates with merintA during
gel electrophoresis. A non-specific antibody (pre-immune serum) was employed as a
second control and no signal was detected here, demonstrating that Tim3 specifically
immunoprecipitates merintA (Figure 19B, lane 4).
Next, full-length HA-tagged merintA protein was overexpressed in CAD (Cath
a-differentiated) cells. Protein lysates were subjected to Western blot analysis and
membranes were probed with a HA-tag antibody (12CA5, Roche). This fusion protein
migrates slightly slower than endogenous merintA presumably due to the tag. This band
is not seen upon transfection of vector alone (Figure 19C). The antibodies 7E1 and
Tim3 also recognize the overexpressed protein (data not shown). Thus, specificity of
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Figure 19. Characterization of MerintA Antibodies and HA-MerintA. CAD cell lysates
were fractionated on a 12% SDS-polyacrylamide gel and blotted onto nitrocellulose. Strips of
this blot were immunoprobed with the monoclonal antibody 7E1 (lane 1) and preabsorbed 7E1
(lane2). A specific band of 24kD is detected, which represents merintA (A). CAD cell lysates
were subjected to immunoprecipitation with the rabbit polyclonal anti-peptide antibody (Tim3).
Precipitates were immunoprobed with the monoclonal antibody 7E1. Lane 1 shows a positive
control where a total CAD cell lysate was examined. Lane 2 shows the complete reaction where
Tim3 immunoprecipitated merintA form the cell lysate. Lane 3 shows a control with the Tim3
antibody but no lysate, and lane 4 shows a control with lysate but a non-specific antibody (B).
CAD cell lysates overexpressing HA-tagged merintA (lane 1) and vector alone (lane 2) were
immunoprobed with the HA-antibody 12CA5 (C).
the two independent merintA antibodies (Tim3 and 7E1) was confirmed since they
detect the same 24kD endogenous protein. Moreover, the antibodies detect the same
band as HA-tag antibodies upon overexpession of full-length HA-merintA (A4).
To investigate the length of the merintA transcript as well as developmental and
tissue distribution of merintA on the level of RNA, fetal and adult human multiple-
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tissue RNA blots (Clontech) were probed with the 32P labeled merintA cDNA.
Multiple transcripts with sizes of ~1, ~1.3, ~3.4 and ~6.3kb were detected in the adult
human tissues. Strongest levels of expression were detected in skeletal muscle and heart
where all transcripts are expressed. Less expression was seen in brain, placenta, lung,
liver, kidney and pancreas. Furthermore, the ~1.3kb transcript was below detectable
levels in these tissues (Figure 20A). The same ~1 and ~1.3kb in addition to a ~3.2kb
transcript was detected in fetal human tissues. Interestingly, the sizes of these
transcripts match those deposited in GenBank indicating that they all translate into the
same protein and differ only in the untranslated regions. Again, all transcripts were
expressed in all the tested fetal tissues brain, lung, liver and kidney (Figure 20B). Thus,
merintA is widely expressed in various tissues and has different transcripts. Here, the
1kb transcript was isolated which results in the expression of the merlin binding protein
merintA.
The expression and distribution of endogenous merintA was examined next in
various cell lines by Western blot analysis. Analysis of normalized protein lysates
indicate that merintA is expressed in many of the tested cell lines including CAD
(mouse neural cells), Met5A (mesothelioma), H237 (glioma), 293T (kidney), Cos-7
(kidney), HeLa (adenocarcinoma; cervix) and RD135 (fibroblast). It is of interest to
note that merintA is hardly expressed in merlin positive or negative meningioma cell
lines (Figure 20C, lane 1 and 2). However, a ~50kD band is detected in these and some
other cell lines with 7E1. This species was not further characterized but it may
represent a potential alternatively spliced merintA isoform, a strong dimer that resists
the denaturing conditions of SDS-PAGE, a closely related protein or an unrelated
protein with a conserved epitope. Furthermore, the expression of merintA was
examined at different stages of rat development by quantitative Western blot analysis.
Interestingly, levels of merintA expression decreased from embryo to newborn and
adult (data not shown). These findings suggest that merintA is of general importance
during development and might play a significant role in cell proliferation and/or
differentiation.
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 A B
C
Figure 20. Expression of MerintA in Different Tissues and Cell Lines. A multiple tissue
poly(A)+ RNA blot (Clontech) was probed with 32P- labeled merintA cDNA as recommended by
the manufacturer (A). Western blot analysis reveals that merintA is expressed as a 24kD protein.
Equal amounts of protein lysates (NP40) were separated on 12% SDS-PAGE and
immunoblotted with the monoclonal antibody 7E1 (B).
Human Multiple
Tissues
Fetal Multiple
Tissues
9.5 kb -
7.5 kb -
4.4 kb -
2.4 kb -
1.35 kb -
- 
he
ar
t
- 
br
ai
n
- 
pl
ac
en
ta
- 
lu
ng
- 
liv
er
- 
sk
. m
us
cl
e
- 
ki
dn
ey
- 
pa
nc
re
as
- 
liv
er
- 
br
ai
n
- 
lu
ng
- 
ki
dn
ey
9.5 kb -
7.5 kb -
4.4 kb -
2.4 kb -
1.35 kb -
220 kD -
97 kD -
66 kD -
46 kD -
30 kD -
21 kD -
14 kD -
- 
29
3T
- 
F2
93
- 
M
N
53
- 
C
A
D
- 
M
et
5A
- 
H
23
7
- 
G
23
8
- 
C
os
-7
- H
eL
a
- 
M
R
C
5
- 
R
D
13
5
- 
M
N
52
Results                                                                                                                                     87
During the course of this study a number of expressed sequence tags (ESTs)
identical in part to merintA were deposited in public databases. These database
searches confirm that merintA is expressed in a broad spectrum of tissues and cells
which include adrenal gland, aorta, B-cells, brain, breast, cervix, central nervous system,
colon, foreskin, gall bladder, germ cell, heart, kidney, lung, ovary, pancreas, parathyroid,
prostate, stomach, testis, tonsil and uterus from adult cDNA sources. Strong expression
of merintA was also confirmed in the following fetal tissues: whole embryo, bone,
brain, breast, cervix, colon, connective tissue, eye, genitourinary tract, kidney, liver,
lung, marrow, muscle, ovary, placenta, prostate, skin, spleen, testis, thymus, thyroid
and uterus (http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&CID=33032). It
is also of interest to note that merintA fragments were also isolated from a large number
of different tumors originating from organs such as brain, (glioblastoma and
neuroblastoma), eye (retinoblastoma), placenta (choriocarcinoma), lung (small cell
carcimoma), testis (embryonal carcinoma), uterus, colon, liver (hepatocellular
carcinoma) and mammary (gross tissue tumor). In conclusion, the merlin binding protein
merintA is ubiquitously expressed in normal and tumor tissues.
3.4.4 Merlin but not Moesin binds to MerintA In Vitro and In Vivo
To confirm the association between merlin and merintA beyond the yeast two-hybrid
system, in vitro binding assays were performed. These experiments were conducted
prior to isolating the full-length cDNA of merintA and generating antibodies against
merintA. However, the results are presented together with in vivo binding studies (co-
immunoprecipitation) using merintA specific antibodies to demonstrate the interaction
of merintA and merlin.
First, GST-merlin was used to precipitate merintA that was expressed in
mammalian cells. The HA-tagged merintA expressed in Cos-7 cells encoded amino acids
13-178. Additional 90 amino acids deriving from the vector sequence (pJG4-5) were
expressed between the HA-tag and merintA as a fusion protein. Thus, this protein
migrates above the 30kD marker, which is slower than the endogenous full-length
protein. Cell lysates expressing epitope tagged merintA were tested for there ability to
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bind with different segments of merlin expressed as bacterial GST fusion proteins and
immobilized on Sepharose beads. The bound protein was detected in immunoblots,
using an anti-HA antibody (hybridoma supernatant provided by Dr. Ed Harlow).
MerintA bound specifically to the carboxy-terminal and full-length merlin fusion
proteins, but did not bind to either the amino-terminus of merlin or to GST alone
(Figure 21A). The results further demonstrate that the carboxy-terminal GST fusion
protein of merlin isoform 2 captured more merintA than the truncated carboxy-terminal
protein common to both isoforms. Less merintA was captured by the carboxy-terminal
GST fusion protein of isoform 1 compared to the other carboxy-terminal proteins.
These results were confirmed by three independent experiments.
For the reciprocal experiment, merlin isoforms 1 and 2 were expressed as
FLAG-tagged proteins in 293T cells, which were then utilized in affinity binding assays
with GST-merintA fusion protein. The FLAG-tagged merlin isoform proteins were
examined by Western blot analysis with an anti-FLAG antibody (M2, Sigma) prior to
the affinity binding assay to ensure equal expression. Cell lysates, expressing
approximately the same amount of merlin isoform 1 and 2, were then incubated with
GST-merintA or GST alone bound to beads. The proteins that precipitated with the
beads were again analyzed by Western blot analysis for the presence of merlin with the
M2 antibody. These experiments demonstrated that merlin isoforms expressed in
mammalian cells also bind differentially to merintA (data not shown). GST-merintA
also captured more merlin isoform 2 than isoform1. Western blots were stained with
Ponceau-S for total proteins before probing with the FLAG-antibody. This staining
confirmed that equal amounts of GST fusion proteins and GST alone were bound to the
beads in the experiments (data not shown).
To test whether merintA binds exclusively to merlin and not to ERM family
members, different segments of moesin, expressed as bacterial GST fusion proteins,
were tested as a representative. No binding of merintA to moesin was detected in this
assay (Figure 21B). Thus, as was predicted by the two-hybrid analysis, merintA
associates with the carboxy-terminal but not with the amino-terminal domain of merlin.
Moreover, as predicted by sequence comparison merintA binds specifically to merlin
but not to moesin.
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A
B
Figure 21. Binding of MerintA to Merlin but not to Moesin. NP40 lysates from Cos-7 cells
overexpressing HA-merintA were incubated with various GST-merlin fusion proteins
immobilized on glutathione Sepharose 4B beads. The beads were washed extensively, and bound
proteins were separated on 10% SDS-PAGE and immunoblotted with an anti-HA antibody (A).
The same assay was performed as in (A). However, various GST-moesin fusion proteins were
tested for binding to merintA. Full-length merlin isoform 2 was used as positive control (B).
Note: The HA-tagged merintA expressed in Cos-7 cells encoded amino acids 13-178. Additional
90 amino acids deriving from the vector sequence (pJG4-5) were expressed between the HA-tag
and merintA as a fusion protein. Thus, this protein migrates above the 30kD marker, which is
slower that the endogenous full-length protein.
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Figure 22. MerintA Binds to Merlin in vivo. A specific antibody (pAb: N21) was employed
to immunoprecipitate merlin from CAD cell lysates followed by fractionation of the
immunoprecipitates by 12% SDS-PAGE. Immunoblotting was performed for merlin (mAb
1C4) and merintA (mAb 7E1). Control lanes show N21 used without cell lysate (N21+buffer)
and cell lysate employed with a non-specific antibody (NRS: normal rabbit serum).
Finally, co-immunoprecipitation experiments were conducted to test if the
association between merlin and merintA also takes place in vivo. Towards this end, full-
length merlin isoform 2 was overexpressed in CAD cells and cell lysates were incubated
with a merlin antibody bound to protein A that is covalently coupled to an agarose
matrix. Immunoprecipitates were tested for the presence of merlin as an internal control
with a second merlin-specific antibody. In addition, merintA could be detected in these
samples in three independent experiments indicating that it co-immunoprecipitated with
merlin (Figure 22). Two controls ensure specificity of the antibody used to
immunoprecipitate, and the signal detected by the antibody used for Western blot
analysis. Immunoprecipitation experiments were carried out with the merlin antibody
but the cell lysate was substituted with lysis buffer (Figure 22, lane 2). No signal was
detected in this control indicating that the band detected in the complete reaction
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represents merintA as opposed to the light chain of immunoprecipitating antibody that
approximately co-migrates with merintA during gel electrophoresis. A non-specific
antibody (normal rabbit serum) was employed in the second control and again no signal
was detected, demonstrating specificity of these co-immunoprecipitation experiments
(Figure 22, lane 3). Thus, merintA and merlin interact beyond the yeast-two hybrid
system in vitro and in vivo.
3.4.5 MerintA Localization and Co-localizaton with Merlin
Previously, members of the Ramesh laboratory localized endogenous merlin to
submembranous regions with an enrichment in motile regions, such as leading or ruffling
edges in human fibroblast and meningioma cells. Merlin was also co-localized with F-
actin in these motile regions but did not associate with stress fibers (Gonzalez-Agosti et
al., 1996). This localization pattern of merlin has been confirmed by a number of other
studies (Deguen et al., 1998; den Bakker et al., 1995; Sainio et al., 1997; Shaw et al.,
1998). In addition, the localization of merlin is in agreement with the direct and indirect
interactions of merlin with the actin cytoskeleton and integral membrane proteins.
CAD cells were transiently transfected to express full-length HA-tagged
merintA (A4) and GFP-merlin isoform 1 or 2 to examine the localization of these
proteins. In these cells, merintA specifically localizes to submembranous regions and
neurites (Figure 23, B+E). The co-transfection of epitope tagged merintA and GFP-
merlin permitted comparison of the distribution of merintA with merlin isoform 1 or 2.
This staining revealed that merintA co-localizes precisely with merlin isoform 2 in
submembranous regions and neurites (Figure 23). Similar results were obtained in cells
that were examined for co-localization of merintA and GFP merlin isoform 1 (data not
shown). Furthermore, merintA was transfected alone into CAD cells to test if the
observed localization is dependent on GFP-merlin. MerintA showed identical staining
patterns in these singly transfected cells compared to the double transfected cells. Again
merintA localized to submembranous regions and neurites of CAD cells (data not
shown).
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Figure 23. Localization of GFP-Merlin and HA-tagged MerintA (A4). GFP-merlin isoform 2 (A
and D) was directly visualized in CAD cells that were also stained with 12CA5 (B and E). Merged
images (C and F). Merlin co-localizes with merintA in neurites and underneath the plasma
membrane. Bar, 10µm.
The localization studies of merlin and merintA resulted in two other
observations and both occurred in single (merintA alone) and double transfected cells.
First, many of the cells that stained positive showed membrane blebbing as opposed to
neighboring cells that did not stain presumably because they did not express epitop
tagged merintA and merlin. Cells undergoing apoptosis are characterized by phenotypes
such as membrane blebbing as well as condensation of the nuclei, fragmentation of
chromatin at nucleosome linkage sites and the formation of apoptotic bodies (Merino et
al., 1998). Second, a high percentage of cells that expressed epitope tagged merintA died
~48 hours after tranfection. To test if merintA could be involved in programmed cell
death, transfected cells were analyzed for nuclear condensation by staining with
Hoechst 33342 (Sigma). This fluorescent dye specifically stains the nucleus of cells and
allows comparison of cells that express epitope tagged merintA with neighboring cells
that do not express these proteins. No condensation of nuclei was observed in these
transfected cells that expressed merintA alone or co-expressed merintA and merlin (data
not shown). An involvement of merintA or merlin in apoptosis thus appears unlikely.
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Figure 24. Endogenous Localization of MerintA. CAD cells were stained with 7E1 (A and
B) and no primary antibody (C). Endogenous merintA localizes in neurites and underneath the
plasma membrane. Bar, 10µm.
The localization pattern of exogenous merintA could be confirmed when CAD
cells were stained with the monoclonal antibody 7E1 for visualization of the
endogenous protein. Again, the protein was localized to submembranous regions and
neurites (Figure 24A+B) whereas no specific staining was obtained when the primary
antibody was omitted (Figure 24C). In conclusion, merintA co-localizes with merlin in
CAD cells and thus fulfills this requirement of a merlin binding protein in vivo.
3.4.6 MerintA Associates with the Actin Cytoskeleton
Previously, members of the Ramesh laboratory have co-localized merlin with F-actin
and the physical interaction between merlin and actin was characterized in detail during
the course of this study (Gonzalez-Agosti et al., 1996; James et al., 2001). Merlin lacks
the high-affinity actin-binding site present in the carboxy-terminal end of ERM proteins
(Huang et al., 1998). However, it can bind actin either directly through a low-affinity
binding site in the carboxy-terminal end of its FERM-domain (residues 178-367) (Xu
H. et al., 1998; James et al., 2001), or indirectly via the actin-binding protein βII-
spectrin (Scoles et al., 1998).
Since the localization patterns of merintA and merlin are extremely similar, a
possible relationship between merintA and actin was examined by immunofluorescence
studies. CAD cells expressing HA-merintA were stained with HA-tag antibody 12CA5
BA C
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Figure 25. Localization of HA-tagged MerintA (A4) and Actin. CAD cells were
stained with 12CA5 (A and D) and rhodamine phalloidin (B and E). Merged images (C
and F). MerintA co-localizes with actin in neurites and underneath the plasma membrane.
Bar, 10µm.
and with rhodamine phalloidin for actin. A strong co-localization of merintA with actin
is observed in these cells in neurites and underneath the plasma membrane (Figure 25).
These data imply that merintA and actin can associate directly or indirectly.
Merlin is detergent (Triton X-100) insoluble, indicating an ability to interact
with the cytoskeleton (Deguen et al., 1998; Stokowski et al., 2000). Here, merintA was
tested for an association with the cytoskeleton by similar fractionation experiments.
Therefore, FLAG-tagged merlin isoform 2 and HA-tagged merintA were co-expressed in
CAD cells. As expected, merlin fractionated in the insoluble moiety. MerintA was
analyzed with the monoclonal antibody 7E1 to detect exogenous and endogenous
proteins. Both proteins were found in the insoluble/cytoskeletal fraction (Figure 26).
These investigations indicate that merintA is associated (directly or indirectly) to the
actin cytoskeleton.
The co-localization and co-fractionation of actin and merintA led to the question
whether merintA can bind actin directly or whether this association is mediated through
other proteins such as merlin. Therefore, purified F-actin and merintA were submitted
to high g-forces that cause purified actin filaments to pellet. The results of these
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Figure 26. Analysis of Merlin and MerintA Protein Solubility. CAD cells were
transfected with FLAG-merlin (isoform 2) and HA-merintA (A4) constructs, and cell lysates
were recovered 48 hours after transfection. Total amounts of soluble (S) and insoluble (I)
protein were separated on 12% SDS-PAGE and immunoblotted for merlin (1C4) and for
merintA (7E1). Merlin and merintA localize to the insoluble cytoskeletal fraction.
experiments were inconclusive since merintA showed strong sedimentation in the
absence of actin (data not shown). Next, a solid phase binding assay was utilized to test
if merintA can bind to actin directly. Here, purified GST-merintA, GST-merlin or GST
alone was coated in wells of plates and overlayed with purified F-actin. The samples
were analyzed for the presence of actin after extensive washing. A two-fold increase in
binding of actin to merintA was detected by ELISA over the background from the
negative control (GST alone). In contrast, a five-fold increase in binding to merlin was
detected by this assay. These experiments indicate moderate direct binding of merintA
with actin.
The association of merintA with the cytoskeleton was further investigated by
immuno-electron microscopy. These studies were carried out in collaboration with Drs.
Ralph Neujahr and John Hartwig from the Division of Experimental Medicine, at the
Brigham and Women’s Hospital, Boston. Immunogold staining of CAD cells with the
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Figure 27. Localization of MerintA in a Neurite of a CAD Cell Determined by Electron
Microscopy. MerintA was detected in the Triton X-100 insoluble cytoskeleton from a CAD cell
using the merintA specific monoclonal antibody 7E1 followed by 10nm colloidal gold particles
conjugated to secondary antibodies. Immunogold-labeled specimens were photographed after
rapid freezing, freeze-drying, and tantalum-tungsten and carbon coating in a Jeol 1200-EX
electron microscope. Bar, 200nm.
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monoclonal antibody 7E1 showed that endogenous merintA resides on cortical actin
filaments. MerintA is evenly distributed along these filaments and does not localize
preferentially to substructures such as branching points or filament ends. Extensive
staining of merintA can also be seen along the actin cytoskeleton within neurites (Figure
27). Next, CAD cells were investigated for merintA and merlin co-staining by immuno-
electron microscopy. MerintA was again detected with 7E1 followed by 10nm colloidal
gold particles conjugated to secondary antibodies while merlin was detected with the
polyclonal antibody A19 followed by 5nm gold particles conjugated to secondary
antibodies. MerintA and merlin co-localize in the cortex of the cytoskeleton from CAD
cells. However, there are areas where distinct merintA and merlin staining, respectively,
is seen at this subcellular resolution (Figure 28A). The primary antibodies were omitted
in the negative control that shows no gold particles (Figure 28B). This distribution
suggests that merintA was targeted to this location either through merlin, through other
binding proteins or through independent actin-binding sites. Moreover, these results
support a physiological relevance of the interaction between actin, merintA and merlin.
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Figure 28. Co-localization of MerintA and
Merlin in the Cortex of a CAD Cell
Determined by Electron Microscopy.
MerintA and Merlin were detected in the
Triton X-100 insoluble cytoskeleton from a
CAD cell using the merintA specific
monoclonal antibody 7E1 and the polyclonal
merlin antibody A19 (Santa Cruz) followed
by 10nm and 5nm colloidal gold particles
conjugated to secondary antibodies. MerintA
and merlin co-localize in many areas along
the cytoskeleton (arrows). However, some
regions show distinct merintA and merlin
staining (arrowhead). Bar, 100nm (A). CAD
cells were treated as above except for the
omission of primary antibodies. No staining
can be detected. Bar, 100nm (B).
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3.4.7 MerintA Binds to Grb2
GenBank database searches did not associate merintA with any known functional
protein families. Therefore, other databases were searched extensively to obtain clues of
merintA function. Analysis of the merintA sequence for the occurrence of ProSite
patterns (http://ca.expasy.org/tools/scnpsit1.html) predicted one N-glycosylation site
(aa 66-69 NGTD) and three N-myristorylation sites (aa 6-11: GGMFSG; aa 7-12:
GMFSGQ; aa 76-81: GVDQCI). The phophorylation prediction program NetPhos2.0
(http://www.cbs.dtu.dk/services/NetPhos/) identified six serine, two threonine and one
tyrosine residue (Y64) that could be phosphorylated. The consensus sequences of
different protein kinases were scanned against the merintA sequence for potential
phosphorylation sites at
http://www.cbs.dtu.dk/databases/PhosphoBase/predict/predform.html. The results of
this analysis can be found in Table 4 and they predict several potential
phosphorylation sites and the kinases including calmodulin-dependent protein kinase II
(CaM II), casein kinase I (CK I), casein kinase II (CK II) and protein kinase A (PKA).
Finally, merintA was examined with Scansite (http://cansite.bidmc.harvard.edu)
to predict protein motifs and binding sites. Here, the binding motif for the Src
homology 2 (SH2-) domain of the growth factor receptor bound 2 (Grb2) protein was
found in a high stringency scan between amino acids 63 and 67 (Y64 of merintA). The
consensus sequence of this binding motif is pYV/INX (Schlessinger, 1994) and only
0.13% of all proteins can be found in SwissProt with this motif.
Grb2 is 25kD protein that localizes in submembranous regions and membrane
ruffles of the cell (Bar-Sagi et al., 1993). It is composed of one SH2-domain flanked by
two Src homology 3 (SH3-) domains. The SH2-domain has been shown to bind to a
number of autophosphorylated receptor protein tyrosine kinases (RTKs) and several
cytoplasmic proteins, including Shc, SHP-2, Syp and Bcr-Abl, in a tyrosine
phosphorylation-dependent manner (Buday, 1999; Li et al., 1994; Pendergast et al.,
1993). The SH3-domains on the other hand are known to physically associate with
proline-rich proteins including the Ras guanine-nucleotide exchange factor, Sos and
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Kinase Consensus Sequence Potential Phosphorylation
Sites of MerintA
CaM II R-X-X-S/T-X S-41 RPSSSTL
CK I * Sp/Tp-X2-3-S/T-X T-43 SSSTLVD
S-61 SLVSQDY
CK II X-S/T-X-X-D/E T-43 SSSTLVD
S-50 ELESSFE
T-68 VNGTDQE
T-75 EIRTGVD
GSK3 X-S/T-X-X-X-Sp non
MLCK X-K-K-R-X-X-S-X non
p34cdc2 X-S/T-P-X-R/K non
p70s6k K/R-X-R-X-X-S/T-X non
PKA R-X1-2-S/T-X S-41 RPSSSTL
T-91 RQTECF
PKC X-S/T-X-R/K non
PKG (R/K)2-3-X-S/T-X non
Table 4. List of Protein Kinases and Consensus Sequences for Potential
Phosphorylation Sites of MerintA. Predicted phosphorylation sites were obtained for
merintA at   http://www.cbs.dty.dk/databases/PhosphoBase/predict/predform.html. The
consensus sequences of individual kinases and potential phosphorylation sites of merintA are
shown. (* Amino-terminal serine/threonine must be prephosphorylated for the potential
phosphorylation sites of the protein kinase CKI).
N-WASP (Buday, 1999). For example, the Grb2-Sos complex binds to the
autophosphorylated EGF receptor (EGFR) upon EGF stimulation. This complex
formation brings the exchange factor Sos into contact with its substrate Ras at the
plasma membrane. Thus, Ras is activated through the formation of a ternary complex of
EGFR-Sos-Grb2 and a signal is transmitted to other effector molecules such as Rac
(Buday, 1999). Although this is a well-characterized signaling pathway, Grb2 is also
involved in the activation of many others. While most studies indicate that the tyrosine
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Figure 29. MerintA Binds Grb2 In Vitro.
NP40 lysates from CAD cells were incubated
with GST or GST-merintA proteins
immobilized on glutathione Sepharose 4B
beads. The beads were washed extensively,
bound proteins were separated on 12% SDS-
PAGE and immunoblotted with an anti-Grb2
(sc-255) antibody.
in the YN/IVX sequence needs to be phosphorylated for the Grb2 SH2-domain to bind,
there are also more recent studies that support binding of non-phosphorylated peptide
ligands for this SH2-domain (Long et al., 1999; Oliginao et al., 1997).
Here, the interaction of merintA with endogenous Grb2 was tested in vitro.
Equal quantities of merintA expressed as GST fusion protein or GST alone were bound
to glutathione Sepharose beads and incubated with equal amounts of CAD cell lysates.
After extensive washes, the coupled proteins were removed from the beads by boiling
and were detected by Western blot analysis using an anti-Grb2 (sc-255; Santa Cruz)
antibody. The results demonstrate that merintA specifically captured Grb2, which did
not bind to the GST control protein (Figure 29). Western blots were stained with
Ponceau-S for total proteins before probing with the specific Grb2 antibody. This
staining confirmed that equal amounts of GST fusion proteins and GST alone were
bound to the beads in the experiments (data not shown).
The interaction between merintA and Grb2 was confirmed by blot overlay
assays. His-merintA and BSA were subjected to SDS-PAGE and transferred to
nitrocellulose membranes. Ponceau-S staining confirmed equal quantities of the proteins
(Figure 30). Membranes were then overlayed with full-length GST-Grb2 followed by
Western blot analysis using a GST-antibody. Grb2 bound specifically to merintA, but
not to the control protein (Figure 30). These experiments demonstrate that merintA can
bind directly to Grb2.
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Figure 30. MerintA Binds Directly to Grb2 In Vitro. His-merintA and BSA were subjected to
12% SDS-PAGE and transferred to nitrocelullose membranes. Ponceau-S staining shows equal
amounts of His-merintA and BSA (A). Full-length GST-Grb2 or GST alone was incubated with the
membrane and then immunoblotted with an anti-GST (B14) antibody. GST-Grb2 binds specifically
and directly to His-merintA (B).
As mentioned above, the tyrosine of the SH2-domain binding motif YV/INX is
phosphorylated in many cases in order for Grb2 to bind (Schlessinger, 1994).
Therefore, in addition to the fact that merintA has several predicted phosphorylation
sites, it was tested whether this protein indeed gets phosphorylated. MerintA is not
constitutively tyrosine phosphorylated based on three lines of evidence. First, merintA
was immunoprecipitated as in Figure 4 and probed with the anti-phophotyrosine
antibodies 4G10 and pY20 (Upstate Biotechnology and TaKaRa). While the control
shows that merintA precipitated, neither antibody cross-reacts with merintA indicating
that no tyrosine residues are phophorylated under these conditions. Alternatively, the
tyrosine phosphorylation is below detectable levels (data not shown). Second, cell
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lysates were treated with calf intestine phosphatase (CIP) and merintA was analyzed
for shifts in mobility by Western blot analysis similar to those experiments shown in
Figure 5B. While the positive control NHE-RF showed an obvious shift, no such
change was detected for merintA (data not shown). Finally, cells were metabolically
labeled with 32P and merintA was immunoprecipitated as above. Again, merintA
precipitated but did not show detectable levels of phosphorylation (data not shown).
These results demonstrate that merintA is not constitutively phosphorylated but is still
able to bind to Grb2 in vitro. One of the next questions that arise is whether merintA
becomes transiently phosphorylated upon specific growth factor induction such as
EGF or PDGF. This and other questions will need further investigation. In summary,
the novel protein merintA is widely expressed, binds and co-localizes specifically with
merlin, is associated with the actin cytoskeleton and could be linked to signal
transduction pathways in which Grb2 is involved in such as mitogenesis or cytoskeletal
reorganization. However, further investigations need to be conducted in order to link the
merlin-merintA and/or merintA-Grb2 complex specifically to one of these pathways.
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4. Discussion
Merlin shares many properties with its family members, the ERM proteins, but it
differs from these relatives in having two isoforms with alternative carboxy-termini and
in having an established tumor suppressor function. The two major isoforms of NF2 are
expressed at the RNA and protein level in a variety of cell lines examined including NF2
target cells such as Schwann and meningeal cells (Arakawa et al., 1994, Haase et al.,
1994; Pykett et al., 1994, Ramesh V., pers. commun.). Affinity co-electrophoresis
experiments performed in the laboratory of Dr. V. Ramesh demonstrated a difference
between merlin isoforms with respect to their interdomain interactions and defined the
affinities of these interactions (Gonzalez-Agosti et al., 1999). The measured affinities
for the self-interaction of merlin isoform 1 and for the merlin-moesin interaction were in
the same order of magnitude as the reported affinities for intramolecular associations of
radixin (Magendantz et al., 1995). It is believed that the isoform 1 specific carboxy-
terminal residues (aa 580-595) are critical for the interdomain binding because the
carboxy-terminal halves of merlin containing residues either common to both isoforms
(aa 340-579) or isoform 2 (aa 340-590) did not exhibit the self-interaction (Gonzalez-
Agosti et al., 1999). The yeast two-hybrid system, blot overlay assays, affinity
precipitation assays and co-immunoprecipitation experiments performed in other
laboratories confirmed the interdomain interaction of merlin isoform 1 (Gronholm et al.,
1999; Huang et al., 1998; Sherman et al., 1997).
4.1 Characterization of the Interaction of Merlin Isoform 1 and 2 with NHE-RF
The intramolecular self-associations of the ERM proteins are known to mask the
binding sites for other ligands, thus suppressing the association with their membrane
partners and the actin cytoskeleton (Bretscher et al., 1999; Tsukita et al., 1997).
Moreover, binding of the ERM proteins to NHE-RF is blocked by the interdomain
interaction of the full-length molecules which does not occur in the truncated amino-
terminal proteins (Ramesh V., pers. commun.; Reczek et al., 1998). Interdomain
interactions, however, are disrupted either by phosphorylation or phospholipids such
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as phosphatidylinositol 4-phosphate (PIP) or phosphatidylinositol 4,5-bisphosphate
(PIP2). These phospholipids bind directly to the amino-terminus of the ERM proteins
and expose other ligand binding sites (Heiska et al., 1998; Hirao et al., 1996; Niggli et
al., 1995).
These data raised the following questions: Do merlin isoform 1 and 2 have
different binding properties towards the ligand NHE-RF based on their different
conformations? Do phospholipids affect ligand binding? Indeed the observed head-to-
tail association of merlin isoform 1 interferes with the binding to the ligand NHE-RF. In
addition, the experiments conducted illustrate a difference in the ability of the two
alternatively spliced isoforms of merlin to interact with NHE-RF. The carboxy-
terminus of merlin isoform 1 competes with NHE-RF for the amino-terminal binding
site. On the other hand, merlin isoform 2 exists in a constitutively open conformation
that allows the binding of NHE-RF without being hindered by the intramolecular
associations that occur in merlin isoform 1. Merlin expressed in bacteria or in
mammalian cells illustrated this phenomenon. The phospholipid PIP2 enhances the
binding properties of this merlin isoform to NHE-RF. Phospholipids might, as in the
case of to the ERM proteins, bind to merlin to reveal the binding sites for NHE-RF
which are masked otherwise. NHE-RF is constitutively phosphorylated and
hypophosphorylated NHE-RF shows no difference in binding to merlin isoforms, in
contrast to hyperphosphorylated NHE-RF, which binds exclusively to merlin isoform
2. However, in the reciprocal experiment, when GST-NHE-RF was utilized to capture
merlin isoform 1 or 2, NHE-RF is not phosphorylated and a clear difference in the
amount of merlin binding is seen. Here, more merlin isoform 2 binds to GST-NHE-RF
than isoform 1.
The intramolecular interaction of merlin, which is quite dynamic, is of lower
affinity than for ezrin (Nguyen et al., 2001). This phenomenon has been established by
analyzing both the full-length molecules and the respective domains in solution. The
interaction of NHE-RF with the amino-terminus of ezrin can be inhibited by the
presence of the carboxy-terminus of ezrin. In contrast, the interaction of NHE-RF with
the amino-terminus of merlin is not inhibited by the carboxy-terminus of either ezrin or
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merlin (Nguyen et al., 2001). These competitive binding studies provide evidence of the
potential dynamic exchange between binding partners even though associations may
appear stable in the absence of a competing species. Moreover, these studies suggest
selection of proteins between multiple binding partners. Differential binding of NHE-
RF to merlin isoforms and different family members may have functional significance in
vivo. The interaction of merlin with the ERM proteins indicates that these proteins
could also regulate the activities of each other.
RhoA-induced phosphorylation of a carboxy-terminal threonine (T558 in
moesin) has also been implicated in conformational regulation of the ERM proteins
(Matsui et al., 1998; Matsui et al., 1999; Nakamura et al., 1995; Nakamura et al., 1999;
Pietromonaco et al., 1998; Simons et al., 1998). This threonine residue is conserved in
both isoforms of merlin (T577); however, while the sequence surrounding this amino
acid is quite distinct in merlin, it is conserved in all three ERM proteins. This distinct
sequence suggests that phosphorylation of this particular threonine has no effect on
merlin’s conformation and should not influence the binding to ligands such as NHE-RF.
Recently, it has been reported that Rho activation has no effect on merlin
phosphorylation (Shaw et al., 2001) supporting the idea that this mechanism of action
might be unique for the ERM proteins. Nonetheless, further studies are required to
understand whether the phosphorylation of this residue is indeed not involved in
regulating the intramolecular association of merlin isoform 1 and to determine the role it
might play in merlin isoform 2.
Comparing merlin with the related ERM proteins is expected to reveal
similarities that are instructive concerning the overall function of these proteins. In
addition, differences are predicted that could reveal specific functions of these proteins,
such as the tumor suppressor activity of merlin. Both similarities and differences came
out of characterizing the interaction of merlin isoform 1 and 2 with NHE-RF. Merlin
specific functions could be attributed to the regulation of merlin isoform 2 versus merlin
isoform 1 and the ERM proteins. Merlin isoform 2 does not undergo intramolecular
head-to-tail associations and exists always in the open state. These interactions with
NHE-RF and potentially other merlin binding proteins may occur when the equivalent
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sites in merlin isoform 1 and in the ERM proteins are masked due to intramolecular
head-to-tail associations (closed state). The full range of merlin interactions with other
proteins remains to be delineated (see 4.4 Merlin Binding Proteins). However, it is quite
possible that merlin mediates many interactions with multiple partners. Merlin,
therefore, could be involved in different signaling pathways, some of which may be
shared with the ERM family members. The distinct tumor suppressor role of merlin
could lie in the participation in a signaling pathway that is not shared with the ERM
proteins and is uniquely important to NF2 target cells such as Schwann and meningeal
cells. At this point, it remains unclear which merlin isoform conducts tumor suppressor
function since both isoforms are ubiquitously expressed including in the NF2 target
cells and no mutations have been found in the isoform defining exons.
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4.2 NHE-RF Binding Proteins
The interaction of NHE-RF with merlin and the ERM proteins is mediated by the
extreme carboxy-terminus of NHE-RF (Murthy et al., 1998; Reczek et al., 1998; Yun et
al., 1998). NHE-RF possesses two PDZ-domains that are known to mediate protein-
protein interactions, and during the course of this study a number of proteins have been
shown to bind to these domains (see below). Proteins binding to the PDZ-1domain of
NHE-RF have the consensus sequence DS/TXL (Hall et al., 1998a), and database
searches (GenBank) reveal proteins with this motif at the extreme carboxy-terminus
(see Table 3).
The B1 subunit of the H+ ATPase has the PDZ-binding motif DTAL, which
suggests it is a potential binding partner of NHE-RF, and a possible interaction was
analyzed between NHE-RF and the H+ ATPase by localization and binding studies.
NHE-RF and the H+ ATPase physically associate in affinity binding- and co-
immunoprecipitation experiments. Competition experiments show that the interaction
occurs through the PDZ-binding motif of the H+ ATPase. Immunolocalization studies
of NHE-RF show that the two proteins co-localize in the kidney (in the collecting duct
and connecting segment), supporting the relevance of this interaction.
In the collecting duct of the kidney, A-type intercalated cells contain high levels
of H+ ATPase and always have an apical staining pattern for this protein (Alper et al.,
1989; Brown et al., 1988a). In B-type intercalated cells, the H+ ATPase is also highly
expressed and it localizes to the apical or the basolateral membrane (Alper et al., 1989;
Brown et al., 1988a). These B-cells express ample amounts of NHE-RF in contrast to
A-cells. Thus, B-cells represent a distinct cell type with respect to NHE-RF expression
just like they do for the Cl-/HCO3
- exchanger (AE1). A-cells express AE1 with a
basolateral staining pattern while this protein is not expressed in B-cells (Alper et al.,
1989). The results of the experiments carried out here clearly indicate that the polarity
of NHE-RF and the H+ ATPase is not unidirectional (i.e. exclusively apical) in every
cell type.
The mechanism of action by which B-cell generate and maintain H+ ATPase
polarity has not been established but NHE-RF could be involved. Hensin, an
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extracellular matrix protein, is involved in generating plasticity of the intercalated cell
phenotype in vitro (Al-Awqati, 1996; Al-Awqati et al., 1998). Similar to hensin, NHE-
RF may play a role in establishing H+ ATPase polarity. NHE-RF could bind to the
cytosolic subunits (V1 sector), including the B subunit, and recruit this complex to the
transmembrane portion (V0 sector). The diffuse intracellular localization of NHE-RF
and the H+ ATPase in some B intercalated cells supports that NHE-RF might play a
role in trafficking. Alternatively, NHE-RF could maintain H+ ATPase localization
through its association with merlin or the ERM proteins, which in turn could anchor
this entire complex to the actin cytoskeleton. In fact, phosphorylation of NHE-RF is
known to interrupt the physical link between the β2-adrenergic receptor and the actin
cytoskeleton, an interruption which affects the endocytic sorting of this receptor (Cao
et al., 1999). Also, the B1 or B2 subunits of the H+ ATPase are capable of binding actin
directly via their amino-terminus (Lee et al., 1999). The H+ ATPase could, therefore,
interact with the actin cytoskeleton directly via a B subunit or indirectly via the NHE-
RF-merlin/ERM protein complex.
The concept of NHE-RF stabilizing a formed complex once it has reached its
target membrane is supported by other studies. For example, NHE-RF is thought to
stabilize the cystic fibrosis transmembrane conductance regulator in the apical plasma
membrane (Hall et al., 1998a). Other PDZ proteins appear to be involved in basolateral
anchoring and targeting of various receptors in Caenorhabditis elegans (Kim, 1997).
Disc lost, a Drosophila PDZ-domain protein, has been shown to have a dual role in
maintaining apical and basolateral epithelial cell polarity (Bhat et al., 1999). Further
investigations should establish the relevance of the two mechanisms by which the H+
ATPase can interact with the actin cytoskeleton, should elucidate their respective roles
and should give clues with respect to H+ ATPase cell polarity.
In proximal tubules, large amounts of NHE-RF are detected; NHE-RF co-
localizes with NHE-3 in the apical membrane (Biemesderfer et al., 1997) and in the
apical brush border (Brown D. pers. commun.). Interestingly, the B2 subunit of the H+
ATPase, which lacks the carboxy-terminal DTAL residues, is expressed in these tubule
segments (Nelson et al., 1992). Therefore, it is anticipated that in this cell type, the H+
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ATPase is incapable of binding to NHE-RF. Localization studies reveal that in proximal
tubules the H+ ATPase does not co-localize with NHE-RF. It is unclear why it may be
favorable for these cells to express the B2 subunit of the H+ ATPase that cannot
associate with NHE-RF at the apical membrane, but these data support that the DTAL
motif is required to mediate the interaction of NHE-RF and the H+ ATPase.
At least two major cytosolic subunits (B1 and E) associate with NHE-RF in
affinity binding assays. Other subunits are expected to bind in a complex through the
B1 subunit to NHE-RF although only the B1 and E subunits were tested as markers.
Competition experiments confirm that the DTAL PDZ-binding motif of the B1 subunit
is responsible for the interaction of the H+ ATPase and NHE-RF. A peptide derived
from the carboxy-terminus of the B1 56kD subunit, in contrast to the B2 isoform,
inhibits the interaction of NHE-RF with the H+ ATPase. All affinity-precipitation
experiments were carried out with cytosolic preparations from the inner medulla for
various reasons. First, kidney cytosol contains large amounts of free cytosolic H+
ATPase subunits. Secondly, this kidney region contains high levels of the B1-H+
ATPase isoform, and finally this region contains no proximal tubules, which express
abundant endogenous NHE-RF that could potentially compete with protein binding to
the affinity matrix.
In order to attempt co-immunoprecipitation experiments, validation of the only
NHE-RF antibody (IC270) available at the time was necessary to confirm that NHE-
RF precipitates in the first place. Conventional methods impede this determination
because of the interference of the immunoglobulin visualized by secondary antibodies
used for Western blot analysis and the antigen NHE-RF at ~50kD. Therefore, IC270
was biotinylated prior to utilizing it in Western blot analyses of immunoprecipitates.
Streptavidin binds with high affinity to biotin, and horseradish peroxidase conjugated to
streptavidin allows visualizing the immunoprecipitate-biotinylated primary antibody
complex. This strategy successfully demonstrated that IC270 immunoprecipitates
NHE-RF. Biotinylation of the primary antibody is rapid and can be used with small
amounts of the antibody. This method is highly effective for the analysis of
immunoprecipitates and protein-protein interactions.
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IC270 immunoprecipitates NHE-RF from rat kidney cytosol. Furthermore, the
E subunit of the H+ ATPase co-immunoprecipitates with NHE-RF suggesting that
NHE-RF exists indeed in a complex with the cytosolic subunits of the H+ ATPase. The
E subunit is a reliable marker of the assembled cytoplasmic subunits since previous data
show that the cytoplasmic domains of the H+ ATPase exist preassembled in the
cytosol (Nelson et al., 1999). These studies confirm the physiological relevance of the
interaction between NHE-RF and the H+ ATPase, and the competition experiments
indicate that the interaction is direct and through the DTAL motif at the carboxy-
terminus of the H+ ATPase.
NHE-RF2 also possesses two PDZ-domains similar to NHE-RF, and the PDZ-
1 domains are 73% identical between NHE-RF and NHE-RF2. The PDZ-1 domain of
NHE-RF2 has also been shown to bind to both the consensus sequence DS/TXL and
the carboxy-terminal motif DTRL of the cystic fibrosis transmembrane regulator
(CFTR). Hence, it is likely that NHE-RF2 can also bind to the H+ ATPase, and it
would be valuable to investigate whether NHE-RF2 localizes to A-cells where NHE-RF
expression is low and conducts analogous functions in these cells. While these two
family members have been shown to bind to the same consensus sequence, it is unlikely
that other PDZ-domain proteins also bind to this sequence. PDZ-domains were first
identified in the post-synaptic density protein (PSD-95), Drosophila septate junction
protein disc-large (Dlg) and the epithelial tight-junction protein zona occludens-1 (ZO-
1) (Cho et al., 1992; Stevenson et al., 1986; Woods et al., 1991; Woods et al., 1993).
PSD-95 has been shown to bind to the carboxy-terminal motif SXV (Kornau et al.,
1995), and INAD, another Drosophila PDZ-domain protein, has been shown to bind to
the carboxy-terminal motif XF/Y/WCF (van Huizen et al., 1998). These examples
indicate that not all PDZ-domains can bind to the DS/TXL motif but that so far it is
specific for the PDZ-1 domain of NHE-RF and NHE-RF2.
During the course of this study a number of proteins have been shown to bind
to PDZ-domains of NHE-RF including β2-adrenergic receptor, CFTR, EPI64, GRK6A,
NHE3, P2Y1, PDGFR, PLCβ 1, 2 & 3, Trp 4 & 5 and Yap 65 (for review see Voltz et
al., 2001), and most of these proteins have been shown to bind through the PDZ-1
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binding motif. This rapidly growing list of proteins that bind NHE-RF and NHE-RF2
generates urgent questions: Are all reported interactions functionally significant or just
some? What is the context of significant interactions? Are they regulated in a spatial or
temporal manner, or do the receptors and binding partners of NHE-RF compete with
each other? An apparent difference in stoichiometry of NHE-RF and candidates that
bind the PDZ-domains of NHE-RF has been reported (Reczek et al., 2001). The high
levels of NHE-RF suggest that many different proteins can bind to NHE-RF even in
one structure of a given cell. This idea is supported by the findings that many different
NHE-RF binding proteins associate with NHE-RF in extracts of placental microvilli
(Reczek et al., 2001). Thus, it is possible that many of the reported interactions occur
in parallel and that NHE-RF may function in different processes and pathways.
In summary, the B1 subunit of the H+ ATPase is a physiologically relevant
binding protein of NHE-RF and may link the H+ ATPase to the cytoskeleton. The two
proteins co-localize in B-intercalated cells but not in A-cells, suggesting a possible
function in generating, maintaining or modulating the B-cell phenotype. In contrast,
NHE-RF and H+ ATPase do not co-localize in proximal tubules, which express a
truncated B2 subunit of the H+ ATPase that lacks the PDZ-binding motif DTAL.
These studies could be extended to Schwann and meningeal cells to test the relevance of
this interaction in the context of NF2.
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4.3 The Potential Role of NHE-RF in Cancer
NHE-RF is highly expressed in epithelial cells of many tissues, especially in those with
numerous microvilli. Prominent NHE-RF expression is also seen in specialized ion
transporting cells such as renal proximal tubules, eccrine glands, parietal cells in gastric
glands, colonic absorptive cells and ependymal cells (Stemmer-Rachamimov et al.,
2001).
4.3.1 NHE-RF Expression is Regulated by Estrogen in Breast Cancer Cells
The expression and localization of NHE-RF were investigated in meningiomas and
tumors deriving from other organs including colon, ovary and breast. An enormous
upregulation of NHE-RF was found in the breast cancer cell lines MCF-7, ZR-75-B and
T-47-D compared to other breast cancer cell lines and normal mammary cell lines.
NHE-RF and the related NHE-RF2 appear to share many functions; however, an
upregulation of NHE-RF2 was not observed in any of the tested breast cancer cells.
Various mechanisms can explain upregulation of genes, in general and some examples are
insertional mutations, gene translocations or gene amplification. All cell lines analyzed
earlier were subjected to Southern blot analysis to detect gene amplification. These
studies, however, gave no evidence for gene amplification (data not shown) and other
means of upregulation of NHE-RF had to be considered. The breast cancer cell lines
where NHE-RF is upregulated are all positive for the estrogen receptor (ER-). Our
study suggests that induction of NHE-RF expression is a primary response to estrogen.
Interestingly, during the course of this work, Ediger et al. (1999) reported that NHE-RF
is under estrogen regulation. Using differential display RNA methods, the authors
showed that NHE-RF was under rapid and direct regulation by estrogen in the ER-
containing cell line MCF-7. This stimulation appeared selective for estrogen ligands,
since no stimulation was detected by other classes of steroid hormones. In addition, the
anti-estrogens tamoxifen and ICI 182,780 suppressed stimulation by estrogen. Thus,
the results of our study were consistent with those reported by Ediger et al. (1999). In
addition, our study gathered evidence for the upregulation of NHE-RF in a majority of
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ER- positive primary breast tumors, establishing that NHE-RF expression is regulated
by estrogen in vivo.
4.3.2 The Role of Estrogen and NHE-RF in Breast Cancer
Estrogen stimulation of mammary epithelial cells is considered a key factor in the
development of breast cancer. The intracellular, nuclear estrogen receptor (ER) binds
estrogen and is then transformed into an active transcription factor that mediates
proliferative effects. Two closely related receptor families, ER- α and ER- β, are known
to mediate estrogen stimulated responses, and the expression of ERs is used as an
important prognostic marker in breast cancer. Therefore, antiestrogens may be
therapeutically effective in ER- positive breast cancers. Patients with ER- negative
tumors tend to have a higher recurrence rate compared to patients with ER- positive
tumors. ER- negative tumors are also more aggressive, do not respond to antiestrogen
treatment in general and result in poor patient survival (Knight et al., 1977; Sigurdsson
et al., 1990). Although ER- positive tumors are more likely to respond to hormonal
therapy, there is no absolute correlation between ER expression and hormone response
(Osborne 1998). Endocrine manipulations have no effect on approximately 40% of
patients with ER- positive cancer while approximately 10% of ER- negative tumors
respond (Henderson et al., 1997; Nagai et al., 1979). Moreover, ER- positive tumors
can convert into refractory tumors and these mechanisms are poorly understood.
In our study, high levels of NHE-RF expression were observed in
approximately 30% of the ER- negative breast tumors. Some ER- negative tumors
express a variant form of ER with an exon 5 deletion, which is transcriptionally active
and capable of inducing the expression of specific genes (Fuqua et al., 1995; Lemieux et
al., 1996). The expression of NHE-RF in ER- negative tumors raises the question
whether this variant form is present in these tumors. Other mechanisms by which
NHE-RF is induced in the ER- negative tumors cannot be ruled out. Several signaling
cascades, including epidermal growth factor, insulin like growth factor and MAP- kinase
pathways are involved in estrogen signaling (Aronica et al., 1993; Katzenellenbogen,
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1996; Korach et al., 1996; Migliaccio et al., 1993; Smith, 1998). These overlapping
pathways may partly explain ER- independent upregulation of NHE-RF and explain
those breast cancer cells that adapt to or bypass antiestrogen therapy.
Estrogen binds and activates ER, which then binds to estrogen responsive
elements (ERE) often located in the 5' flanking region of estrogen responsive genes.
Additional investigations are necessary to identify and characterize such EREs in the
NHE-RF gene. In this context, it is worth noting that the BRCA1 protein is thought to
suppress estrogen-dependent transcriptional pathways related to mammary epithelial
cell proliferation, and the loss of this ability might contribute to tumorigenesis (Fan et
al., 1999). Testing whether BRCA1 has any influence on the induction of NHE-RF by
estrogen would be of potential interest.
4.3.3 The Role of NHE-RF in the Organization of Microvilli
It is well documented that NHE-RF localizes to microvilli of cultured cells (Murthy et
al., 1998; Reczek et al., 1997). Estrogen induces cytoskeletal alterations in ER-
containing breast cancer cells such as increasing the number and length of microvilli at
the cell surface. In fact, MCF-7 cells are uniformly covered with microvilli 2 days after
β-estradiol treatment (Coutts et al., 1996; Vic et al., 1982).
It is remarkable to observe the abundance of NHE-RF in microvilli of MCF-7
cells treated with estrogen for 48 hours. Molecular mechanisms behind the organization
of these membrane surface structures are not completely understood and remain a focus
of study. Overexpression of some cytoskeletal or lipid-binding proteins results in the
elongation of microvilli (Arpin et al., 1994; Friederich et al., 1989; Ma et al., 1997).
Small GTPases (e.g. Rho and Rac) and the ERM proteins are known to function in
cortical actin polymerization (MacKay et al., 1997). Furthermore, ERM proteins are
thought to play a key role in the formation of microvilli through cross-linking actin
filaments and integral membrane proteins such as CD43, CD44, and ICAM2 (Bretscher
et al., 1999). A recent study has shown that overexpression of ERM binding membrane
proteins (e.g. CD44) in fibroblasts induces microvillar elongation with the recruitment
of the ERM proteins and actin filaments (Yonemura et al., 1999). In light of these
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findings, it is tempting to consider the possibility that a cytosolic ERM binding protein
such as NHE-RF could be involved in microvillar organization in ER- positive breast
cancer cells. Further studies are required to address whether estrogen simply induces
the formation of a large number of microvilli and whether they are also elongated. NHE-
RF could be involved in the de novo formation of microvilli or recruited in concert with
the MERM proteins to this location and influence microvilli length.
NHE-RF is a multi-phosphorylated protein, interacts with many different
proteins (Reczek et al., 2001) and has roles in the apical surfaces of ion transporting
epithelia (Breton et al., 2000). This study demonstrates that estrogen stimulates NHE-
RF expression in breast carcinomas, that it binds differentially to merlin isoform 1 and 2
and that it interacts with the H+ ATPase. Other reports have connected NHE-RF to
many other membrane proteins. Consequently, NHE-RF is a multifunctional protein
and appears to be a key adaptor within a web of interactions involving membrane
proteins/NHE-RF/MERM/F-actin (Figure 31). Cross talk among different signal
transduction pathways may be mediated by the interactions of NHE-RF. Moreover,
the study of NHE-RF provides new possibilities for future insights into normal and
abnormal intracellular signaling. Defining the pathways through which ER mediated
signaling is linked to NHE-RF will certainly provide a better knowledge of the role that
NHE-RF might play in breast cancer and may enable the development of novel
therapeutic intervention for such growth pathways.
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Figure 31. A Model of Merlin, NHE-RF and Their Binding Partners. See text for details.
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4.4 Merlin Binding Proteins
The function of merlin is the subject of many studies, and insights into possible roles of
merlin have come in part from animal models. Limited information on merlin binding
proteins was available at the time this work began. Several cellular proteins have been
shown to interact with merlin in vitro; however, the identities of these proteins have
not been revealed (Takeshima et al., 1994). NHE-RF was one of the first discovered
merlin binding proteins which was also shown to bind the ERM proteins (Murthy et
al., 1998; Rezcek et al., 1997). Accordingly, it was of great interest to identify and to
characterize further merlin binding proteins.
4.4.1 Identification of Merlin Binding Proteins
Prior to this work, the yeast two-hybrid system had been employed in the Molecular
Neurogenetics Unit at Massachusetts General Hospital, Boston to identify merlin
binding proteins. Three candidates were found, and one of these was NHE-RF
(merintC). The two other binding partners, merintA and merintB, were characterized in
this study and gave mixed results. MerintB, a novel gene at the time of isolation,
interacts consistently in the yeast two-hybrid system; however, affinity binding assays
did not confirm that merintB truly binds to merlin. It is not clear why this candidate
was identified numerous times in the original yeast two-hybrid screen but merintB
might simply be a false positive. On the other hand, a number of reasons might explain
why no binding was seen by other methods. Only a partial cDNA was available at the
time the interaction was tested. Expressing parts of a protein in mammalian cells might
not allow the right conformation that is needed for the interaction. In the affinity
binding assay, merlin was expressed as a GST fusion protein and merintB was
overexpressed in Cos-7 cells. The reciprocal experiment could be tested to see a
possible interaction. It is known that affinity binding assays sometimes work only
unidirectionally because important post-translational modification might be missing for
the bacterially expressed protein. Hence, GST-merlin used in this assay might lack
post-translational modifications that are necessary for this particular interaction.
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Nonetheless, the affinity binding assay did not show an interaction of merintB with
merlin, and, therefore, merintB was not further analyzed.
4.4.2 The Interaction of MerintA with Merlin
MerintA, on the other hand, has proven to be a new merlin binding protein. Initial
affinity binding assays quickly demonstrated that merintA binds to merlin beyond the
yeast two-hybrid system, and these findings encouraged further studies. Co-
immunoprecipitation experiments, in addition to the yeast two-hybrid system and
affinity binding assays, demonstrate that merintA and merlin bind to each other in vitro
and in vivo. Immunofluorescence and electron microscopy studies show a high and
significant degree of co-localization between merintA and merlin supporting the
relevance of this interaction. Merlin isoform 2 captures more merintA than merlin
isoform 1 in the affinity binding assays. These observed binding properties might be
different from the preferential binding of NHE-RF to merlin isoform 2. In the case of
merintA, the binding might be sequence specific. Unlike full-length merlin isoform 1, the
carboxy- terminal domains used in this assay do not undergo intramolecular
associations. The preference of merintA to merlin isoform 2 might be caused by the
amino acid sequence encoded by exon 16. However, merintA does not bind exclusively
to merlin isoform 2. MerintA was originally identified by screening for merlin binding
proteins using merlin isoform 1, and affinity binding assays confirm an interaction
between merintA and merlin isoform 1. The carboxy-terminus of merlin is less
homologous to the ERM proteins than the amino-terminus (Figure 2). As expected,
merintA binds specifically to merlin and not to the ERM protein moesin. The
specificity of the merintA-merlin interaction illustrates a unique property of merlin, and
may provide clues to the tumor suppressor function of merlin, which is not shared with
the ERM proteins. In summary, the binding analyses and subcellular localization data
indicate that merintA is a physiologically relevant binding partner of merlin.
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4.4.3 Characterization of MerintA
Sequence analysis revealed that merintA is a novel gene that has not been characterized
to date, and a cDNA was isolated corresponding to the shortest transcript seen by
Northern blot analysis. The original transcript isolated from the yeast two-hybrid
screen did not have a start codon. 5’ rapid amplification of cDNA ends (5’-RACE) was
employed to identify a full-length transcript. Sequence analysis of the 5’-RACE
products distinguished a start codon with surrounding sequence that roughly fulfills the
requirements of the Kozak-sequence. A second ATG encodes the eighth amino acid of
merintA although the surrounding sequence of this codon does not fulfill the
requirements of the Kozak-sequence. Therefore, it is unlikely that this second ATG is
indeed a start codon. The other transcripts seen by Northern blot analysis raise the
possibility of alternative splice products. During the course of this study, mRNA
sequences have been deposited at GenBank, and they account for most of the other
transcripts. Interestingly, all these sequences, including the one isolated here, have the
same open reading frame indicating that the full-length sequence was obtained. Further
studies are necessary to explore temporal and spatial expression of the various
transcripts, which might regulate merintA by the different untranslated regions. One
larger transcript, seen only in adult tissues, is unaccounted for, and a different open
reading frame is possible.
MerintA is a 178 amino acid protein, which is predicted to be encoded by a
four-exon gene on chromosome 4p15.3. The existence of anonymous orthologues in
mouse, rat, cow, zebrafish and fly demonstrate that this gene is of general significance.
A sequence (AF358829) identical to merintA was also submitted to GenBank in April
2001 and is entitled “novel gene as tumor angiogenesis marker.” In the absence of any
published information, it is reasonable to assume that merintA might play a role during
angiogenesis in general or specifically during tumor angiogenesis. The protein consists
of an amino-terminal low-complexity region with several glycines and prolines followed
by a coiled-coil domain (aa 109-145). The latter domain is often found in adaptor or
structural proteins and is known to mediate protein-protein interactions (Alberts et al.,
1994). It would be worthwhile to investigate whether the interaction of merintA and
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merlin is mediated through this coiled-coil domain and to identify other proteins that
bind to this domain. Analysis of the merintA sequence for the occurrence of ProSite
patterns predicted N-myristoylation sites. An appreciable number of eukaryotic
proteins are N-myristoylated, which is the covalent addition of myristate (a C14-
saturated fatty acid) to their N-terminal residue via an amide linkage (Grand et al., 1989;
Towler et al., 1988). Myristoylation of the guanidine nucleotide exchange factor Sos,
for example, targets the protein to the membrane and complements activation of the Ras
signaling pathway (Aronheim et al., 1994). Possible merintA myristoylation could
explain its submembranous localization, and merintA, like Sos, might recruit other
proteins to this site.
To analyze merintA further, polyclonal and monoclonal antibodies were
generated. Several lines of evidence demonstrate that the antibodies raised against
merintA are specific. First, the antibodies cross-react with the exogenous merintA
expressed in bacteria or mammalian cells. Second, pre-absorbing the antibody with the
purified antigen abolishes the signal, and finally the different polyclonal and monoclonal
antibodies recognize the same endogenous protein. These data demonstrate that the
antibodies raised are indeed specific and that they are valuable tools for studying
merintA. The protein is detected with an apparent size of 24kD by Western blot
analysis, slightly larger than the size predicted from its actual sequence. The anomalous
migration might be caused by unidentified post-translational modifications. MerintA is
not constitutively phosphorylated; however, some phosphorylation sites are predicted
based on sequence analysis. On that note, it would be useful to test whether the
predicted kinases CaM II, CK I, CK II or PKA can phosphorylate merintA in vitro or
in vivo.
Expression analysis from different human cell lines shows that merintA is seen
to varying extents in most of the lines examined. An additional band at ~50kD is also
recognized by the monoclonal antibody 7E1 but not by the polyclonal antibodies. This
species might represent one of the following: (A) an alternatively spliced merintA
isoform deriving from the larger unaccounted transcript mentioned above; (B) a strong
dimer that resists the denaturing conditions of SDS-PAGE; (C) a closely related
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protein, or (D) an unrelated protein with a similar epitope. The identity of this species
has not been determined to date. Interestingly, primary meningioma cell lines that are
NF2 positive or negative express the ~50kD protein while merintA (24kD) is expressed
almost below detectable levels. In fact, a longer exposure than the one shown in Figure
20 is necessary to detect merintA in meningioma cell lines. On the other hand, the
relative amounts of merintA and the ~50kD protein are inverted in CAD and Cos-7
cells. Here, the ~50kD protein is almost below detectable levels while merintA is
expressed abundantly. Therefore, CAD cells were used in this study to characterize
merintA and its interaction with merlin.
CAD (Cath a-differentiated) cells derive from the cell line Cath a, which was
established from a brain tumor that arose in a transgenic mouse carrying wild-type
SV40 T antigen under the transcriptional control of the rat tyrosine hydroxylase
promoter. Reversible, morphological differentiation in CAD cells can be initiated by
removal of serum or exogenously added protein to the medium. Differentiated CAD
cells stop proliferating and extend long neurite-like processes (Qi et al., 1997). MerintA
and merlin localize in these neurites and underneath the plasma membrane in
differentiating CAD cells. Merlin has been localized to lamellipodia or membrane ruffles
(Gonzalez-Agosti et al., 1996), but differentiated CAD cells do not exhibit these motile
structures. Thus, neither merlin nor merintA was localized to membrane ruffles in CAD
cells. However, just like merlin, merintA localizes to membrane ruffles in other cell
types that do display these motile structures (data not shown). Examining the
localization of merintA in merlin deficient cells and vice versa would be of great interest
in order to test whether the localization of one protein is dependent on the other.
CAD cells lack an obvious phenotype upon exogenous expression of merintA.
Initial studies suggested that merintA might play a role in apoptosis since a majority of
the cells die ~48 hours post-transfection. Membrane blebbing, a characteristic of
apoptosis, is observed upon exogenous expression of merintA. However, condensed
nuclei, another phenotype of apoptotic cells, are not induced by merintA (data not
shown). Hence, the overexpression of merintA could simply be toxic to the cells.
Interestingly, merlin also prompts membrane blebbing, cytoplasmic shrinking, cell
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rounding, condensed nuclei and cell death, yet this phenotype is not suppressed by co-
expressing the apoptosis inhibitors p35 (caspase family inhibitor) and Bcl-2 (Shaw et
al., 1998). There is no data supporting that merlin normally plays a role in the
regulation of cell death. It is possible that overexpression of merintA sensitizes cells for
apoptosis rather than induces apoptosis and that co-expression of merintA and merlin
induces apoptosis. Detailed studies using an inducible promoter system to drive
expression of merintA and merlin should illuminate on the relationship between cell
death induction and the morphogenetic properties observed.
4.4.4 MerintA and the Actin Cytoskeleton
Merlin is an actin binding protein (James et al., 2001), and based on the high degree of
co-localization between merlin and merintA, it was predicted that merintA also
associates with the actin cytoskeleton. Indeed, co-fractionation, co-localization and
electron microscopy demonstrate a connection between merintA and actin. However,
these proteins appear to bind to each other indirectly since no robust direct interaction
could be seen with various methods that detect the direct binding of merlin to actin.
Thus, merlin and other proteins are likely to mediate the merintA-actin association.
Merlin is thought to stabilize F-actin through a lateral association (James et al.,
2001) similar to ezrin and moesin (Pestonjamasp et al., 1995; Shuster et al., 1995;
Tsukita et al., 1999; Yao et al., 1996). MerintA also resides along actin filaments most
highly concentrated at cortical actin-rich regions as seen by electron microscopy.
MerintA and merlin significantly co-localize at the subcellular resolution achieved by
electron microscopy. It seems reasonable to assume that other proteins might be
involved in the association of merintA and actin because merintA can be found to some
extent along actin filaments in the absence of merlin. MerintA is highly expressed in
skeletal muscle and heart. The major function of muscle cells is to perform contractions
and the cytoplasm of these cells is full of organized actin filaments among other protein
filaments and many mitochondria. Strong expression of merintA in actin rich cells
concurs with the fact that merintA is an actin cytoskeleton associated protein.
Discussion                                                                                                                              124
A large number of germline and somatic mutations have been found in NF2
patients. Mainly inactivating genetic alterations, such as frameshift and nonsense
mutations, have been identified, although rare missense mutations have also been
discovered. Based on mutational analyses, either isoform of merlin could function as a
tumor suppressor since no mutations have been reported in isoform defining exons 16
or 17 (Gusella et al., 1999). Investigations performed with NF2 missense mutations
reveal a significant increase in detergent solubility compared to the wild type protein
(Stokowski et al., 2000). It is assumed that the ability of mutant merlin to interact with
the cytoskeleton is decreased. Localization studies of mutant merlin confirmed an
impaired association with actin (Deugen et al., 1998; Stokowski et al., 2000). It would
be worthwhile to test whether NF2 missense mutations affect the solubility of merintA
and its interaction with merlin.
Originally, the actin cytoskeleton was simply thought to have structural
significance for a cell, playing a role in cell shape and motility events such as cell
movement, intracellular transport, contractile-ring formation and chromosome
movement. However, recent studies demonstrate that the cytoskeleton is of critical
importance in the regulation of various other cellular processes including proliferation,
contact inhibiton, anchorage-independent cell growth and apoptosis (for review see
Pawlak et al., 2001). The small GTPases Rho, Rac and Cdc42 regulate the organization
of the actin cytoskeleton, and results have implicated the cytoskeleton and ERM
proteins in transformation. First, Dbl and Net, Rho guanine nucleotide exchange factors
(RhoGEF), and RhoA are involved in cell transformation and require ezrin-mediated
cytoskeletal changes (Sahai et al., 1999; Tran Quang et al., 2000). Second, the ERM
proteins bind directly with the TSC1 tumor-suppressor hamartin. This physical
interaction is necessary for the activation of Rho by serum or lysophosphatidic acid,
and it results in the assembly of actin stress fibers and formation of focal adhesions
(Lamb et al., 2000). These studies suggest that a Rho-mediated signaling pathway
regulates cell adhesion and may constitute a rate-limiting step in tumor formation. They
may also represent a paradigm for the action of merlin and merintA in a Rac-mediated
signaling pathway, and elucidating these functions will provide fundamental knowledge
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of merlin in the pathogenesis of NF2. Further investigations are necessary to define a
potential role of merintA and cytoskeleton-mediated transformation.
4.4.5 The Association of MerintA with the Adaptor Protein Grb2
Examination of merintA with Scansite predicted the binding motif for the Src homology
2 (SH2-) domain of the growth factor receptor bound 2 (Grb2). The consensus
sequence of this binding motif is pYV/INX (Schlessinger, 1994), and merintA has the
sequence YVNG between amino acids 63 and 68 (Y64 of merintA). Only 0.13% of all
proteins can be found in SwissProt with this motif.
Grb2 was identified by screening a bacterial cDNA expression library with the
tyrosine phosphorylated EGF receptor (Lowenstein et al., 1992). Subsequently, many
proteins have been identified, and they have been shown to bind to the SH2-domain of
Grb2 in a tyrosine phosphorylation dependent manner (for review see Buday, 1999).
Thus, Y64 of merintA is predicted to be phosphorylated, in order to mediate the
interaction with Grb2 via the SH2-domain. Grb2 is composed of one SH2-domain
flanked by two SH3-domains, and these latter domains are known to bind to proline
rich proteins. MerintA has an amino-terminal proline rich region that could conceivably
interact with a Grb2 SH3-domain in addition to or exclusive of an SH2-domain
interaction. The proline rich region of merintA matches the minimal SH3-binding
domain consensus-sequence PXXP (Ren et al., 1993), although Scansite did not predict
an interaction through either SH3-domain of Grb2 and merintA.
Grb2 localizes in submembranous regions and membrane ruffles of the cell (Bar-
Sagi et al., 1993), and this intracellular localization supports an interaction between
merintA and Grb2. Affinity binding assays demonstrate that merintA and Grb2 can
associate. Moreover, blot overlay assays indicate a direct association between full-
length GST-Grb2 and His-merintA. MerintA was bacterially expressed in these assays
and it is not phosphorylated. Thus, Grb2 can bind to merintA even if Y64 is not
phosphorylated. These assays support binding of merintA to Grb2: (A) via the SH2-
domain while merintA is not phosphorylated, (B) via either SH3-domain or (C) via
both SH2- and SH3-domains.
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The data supporting an interaction between merintA and Grb2 open doors for
many further questions and it is important to determine the domains responsible for
this association. Scansite predicted that the SH2-domain of Grb2 binds to (p)YVNG of
merintA. Therefore, the phosphorylation status of the merintA residue Y64 needs to be
determined. Although merintA is not constitutively phosphorylated, Y64 could be
phosphorylated upon certain growth factor stimulation. Hence, it is important to
analyze carefully the phophorylation status of merintA after stimulation with various
growth factors and correlate potential phosphorylated merintA with respect to Grb2
binding. Conversely, while most studies indicate that the tyrosine in the YV/INX
sequence needs to be phosphorylated for the Grb2 SH2-domain to bind to this
consensus sequence, more recent studies support the binding of non-phosphorylated
peptide ligands to this SH2-domain (Long et al., 1999; Oliginao et al., 1997). The data
obtained from the blot overlay assays support binding of non-phosphorylated merintA
to Grb2. If this interaction turns out to be exclusively mediated by non-phosphorylated
merintA and the Grb2 SH2-domain, merintA would inhibit Grb2 signaling by
competing with other phosphorylated proteins.
Alternatively, the interaction of merintA and Grb2 could be mediated through a
SH3-domain of Grb2 and the proline rich domain of merintA, which would also be
consistent with non-phosphorylated merintA binding to Grb2. Grb2, containing SH2-
loss-of-function point mutations, localizes primarily to membrane ruffles similar to the
wild type protein. On the other hand, Grb2, with SH3- loss-of-function point
mutations, exhibits diffuse cytoplasmic distribution (Bar-Sagi et al., 1993).
Consequently, the localization of Grb2 to membrane ruffles does not require SH2-
mediated interactions, and SH3-domains are responsible for the correct targeting to the
specific subcellular location. A possible binding of Grb2 to merintA via the SH3-
domain could target Grb2 to membrane ruffles and submembranous regions of the cell.
Finally, the interaction of merintA and Grb2 could be mediated through both
SH2- and SH3-domains of Grb2. The SH3-domain of Grb2 could bind to the proline
rich domain of merintA in a non-phosphorylation dependent manner. In contrast, the
SH2-domain might enhance the interaction in a phospho-dependent manner to pYVNG
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of merintA. It is well established that the SH2-domain of Grb2 binds to
autophosphorylated receptor protein tyrosine kinases (RTKs) such as EGFR or
PDGFR (Lowenstein et al., 1992) and mediates EGF signaling pathways (for review
see Buday, 1999). The following question remains if the SH2-domain of Grb2 indeed
binds to merintA in a phospho-dependent manner. Assuming that merintA, Grb2 and
EGFR, for instance, are in the same signaling pathway, how can the SH2-domain of
Grb2 bind to EGFR and merintA? Cytoplasmic linker proteins, such as Shc and SHP-2,
are known to recruit Grb2 to a number of different receptors in the plasma membrane.
The interaction between these linker proteins is also mediated by the SH2-domain of
Grb2 (Buday, 1999). However, unlike merintA, Shc and SHP-2 have SH2-domains
themselves that bind to membrane-bound tyrosine phosphorylated receptors.
Consequently, merintA might compete with the two “linker” proteins Shc and SHP-2,
and membrane-bound tyrosine phosphoproteins known to bind directly to Grb2. In
this case, merintA would inhibit Grb2 signaling pathways (see Figure 32). This
hypothesis is in agreement with the data obtained so far, and would be consistent with
the fact that merlin is a tumor- and growth suppressor.
Initial attempts to co-immunoprecipitate the two proteins were not successful.
A polyclonal rabbit antibody was used to immunoprecipitate merintA, and an antibody
from the same species against Grb2 cannot detect the protein since it co-migrates with
the light chain of the merintA antibody (data not shown). A different strategy needs to
be sought to identify a possible interaction in vivo, and a similar approach to the one
used to demonstrate that NHE-RF immunoprecipitates (see Figure 10 C) could be
applied. Alternatively, monoclonal antibodies raised in mice are commercially available
and could also be used with little or no background staining derived from the binding of
the horseradish peroxidase-conjugated secondary antibody (Western blot analysis) to
the immunoglobulin used for immunoprecipitation. Furthermore, the reciprocal
experiment was performed where Grb2 was successfully immunoprecipitated with a
polyclonal rabbit antibody, and immunoprecipitates were subsequently probed with a
monoclonal mouse antibody against merintA. Here, the problem of background staining
mentioned above was circumvented; however, merintA did not co-immunoprecipitate
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Figure 32. A Potential Model Connecting Merlin and MerintA to Signaling Pathways
through Grb2. See text for details.
with Grb2 (data not shown). These experiments demonstrate the difficulty of co-
immunoprecipitating two proteins. Certain signals might be necessary for the
interaction of merintA and Grb2 in vivo that are not controlled in the co-
immunoprecipitation experiments performed to date. Growth factors such as epidermal
growth factor (EGF) and platelet-derived growth factor (PDGF) are candidates that
might facilitate this interaction (see below). The data suggest that the interaction
observed between merintA and Grb2 is relevant, but further experiments are necessary
to draw a conclusion.
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Again, the SH2-domain of Grb2 binds to autophosphorylated receptor protein
tyrosine kinases (RTKs) such as EGFR or PDGFR (Lowenstein et al., 1992) and the
SH3-domains physically associate with proline-rich proteins including the Ras guanine-
nucleotide exchange factor, Sos (Buday et al., 1993; Egan et al., 1993). For example, the
Grb2-Sos complex binds to the autophosphorylated EGF receptor (EGFR) upon EGF
stimulation. This complex formation brings the exchange factor Sos into contact with its
substrate Ras at the plasma membrane. Thus, Ras is activated through the formation of
a ternary complex of EGFR-Sos-Grb2, and a signal is transmitted to effector molecules
and other GTPases such as Rac (Nimnual et al., 1998; Ridley et al., 1992). Rac, on the
other hand, has been shown to induce membrane ruffles linking growth factors such as
PDGF and EGF to the organization of polymerized actin (Ridley et al., 1992). Merlin
localizes to membrane ruffles upon PDGF induction (Ramesh V., pers. commun.) and
has been placed in a Rac signaling pathway (Shaw et al., 2001). It is tempting to place
merintA into this scenario, but further studies are required to demonstrate its
authenticity. Additional investigations might both, distinguish among EGF, PDGF or
other growth factor mediated induction and define a role for merintA in such a pathway.
Although these are well characterized Grb2 signaling pathways, others are known and
may also be influenced by merintA or vice versa. The linkage of merlin-merintA to
Grb2 should be further analyzed and should be valuable in terms of understanding the
functions of merintA and merlin.
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4.5 Possible Biological Functions of Merlin
Studies of merlin and the ERM proteins reveal that some, but not all of the
characteristics of merlin are shared with the ERM proteins. Subcellular localization
patterns overlap to some extent but are not identical. In contrast to the ERM proteins,
merlin has two major isoforms that differ at the extreme carboxy-terminus. And it is
isoform 1 that forms head-to-tail associations similar to the ERM proteins. Again, some
but not all merlin binding proteins also bind to the ERM proteins. These observations
raise the following question: Why do merlin and the ERM proteins share sequence and
structural properties? The following three points discuss this question: (A) Merlin and
the ERM proteins could be functionally redundant. However, merlin-deficient mice are
embryonic lethal (McClatchey et al., 1997), as opposed to moesin-deficient mice that
develop normally, are fertile and have no obvious histological abnormalities in any
tissues (Doi et al., 1999). In addition, it is merlin that has a known tumor suppressor
function. These data contradict functional redundancy. (B) Merlin and the ERM
proteins might compete for the same binding partners. The molar ratio of endogenous
merlin/ERM proteins was calculated to be between 0.05 and 0.15 in cultured fibroblast
and epithelial cells (Maeda et al., 1999). NHE-RF has been shown to bind with higher
affinity to ezrin than to merlin in vitro (Nguyen et al., 2001). Hence, a merlin-ERM
competition does not seem likely based on the molar ratio and the affinity towards
NHE-RF. However, a recent study suggests that merlin acts as a molecular switch.
When merlin is phosphorylated, it is growth permissive and exists in a complex with
ezrin, moesin and CD44 (transmembrane HA receptor). In contrast, merlin's growth-
inhibitory activity was suggested to depend on a dephosphorylated, specific and
exclusive interaction with the cytoplasmic tail of CD44 (Morrison et al., 2001). Thus,
the affinities for their ligands may-be higher for the ERM proteins than for merlin, but
these might also change temporally giving an advantage to merlin, which is less
abundant and may have lower affinities for ligands. Further studies are necessary to
conclude if the shared sequence is reflected in competition for the same ligands. (C) It is
possible that the similarities of the family members mirror analogous mechanisms and
functions in specific pathways. It is reasonable to hypothesize that merlin and ERM
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proteins function in small GTP-binding protein-dependent signaling pathways. While
merlin could be involved in a small GTPase dependent pathway that regulates cell
growth, cell proliferation and/or cell death, other family members could be responsible
for regulating another small GTPase with different outputs. Understanding the
pathway(s) unique to merlin remains a challenge that will certainly give clues to the
tumor suppressor function of merlin.
This work manifests both similarities and differences between merlin and the
ERM proteins. Merlin isoform 1 behaves similar to the ERM proteins with respect to
binding to the ligand NHE-RF and enhanced binding to NHE-RF in the presence of
phospholipids such as PIP2. In contrast, merintA binds specifically to merlin and not to
the ERM proteins suggesting that the characterization of this protein might lead to the
identification of merlin specific functions. The function of merintA is still under
investigation; however, the possible connection to Grb2 signaling pathways might
illuminate on the function of merintA and the tumor suppressor function of merlin.
Although many binding proteins have been identified during the past few years, a
critical question still remains. How can a cell orchestrate interactions with different
proteins in a way that allows specific signals to be translated into specific responses?
Answering this question in the context of Schwann and meningeal cells will give an
increased understanding of Neurofibromatosis 2 in the future.
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5. Summary
Neurofibromatosis 2 (NF2) is a dominantly inherited disorder that is characterized by
the occurrence of vestibular schwannomas, meningiomas and other nervous system
tumors. Both the familial tumors of NF2, and equivalent sporadic tumors in the general
population, are caused by inactivation of a tumor suppressor gene located on
chromosome band 22q12. By a positional cloning strategy, the NF2 gene has been
isolated and the identity of this tumor suppressor has been discovered. The NF2 gene
has two major isoforms with altered the carboxy-termini, and the NF2 gene product has
been named merlin (moesin, ezrin and radixin like protein) because of its striking
similarity to ezrin, radixin and moesin (ERM). Regulation of the merlin and ERM
proteins (MERM) involves intramolecular and intermolecular head-to-tail associations
between family members. However, in the case of merlin, only the carboxy-terminus of
merlin isoform 1 is able to associate with its amino-terminal domain in a head-to-tail
fashion whereas the carboxy-terminus of isoform 2 lacks this ability. The next step is to
further analyze the normal function of merlin and its role as a growth regulator.
Towards this end the MERM binding protein, NHE-RF, was further characterized and
other merlin binding proteins were sought.
First, the effect of merlin’s self-association on binding to NHE-RF was
examined. Merlin isoform 2 captured more NHE-RF than merlin isoform 1 in affinity
binding assays, suggesting that in full-length merlin isoform 1, the NHE-RF binding site
is masked because of the self-interactions of merlin. Treatment with a phospholipid
(PIP2) known to decrease self-association of ERMs enhanced the binding of merlin
isoform 1 to NHE-RF. Thus, although isoform 1 resembles the ERM proteins, which
transition between inactive (closed) and active (open) states, isoform 2 is distinct,
existing only in the active (open) state.
Next, interactions between NHE-RF and potential binding proteins were
investigated. It had been shown that the PDZ1-domain of NHE-RF binds to the amino
acid motif DS/TXL. The B1 (56kD) subunit of the vacuolar H+ ATPase has the
carboxy-terminal DTAL amino acid motif suggesting a possible association with NHE-
RF. This B1 isoform is amplified in intercalated cells in collecting tubules of the kidney.
Summary                                                                                                                               133
These cells play a role in distal urinary acid-base transport. In contrast, proximal
tubules of the kidney express the B2 isoform that lacks the carboxy-terminal PDZ1
binding motif. Both the B1 subunit and the E subunit of the H+ ATPase are affinity
precipitated by NHE-RF and this interaction was inhibited by a peptide derived from
the carboxy-terminus of the B1 but not the B2 isoform. Furthermore, it is known that
the B and E subunits associate in vivo as part of the cytoplasmic V1 portion of the H
+
ATPase, and here the E subunit was co-immunoprecipitated from rat kidney cytosol
with NHE-RF antibodies. NHE-RF co-localized with H+ ATPase in either the apical or
the basolateral region of B-type intercalated cells, whereas NHE-RF staining was
undetectable in A-intercalated cells. This co-localization of NHE-RF and H+ ATPase
suggests a role in generating, maintaining or modulating the variable H+ ATPase
localization that characterizes the B-cell phenotype.
During the analysis of NHE-RF expression in various tumor lines, a significant
upregulation of NHE-RF expression was observed in the ER- positive breast carcinoma
cell lines MCF-7, ZR-75-B and T-47-D. The induction of NHE-RF by β-estradiol in
estrogen depleted MCF-7 cells was explored, and a dramatic induction of NHE-RF
expression was observed both at the RNA and protein levels. In addition, the
expression of NHE-RF was examined by immunohistochemistry in primary breast
tumors, and it was observed that 90% of the analyzed ER-positive tumors express high
levels of NHE-RF. As NHE-RF appears to be a multifunctional adaptor protein
involved in many cellular signaling pathways, it is likely that its regulation through
estrogen plays a role in breast neoplasia.
To isolate further merlin binding proteins, a yeast two-hybrid screen of a frontal
cortex library had been conducted and revealed that a novel protein (merintA) interacts
directly with merlin. The carboxy-terminus of merlin binds specifically to merintA in
yeast two-hybrid as well as in affinity binding assays. These experiments did not
demonstrate an interaction with the ERM proteins. Moreover, merintA and merlin can
be co-immunoprecipitated as a complex. The gene for human merintA lies on
chromosome 4 where the predicted four exons encode a 178 amino acid protein with the
Grb2 binding motif (p)YVNG. Anonymous orthologues of merintA are expressed in
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mouse, fish and fly. In addition, expression analyses show that merintA is widely
distributed in tissues and cell lines. MerintA co-localizes with merlin and F-actin in
cultured cells as determined by immunofluorescence and electron microscopy. In
addition, merintA associates with merlin to the actin cytoskeleton. Affinity binding
assays and blot overlay assays demonstrate that merintA binds to Grb2 directly. These
findings reveal that merintA is a specific and relevant merlin binding protein and could
link merlin to Grb2 signaling pathways that might reveal clues to the tumor suppressor
function of merlin.
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Merlin, the neurofibromatosis 2 tumor suppressor
protein, has two major isoforms with alternate C ter-
mini and is related to the ERM (ezrin, radixin, moesin)
proteins. Regulation of the ERMs involves intramolecu-
lar and/or intermolecular head-to-tail associations be-
tween family members. We have determined whether
merlin undergoes similar interactions, and our findings
indicate that the C terminus of merlin isoform 1 is able
to associate with its N-terminal domain in a head-to-tail
fashion. However, the C terminus of isoform 2 lacks this
property. Similarly, the N terminus of merlin can also
associate with C terminus of moesin. We have also ex-
plored the effect of merlin self-association on binding to
the regulatory cofactor of Na1-H1 exchanger (NHE-RF),
an interacting protein for merlin and the ERMs. Merlin
isoform 2 captures more NHE-RF than merlin isoform 1
in affinity binding assays, suggesting that in full-length
merlin isoform 1, the NHE-RF binding site is masked
because of the self-interactions of merlin. Treatment
with a phospholipid known to decrease self-association
of ERMs enhances the binding of merlin isoform 1 to
NHE-RF. Thus, although isoform 1 resembles the ERM
proteins, which transition between inactive (closed) and
active (open) states, isoform 2 is distinct, existing only in
the active (open) state and presumably constitutively
more available for interaction with other protein
partners.
Merlin is the tumor suppressor protein deficient in neurofi-
bromatosis 2 (NF2),1 a dominantly inherited disorder charac-
terized by bilateral vestibular schwannomas and other brain
tumors (1, 2). Merlin has a striking similarity in sequence and
structure with ezrin, radixin, and moesin, commonly referred
to as the ERM proteins. The ERM proteins share ;78% amino
acid identity with each other, and all three are 45–47% iden-
tical to merlin (3). Like the ERM proteins and protein 4.1,
merlin possesses a FERM (protein 4.1, ezrin, radixin, moesin)
domain (;270 amino acids defining membership in the protein
4.1 superfamily) in its N-terminal half, followed by a long
a-helical segment and a charged C-terminal domain (4). The
NF2 gene comprises 17 exons with alternative splicing of the
penultimate exon producing two major merlin isoforms. Iso-
form 1 is a 595-amino acid protein produced from exons 1–15
and exon 17. Isoform 2 results from the presence of the alter-
natively spliced exon 16, which alters the C terminus of the
protein to produce a 590-amino acid protein identical to isoform
1 over the first 579 residues (5–7). Mutational analysis has
revealed a wide variety of mutations in the germline and tu-
mors of NF2 patients as well as in sporadic schwannomas and
meningiomas, confirming merlin’s tumor suppressor function
(8).
ERM proteins act as linkers between integral membrane
proteins and the actin cytoskeleton (9). Proteins identified as
ligands for ERM proteins include CD44, CD43, ICAM1,
ICAM2, and actin (9–13). We and others have recently identi-
fied the human homologue of a regulatory cofactor for Na1-H1
exchanger (NHE-RF) as a novel interactor for the conserved N
terminus of merlin and ERM proteins (14, 15). In addition to
interacting with many binding partners, the ERM proteins are
capable of forming homo- and heterotypic associations between
family members (16, 17). Indeed, several recent studies per-
formed on the regulation of ERM proteins suggest that the
availability of ERM domains to binding partners is controlled
by self-association of the N-terminal and C-terminal regions
(13, 18, 19). Thus the ERM proteins can exist in the “closed”
state, where the N- and C-terminal regions undergo an in-
tramolecular interaction, masking the respective ligand-bind-
ing site. This closed state can be converted to the “open” state
in which intramolecular interaction is disrupted by a variety of
cellular signals, including Rho-mediated signaling and the
phospholipid PIP2. In vitro binding studies performed with
merlin isoforms suggested that the C terminus of isoform 1 can
interact with its N terminus, and the C terminus of isoform 2
lacked this property (20). Homotypic interaction of merlin iso-
form 1 and heterotypic interaction between merlin and the
ERM proteins have also been reported recently by yeast two
hybrid and blot overlay assays (21, 22).
In view of the importance of self-association in regulation of
the ERM proteins, we have used affinity co-electrophoresis
(ACE) assays to explore the capacity of the two major merlin
isoforms to self-associate and to interact with a representative
ERM protein. The uniqueness of this assay is the ability to
determine the dissociation constants of the observed interac-
tions. Although, like the ERMs, the C terminus of merlin iso-
form 1 interacts in a head-to-tail fashion with its N-terminal
domain, the C terminus of isoform 2 lacks this property. The N
terminus of merlin is also able to associate heterotypically with
the C terminus of moesin. Furthermore, in affinity binding
experiments we observe that full-length merlin isoform 2 is
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able to capture greater quantities of NHE-RF than full-length
merlin isoform 1, consistent with the notion that the ligand
binding is suppressed by the self-interaction of merlin isoform
1. In addition, the interaction between merlin isoform 1 and
NHE-RF is enhanced in the presence of the phosphoinositide
PIP2. Thus, merlin isoform 1 behaves like the ERM proteins in
its interdomain interaction and its regulation by phospholipids,
but merlin isoform 2 does not exhibit this property and is
always available for interaction with other ligands. The differ-
ent regulation of inter- and intramolecular domain interactions
of the isoforms of merlin could play an essential role in its
tumor suppressor function.
EXPERIMENTAL PROCEDURES
Expression Constructs—Full-length isoform 1 (aa 1–595), full-length
isoform 2 (aa 1–590), N-terminal (aa 1–332), and C-terminal (isoform 1
aa 340–595; isoform 2 aa 340–590; common to both isoforms aa 340–
579) portions of merlin were expressed as glutathione S-transferase
(GST) fusion proteins in pGEX2T. Also, full-length moesin (aa 1–577),
N-terminal (aa 1–332), and C-terminal (aa 307–577) portions of moesin
were expressed as GST fusion proteins in pGEX4T1. Similarly, full-
length NHE-RF (aa 1–338) was expressed as a GST fusion protein.
Expression and purification of the GST fusion proteins were performed
as described previously for merlin (23) and using standard methods for
moesin and NHE-RF. In addition, full-length merlin isoform 1 and 2
were cloned into the mammalian expression vector pcDNA 3 engineered
to have a FLAG tag at the N terminus. These constructs were tran-
siently expressed in Cos-7 cells as described previously (24).
Antibodies—The polyclonal anti-merlin antibody (N21) and the poly-
clonal anti-GST antibody have been described previously (23, 25). A
rabbit polyclonal antibody IC270 was raised against the GST-NHE-RF
fusion protein (aa 270–358). The anti-FLAG antibody M2 was commer-
cially obtained (Kodak, IBI).
Affinity Co-electrophoresis—For affinity co-electrophoresis (ACE),
purified GST fusion protein products of merlin and moesin were throm-
bin cleaved. ACE gels were prepared using 1% low melting point aga-
rose in 125 mM potassium acetate, 50 mM Hepes, pH 7.5, and carried out
as described (25, 26). Gels were run at 60 volts for 4 h, and the proteins
were then transferred to nitrocellulose by capillary action and analyzed
by immunoblotting using an affinity eluted N terminus-specific anti-
merlin antibody (N21) at a dilution of 1:100 and protein A conjugated to
125I. Retardation coefficients were calculated as described previously
(27). Dissociation constants were calculated from nonlinear, least
squares fitting of plots of corrected retardation coefficient versus con-
centration of retarding protein (27, 28). Data were then fit, using a
nonlinear least squares approach (Kaleidagraph, Synergy Software), to
the equation r 5 R`/[1 1 (Kd/[Ptot])], where r 5 retardation coefficient
and [Ptot] 5 protein concentration in a given lane of an ACE gel. The
variables that were fit simultaneously were Kd, the dissociation con-
stant, and R`, the maximum value of R. Data from two independent
experiments were used for calculating dissociation constants, and the
Kd value is shown with S.E.
Affinity Precipitation Assays—ZR-75-B cells were lysed in Brij lysis
buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 8.0, 30% glycerol, 1%
Brij 96) containing a 13 protease inhibitor mixture (Roche Molecular
Biochemicals), and the lysate was incubated with 600 pmol of GST-
merlin immobilized on glutathione (GSH)-Sepharose 4B beads. The
beads were washed extensively with phosphate-buffered saline contain-
ing Pefabloc, resuspended in Laemmli loading buffer, subjected to 10%
SDS-PAGE, and immunoblotted with IC270 antiserum (1:1000). In
some experiments, GST-merlin immobilized on beads was incubated
with ZR-75-B lysate along with 50 ml/ml phosphatidyl serine or PIP2
(Sigma). Each phospholipid was dissolved in distilled water to a final
concentration of 1 mg/ml and sonicated three times each for 10 s.
Cos-7 cells expressing merlin isoforms 1 and 2 as FLAG-tagged
proteins were lysed in Nonidet P-40 lysis buffer (150 mM NaCl, 50 mM
Tris, pH 8.0, 0.5% Nonidet P-40) containing a 13 protease inhibitor
mixture as described above. The lysates were incubated with 600 pmol
of GST-NHE-RF full-length fusion protein or GST protein alone coupled
to GSH-Sepharose 4B beads. The beads were washed as described
above, and the separated proteins were immunoblotted with the anti-
FLAG antibody M2.
RESULTS
Interdomain Interaction of Merlin Isoforms—To determine
whether merlin as an ERM family member is capable of self-
association and to ascertain whether the two major isoforms of
merlin differ from each other in this property, we used the
technique of ACE. Using this technique we were able to dem-
onstrate direct binding between the N- and C termini of merlin
isoforms in solution and to measure the strength of the binding.
Briefly, the thrombin cleaved N- (aa 1–332) and C-terminal (iso
1, aa 340–595 or iso 2, aa 340–590) polypeptides were sub-
jected to affinity electrophoresis in 1% agarose gel in physio-
logical buffer. The N terminus of merlin (at 125 nM) was loaded
into a long transverse slot. The C terminus of either isoform 1
or 2 of merlin was cast (in agarose) into nine rectangular wells
at concentrations ranging from 750 to 0 nM. The anode was
placed so that the more rapidly migrating N-domain passes
through the zones containing the C-domain during most of the
electrophoresis run. The mobility of the N-domain was then
detected by transferring the proteins to nitrocellulose and prob-
ing with an N-terminal-specific antibody. Fig. 1A demonstrates
the interaction of the N terminus of merlin with the C terminus
of merlin isoform 1, where migrating N-domain encountered
the C-domain. The migration of the former was retarded in a
manner that varied directly with the concentration of the lat-
ter. In contrast, the migration of the N-domain of merlin was
not retarded by the C-domain of merlin isoform 2 over the same
range of concentrations (Fig. 1B).
Because we were able to demonstrate a difference in self-
association between the two isoforms of merlin that differ from
FIG. 1. Affinity co-electrophoresis of N- and C-domain of mer-
lin (homotypic) and N-domain of merlin and C-domain of moe-
sin (heterotypic). Thrombin-cleaved GST fusion protein of merlin
N-domain (125 nM) was loaded into a long gel slot perpendicular to the
direction of electrophoresis. Thrombin-cleaved GST fusion proteins of
merlin C-domains isoform 1 (A), isoform 2 (B), domain common for both
isoforms (C), or moesin (D) were loaded at 0, 750, 375, 188, 94, 47, 24,
12, and 6 mM (lanes 1–9, respectively) into multiple wells parallel to the
direction of electrophoresis. After electrophoresis, during which time
the migrating front of N-domain transversed the zones containing the
C-domain, the contents of the gels were transferred to nitrocellulose
and visualized by immunoblotting with an antibody against the N-
domain of merlin. In E and F, electrophoresis was carried out as in A–D,
except the purified GST protein was used as a control in place of the
N-domain of merlin in the long slot, and C-domain of merlin isoform 1
(E) or C-domain of moesin (F) was loaded into the multiple wells. The
migration of the control protein was detected using a specific antibody
against GST. The arrowhead represents the origin where the C termini
of various proteins were loaded.
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each other only at the extreme C terminus, we further sought
to determine whether the C-domain of merlin lacking both
exons 16 and 17 is capable of self-interaction. To address this
question we performed the same type of experiment described
above except the C-domain of merlin spanned the common
region aa 340–579. The results shown in Fig. 1C indicate that
the migration of the N terminus was not retarded by this
C-domain. These data suggest that the domain responsible for
the self-association of the N terminus of merlin to the C termi-
nus of merlin isoform 1 includes, at least in part, the last 16
amino acids (aa 580–595) specific to this isoform.
To evaluate whether merlin can interact in a heterotypic
fashion with other ERM family members, we performed ACE
experiments where the N-domain of merlin was used as the
faster migrating protein passing through the zones containing
the C-domain of moesin (aa 305–557). Fig. 1D shows the inter-
action of merlin and moesin by the retardation of migration of
the N terminus of merlin. The migration of purified GST used
as a control protein was not affected by the merlin C-domain
isoform 1 and moesin C-domain over the same range of concen-
trations (Fig. 1, E and F). From measurements of mobility
retardation in Fig. 1 (A–F), we can calculate the dissociation
constant for the interaction of the N- and C-terminal polypep-
tides of merlin isoforms 1 and 2 (homotypic) and for the inter-
action of merlin to moesin (heterotypic). To avoid problems
arising from the saturation of the films, ImageQuant software
(Molecular Dynamics) was used to determine the true midpoint
of each of the bands (28). Fig. 2 shows the analyses of the six
representative experiments. For every gel, retardation coeffi-
cients (R) were determined for each C-terminal protein concen-
tration tested. Dissociation constants were measurable for N-
merlin interaction with the C-merlin isoform 1 and N-merlin
interaction with the C-moesin by fitting the data to the equa-
tion r 5 R`/[1 5 (Kd,app/[proteintot])] (see “Experimental Proce-
dures”). Merlin isoform 1 can self-interact with a Kd of 49.0 6
6.45 nM, whereas merlin interacts with moesin with a Kd of
28.5 6 6.5 nM. By contrast, no binding was measurable with
merlin isoform 2 and control proteins.
NHE-RF Binds Differentially to Merlin Isoforms—We re-
cently identified NHE-RF, a regulatory factor for the Na1-H1
exchanger isoform 3 (NHE3), as an interacting protein for
merlin in a two-hybrid screen and demonstrated that NHE-RF
can bind to merlin, moesin, and radixin via their conserved
N-terminal regions (14). It is well documented that the binding
of ERM proteins to their ligands is suppressed in the native
full-length protein (13, 18, 19), a phenomenon explained by the
interdomain interactions of the ERM proteins that could com-
pete with the ligand binding (29). We therefore investigated
whether NHE-RF displays differential binding with isoforms 1
and 2 of merlin by performing affinity precipitation experi-
ments. Briefly, equal quantities of merlin full-length isoforms 1
and 2, N-domain, C-domain of both isoforms 1 and 2, expressed
as GST fusion proteins, were bound to Sepharose beads and
incubated with equal amount of ZR-75-B cell lysates. After
extensive washes, the coupled proteins were removed from the
beads by boiling and were detected on Western blots using a
specific polyclonal antibody against NHE-RF. The results
shown in Fig. 3 demonstrate that the N-domain and full-length
isoform 2 of merlin exhibit a greater affinity for NHE-RF than
merlin isoform 1. As expected NHE-RF did not bind to either
the C-domain of both isoforms of merlin or the GST control
protein. These results were further confirmed by at least three
independent experiments.
To confirm the differential binding of merlin isoforms to
NHE-RF, affinity binding assays were performed utilizing mer-
lin isoforms expressed as FLAG-tagged proteins in Cos-7 cells
and GST fusion protein of NHE-RF. The expression of FLAG-
tagged merlin isoforms in Cos-7 cells were examined with an
anti-FLAG antibody (M2) and found to be equally expressed
(Fig. 4, lanes 1 and 2). Cos-7 cell lysates expressing approxi-
mately the same amount of the isoforms were incubated with
600 pmol of GST-NHE-RF beads. The bound proteins were
separated on a 7.5% SDS-PAGE and probed with M2 antibody
(Fig. 4). Merlin isoforms expressed in mammalian cells also
revealed a differential binding to NHE-RF, and the analysis of
the supernatants that were not bound to the beads clearly
showed that NHE-RF beads capture 3–5-fold more merlin iso-
form 2 than isoform 1 in duplicate set of experiments. These
data are consistent with the ACE results supporting that mer-
lin isoform 2 exists constitutively in an open conformation that
allows its ligand, NHE-RF, to interact without being hindered
by the interdomain interaction that occurs in merlin isoform 1.
FIG. 2. Analysis of binding of the homotypic interaction of
merlin isoforms and heterotypic interaction of merlin to moesin
by affinity co-electrophoresis. Six representative ACE gels were
used for these analyses. For each gel, retardation coefficients (R) were
determined for all protein concentration tested for the C termini. Dis-
sociation constants were measurable for N-mer/C-mer iso 1 and N-mer/
C-moesin gels by fitting the data to the equation r 5 R`/[1 5 (Kd,app/
[proteintot])] (see “Experimental Procedures”). The remaining gels
showed no detectable binding. Data for these gels could not be fit to the
equation above and are instead represented as linear fits.
FIG. 3. Binding of NHE-RF to merlin isoforms. Lysate from ZR-
75-B cells were incubated with various GST- merlin fusion proteins
immobilized on GSH-Sepharose 4B beads. The beads were extensively
washed, and bound proteins were separated on 10% SDS-PAGE and
immunoblotted with an anti-NHE-RF antibody (IC270 serum). The
arrow indicates NHE-RF at ;50 kDa (A). Fl-iso 1, full-length isoform 1;
FL-iso 2, full-length isoform 2). B shows equal amounts of GST-merlin
fusion proteins bound to the beads detected by Ponceau S staining.
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Phospholipids Enhance the Binding of NHE-RF to Merlin
Isoform 1—Phosphatidylinositol 4-phosphate and PIP2 en-
hance the interaction of ERM proteins to its ligands CD44,
ICAM-1, and ICAM-2 (13, 18). ERM proteins bind to phosphati-
dylinositol 4-phosphate and PIP2 (30), and it is believed that
this binding evokes conformational changes in these proteins in
a manner similar to the regulation of vinculin activity by PIP2
(31). We therefore examined whether PIP2 influences the bind-
ing of NHE-RF to merlin isoforms. For this, PIP2 or phosphati-
dyl serine was included in the affinity precipitation assays. In
the presence of PIP2 the amount of NHE-RF bound to merlin
isoform 1 significantly increased (Fig. 5). The intensity of the
bands was further analyzed by densitometric scanning of the
autorads using transmittance analysis (Fluor-S, Multiimager,
Bio-Rad). Results from three independent experiments re-
vealed a 3-fold increase (3.10 6 1.04) in binding of NHE-RF to
merlin isoform 1 in the presence of PIP2. The binding of
NHE-RF to either the N-domain of merlin or merlin isoform 2
(1.07 6 0.45) was not influenced by PIP2 (Fig. 5). The control
phospholipid phosphatidyl serine did not enhance the NHE-RF
binding to merlin isoform 1 (Fig. 5).
DISCUSSION
Despite an overall structural similarity to the ERM proteins,
merlin differs from these relatives in having two isoforms with
alternative C termini and in having a demonstrated tumor
suppressor function. Both isoforms are expressed at the RNA
and protein level in a variety of cell lines examined including
NF2 target cells such as Schwann and meningeal cells (Refs. 6
and 7 and our unpublished data).2 Work from other laborato-
ries has demonstrated the interdomain interaction of merlin
using yeast two hybrid, blot overlay, co-immunoprecipitation,
and in vitro binding assays (20–22). Employing the technique
of ACE, we not only demonstrate the difference between merlin
isoforms in their interdomain interaction but also define the
affinities of these interactions. The affinities that we have
observed for merlin self-interaction and for the interaction of
merlin with moesin are quite comparable with that reported for
radixin using similar analysis (25). Because the C-terminal
construct of merlin containing the common region (aa 340–579)
did not exhibit the self-interaction, we believe that the isoform
1-specific C-terminal residues (aa 580–595) are critical for the
interdomain binding. This is in agreement with a previous
report suggesting that extreme C-terminal protein sequences
encoded by exon 17 is critical for the interdomain interaction
(20).
It is well established that the interaction of ERM proteins
with their membrane partners, as well as with the actin cy-
toskeleton, is suppressed in the full-length molecule, a phe-
nomenon explained by intramolecular self-association that
masks the binding sites for other ligands (32, 33). In the pres-
ence of phospholipids such as phosphatidylinositol 4-phosphate
or PIP2, the interdomain interaction is disrupted, thus expos-
ing the ligand binding sites (13, 18). Interdomain interaction
also blocks the binding of full-length ezrin and radixin to
NHE-RF compared with their N termini (29).2 In our earlier
studies (14), we failed to note a similar difference in binding to
NHE-RF between the full-length merlin isoform 1 and the
N-domain of merlin (aa 1–332). This apparent discrepancy
could be explained by the fact that the previous studies were
designed to answer qualitatively whether merlin binds to
NHE-RF. However, the present studies were done in a quan-
titative fashion to address the differences in binding between
the two isoforms of merlin. Our results demonstrate that the
binding of merlin isoform 1 to its ligand NHE-RF is suppressed
in the full-length molecule, and in the presence of PIP2 this
suppression is relieved. Merlin isoforms expressed in mamma-
lian cells show the same difference in their binding to NHE-RF
as the bacterially expressed proteins. The fact that merlin
isoforms expressed in mammalian cells show differential bind-
ing to NHE-RF suggests that this may have functional signif-
icance in vivo.
The studies performed here illustrate the differences in the
ability of the two alternatively spliced isoforms of merlin to
interact with NHE-RF and further show that a phospholipid
such as PIP2 can regulate the interaction of merlin isoform 1 to
NHE-RF. Thus these results document that merlin isoform 1
behaves in a manner similar to its ERM relatives, whereas
merlin isoform 2 behaves distinctly and binds to NHE-RF more
efficiently. Similarly, betaII-spectrin, a C-terminal interactor
of merlin, has been shown to interact to a greater extent with
the C terminus of merlin isoform 2 than with the C terminus of
isoform 1 (34). Phosphorylation of a critical Thr residue at the
C terminus of the ERM proteins has been implicated in stabi-
lizing the open conformation of these proteins (19). This Thr
residue is conserved in both isoforms of merlin; however, fur-
ther studies are required to understand whether the phospho-
rylation of this residue is involved in regulating the intramo-
lecular interaction of merlin isoform 1 and what role it might
play in the function of merlin isoform 2.2 Solomon, F., personal communication.
FIG. 4. Binding of merlin isoforms 1 and 2 to NHE-RF. Cos-7 cell
lysates expressing either FLAG-tagged merlin isoform 1 or merlin iso-
form 2 were incubated with NHE-RF-GST fusion protein or GST protein
expressed alone (control) immobilized on GSH-Sepharose 4B beads. The
beads were extensively washed, and bound proteins were separated on
7.5% SDS-PAGE and immunoblotted with the anti-FLAG monoclonal
antibody M2. Lysates from Cos-7 cells expressing merlin isoforms are
shown for protein expression level in transfected cells. The superna-
tants that were not bound to the beads are shown to point out that
NHE-RF beads capture more merlin isoform 2 than merlin isoform 1.
FIG. 5. PIP2 enhances binding of NHE-RF to merlin isoform 1.
GST-merlin fusion proteins or GST alone were bound to GSH-Sepha-
rose 4B beads and incubated with ZR-75-B cell lysates. In addition, 50
mg/ml PIP2 or 50 mg/ml phosphatidyl serine (PS) was added to the beads
with the cell lysates. The eluted proteins were detected by Western blot
analysis using IC270 serum (A). B shows Ponceau S staining of GST-
merlin fusion proteins bound to the beads.
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Both NHE-RF and the related NHE-RF2 possess two PDZ
domains known to mediate protein-protein interactions. The
interaction of NHE-RF and NHE-RF2 with merlin and the
ERMs is not mediated by the PDZ domains (14, 29, 35). How-
ever, the PDZ domains of both NHE-RF and NHE-RF2 can
interact with several other membrane proteins, such as
Na1-H1 exchanger isoform 3, the b2-adrenergic receptor, the
purinergic P2Y1 receptor, and the cystic fibrosis transmem-
brane conductance regulator, which functions as a Cl2 channel
(35, 36). Thus, NHE-RF and NHE-RF2 appear to act as multi-
functional adaptor proteins that may link merlin and the ERM
proteins to different ion channels and receptors, providing
many new possibilities for effects on intracellular signaling.
Because merlin isoform 2 exists always in the open state, its
interaction with NHE-RF and potentially with other merlin
interactors may in fact occur when the equivalent sites in
merlin isoform 1 and in the ERM proteins are masked in the
closed state.
The strategy of comparing merlin with the related ERM
proteins can be expected to produce similarities that are in-
structive concerning the overall function of these types of pro-
teins and differences that could reveal the special tumor sup-
pressor activity of merlin. In this study, we have observed both.
The behavior of merlin isoform 1 with respect to interdomain
interactions suggests that its regulation is similar to the reg-
ulation of ERM protein interactions. Moreover, the interaction
of merlin with the ERM proteins suggests that these proteins
could also be involved in mutual regulation of each other’s
activities. Although the full range of merlin interactions with
other proteins remains to be delineated, it is likely that merlin
sits within a web of interactions comprising multiple partners
and signaling pathways, some of which are shared with the
ERM family members. Interestingly, studies of the Drosophila
homologue of merlin suggest that its growth suppression prop-
erties reside within the conserved N-terminal domain of the
protein (37). Thus, the distinct tumor suppressor role of merlin
could lie either in the distinct regulation of isoform 2, which
differs from that of isoform 1 and the ERM proteins, or in the
participation of merlin but not the ERM proteins in a signaling
pathway that is uniquely important to NF2 target cells such as
Schwann and meningeal cells.
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The B1 Subunit of the H1ATPase Is a PDZ Domain-binding Protein
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The 56-kDa B1 subunit of the vacuolar H1ATPase has
a C-terminal DTAL amino acid motif typical of PDZ-
binding proteins that associate with the PDZ protein,
NHE-RF (Na1/H1 exchanger regulatory factor). This B1
isoform is amplified in renal intercalated cells, which
play a role in distal urinary acid-base transport. In con-
trast, proximal tubules express the B2 isoform that lacks
the C-terminal PDZ-binding motif. Both the B1 56-kDa
subunit and the 31-kDa (E) subunit of the H1ATPase are
pulled down by glutathione S-transferase NHE-RF
bound to GSH-Sepharose beads. These subunits associ-
ate in vivo as part of the cytoplasmic V1 portion of the
H1ATPase, and the E subunit was co-immunoprecipi-
tated from rat kidney cytosol with NHE-RF antibodies.
The interaction of H1ATPase subunits with NHE-RF
was inhibited by a peptide derived from the C terminus
of the B1 but not the B2 isoform. NHE-RF colocalized
with H1ATPase in either the apical or the basolateral
region of B-type intercalated cells, whereas NHE-RF
staining was undetectable in A-intercalated cells. In
proximal tubules, NHE-RF was located in the apical
brush border. In contrast, H1ATPase was concentrated
in a distinct membrane domain at the base of the brush
border, from which NHE-RF was absent, consistent with
the expression of the truncated B2 subunit isoform in
this tubule segment. The colocalization of NHE-RF and
H1ATPase in B- but not A-intercalated cells suggests a
role in generating, maintaining, or modulating the vari-
able H1ATPase polarity that characterizes the B-cell
phenotype.
Membrane transport proteins are directed toward and in-
serted into specific cell surface domains by an elaborate series
of sorting mechanisms (1). A relatively recent development in
understanding how some of these proteins are concentrated
into functionally differentiated regions of the plasma mem-
brane has been the discovery of the so-called PDZ domain
family of proteins and associated PDZ-binding proteins. Named
after the initial three members of the family (PSD-95, Drosoph-
ila discs large protein, and ZO-1), PDZ proteins contain 80–
100-amino acid stretches that allow them to interact with other
proteins that have a four amino acid PDZ-binding cassette,
usually at the extreme C terminus of the cytoplasmic domain
(2). One such PDZ-binding cassette is the amino acid sequence
D(S/T)XL. Thus, putative PDZ-binding proteins can be identi-
fied by screening their amino acid sequence for these concensus
cassettes. Among the many proteins identified so far are the
cystic fibrosis transmembrane conductance regulator (3), the
b2-adrenergic receptor (4), neuronal nitric-oxide synthase (5),
GLUT1 (6), and some potassium channels (7–9). One PDZ
protein to which the cystic fibrosis transmembrane conduct-
ance regulator (10), the b2-adrenergic receptor, and P2Y1 re-
ceptor (4) bind is the Na1/H1 exchanger regulatory factor,
NHE-RF, originally identified in rabbit kidney as a soluble
factor that participates in the regulation of the NHE-3 Na1/H1
exchanger at the apical pole of proximal tubule epithelial cells
(11, 12). NHE-RF also binds to the ERM family of actin-binding
proteins via its C terminus outside the PDZ-binding motif (13,
14), thus potentially linking many ion channel and receptors to
the actin cytoskeleton. Furthermore, NHE-RF has been re-
ported to interact with the Na1/HCO3
2 co-transporter, a baso-
lateral protein in proximal tubules (15).
The B1 (56-kDa) subunit of the vacuolar proton-pumping
ATPase (H1ATPase) has a C-terminal DTAL motif, which sug-
gests that it is a candidate PDZ-binding protein. This subunit
of the H1ATPase is expressed in several tissues, but it is
strongly amplified in specialized proton-translocating interca-
lated cells in the kidney (16), as well as similar cells in the
epididymis (17). In contrast, a highly homologous 56-kDa iso-
form, the B2 isoform, is expressed in the kidney proximal
tubule, but it has a C-terminal truncation and lacks the termi-
nal PDZ-binding cassette (16). Most if not all of the PDZ-
binding proteins so-far reported are transmembrane proteins,
but the B1 H1ATPase subunit is part of the V1 portion of the
holo-enzyme and has no membrane spanning domain. It is
tethered to the membrane by interaction with other subunits of
the enzyme, some of which span the lipid bilayer (18). Further-
more, multi-subunit complexes consisting of the cytoplasmic
portion of the H1ATPase can exist as free, cytosolic entities
(18).
In kidney cortex, intercalated cells show a complex regula-
tion of H1ATPase expression at the cell surface (19), and sub-
populations of these cells with apical, basolateral, diffuse, or
even bipolar H1ATPase localization can be detected by immu-
nocytochemistry (20). A-cells always have H1ATPase at their
apical pole and the Cl2/HCO3
2 exchanger AE1 at their basolat-
eral pole (21). These cells secrete protons into the tubule lu-
men. B-cells have no detectable AE1 in either plasma mem-
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brane domain, but the H1ATPase can be apical, basolateral, or
bipolar in these AE1-negative cells. Cells with basolateral
H1ATPase are bicarbonate-secreting cells. Although systemic
acidosis results in more intercalated cells having apical
H1ATPase, and alkalosis shifts more cells to a basolateral
pattern of localization (22, 23), the cell biological mechanisms
underlying these dramatic shifts in the polarized expression of
a membrane protein remain unknown in situ. In this report, we
show that the 56-kDa B1 subunit of the proton pump is a
PDZ-binding protein that can associate with NHE-RF and that
NHE-RF colocalizes with the H1ATPase in all B-intercalated
cells, wherever the pump is located within any individual cell.
We propose that the interaction of this subunit of the proton
pump with NHE-RF could be responsible for the anchoring
and/or targeting of membrane-associated H1ATPase molecules
in this cell type. NHE-RF was barely detectable in A-type
intercalated cells. In contrast, NHE-RF was abundant in the
proximal tubule brush border, but its intracellular location was
clearly distinct from that of the H1ATPase in these cells.
EXPERIMENTAL PROCEDURES
Animals—Male Harlan Sprague-Dawley rats were anesthetized with
sodium pentobarbital (Nembutal, 0.1 ml of a 50 mg/ml solution/100 g of
body weight), and kidneys were fixed by perfusion through the abdom-
inal aorta with a fixative containing 4% paraformaldehyde, 10 mM
sodium periodate, 70 mM lysine (PLP), and 5% sucrose as described
previously (24, 25). After 5 min of perfusion, kidneys were removed,
sliced, and fixed by immersion for a further 6 h before rinsing and
storage in PBS1 (10 mM sodium phosphate buffer containing 0.9% NaCl,
pH 7.4). For preparation of 4-mm sections, tissues were cryoprotected in
30% sucrose before sectioning with a Reichert Frigocut microtome using
disposable knives.
Immunostaining—Tissue sections picked up on Fisher Superfrost
Plus slides (Fisher Scientific) were rinsed for 10 min in PBS and then
treated with 1% SDS for 5 min. This step augments antigenicity of
many proteins in frozen sections of PLP-fixed tissues, as described
previously (26). After three more rinses (5 min each) in PBS to remove
the SDS, sections were incubated for 20 min in PBS/1% bovine serum
albumin to block nonspecific background staining. Primary anti-
NHE-RF antibody (affinity purified rabbit polyclonal antibody IC270
raised against GST-NHE-RF fusion protein amino acids 270–358) was
applied for 2 h at room temperature at a dilution of 1:4. This antibody
has been characterized previously (27). After washing twice for 5 min in
high salt PBS (PBS containing 2.7% NaCl) to reduce nonspecific stain-
ing and one further washing for 5 min in normal PBS, secondary
anti-rabbit antibodies (diluted 1:800) coupled to CY3 (Jackson Immu-
nologicals) were applied for 60 min. After further washing as above,
sections were mounted in Vectashield anti-fading solution (Vector
Labs., Burlinghame, CA), diluted 1:1 in 0.1 M Tris-HCl, pH 8.0.
Some sections were double-stained with anti-H1ATPase antibodies
to identify the cells that were positive for NHE-RF in the collecting
duct. After application of the anti-NHE-RF antibody followed by sec-
ondary antibody coupled to CY3, an affinity purified chicken polyclonal
antibody against the 31-kDa E subunit of the H1ATPase (a marker of A-
and B-intercalated cells, diluted 1:40) was applied for 2 h, followed by a
donkey anti-chicken IgG coupled to FITC, diluted 1:200 (Jackson Im-
munologicals). Sections were mounted in Vectashield diluted 1:1 in 0.1
M Tris-HCl, pH 8.0.
Some sections were double stained using a rabbit anti-AE1 Cl2/
HCO3
2 exchanger antibody that has been previously characterized (28).
Because this antibody is also raised in rabbit, an amplification proce-
dure was used to allow staining of sections with two primary antibodies
raised in the same species. Briefly, the first primary, anti-AE1, was
applied at a dilution of 1:32,000, a concentration that is too low to be
detected by conventional application of a fluorescent secondary anti-
body, as determined in preliminary experiments. The dilute AE1 anti-
body was detected using a tyramide amplification kit (NEN Life Science
Products) with tyramide-CY3 as a fluorescent reagent, according to the
manufacturer’s instructions. The sections were then incubated conven-
tionally with anti-NHE-RF and secondary goat anti-rabbit FITC as
described above. No cross-reactivity between the two sets of reagents
was detectable under these conditions. Sections were photographed in
color on Kodak Ektachrome 400 Elite film exposed at 2500 ASA using
a Nikon Eclipse 800 epifluorescence microscope equipped with specific
CY3 and FITC filter combinations. Using the specific CY3 filter combi-
nation and analog photography, CY3 emission appears yellow (see Fig.
1, A and C). Some micrographs were prepared from digital images
captured from the Nikon Eclipse 800 using a Hamamatsu Orca digital
camera. Pseudocolored images were merged using IP Lab Spectrum
software (Scanalytics Inc, Vianna). In these images, CY3 fluorescence
appears red, and FITC is green (see Fig. 2). Control incubations were
performed in which the primary NHE-RF antibody was incubated with
the GST-NHE-RF fusion protein (at a final concentration of 0.2 mg/ml)
for 1 h at room temperature prior to applying the antibody to the
sections.
Preparation of Rat Kidney Inner Stripe Cytosol—Kidneys of anesthe-
tized rats were perfused with cold PBS for 1–2 min to remove blood, and
the inner stripe was separated under a dissecting microscope. Pieces of
inner stripe (0.4 g) were homogenized in 2 ml of homogenization buffer
(0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCl, pH 7.4, with CompleteTM,
Roche Molecular Biochemicals, mixture of protease inhibitors) using a
Wheaton glass potter fitted with a Teflon pestle (20 complete strokes).
Rat kidney inner stripe cytosol was prepared by centrifugation of the
homogenate for 1 h at 100,000 3 g (41,000 rpm) using a Beckman,
TL-100 Ultracentrifuge equipped with a TLA 55 rotor. Protein concen-
tration of cytosol was measured with the Pierce BCA protein assay
reagent using albumin as a standard.
Affinity Precipitation and Peptide Competition Assay—Pull-down ex-
periments were performed essentially as described previously (27) with
minor modifications. Briefly, rat kidney inner stripe cytosol (0.4 mg of
total protein) was incubated overnight at 4 °C with 600 pmol of GST-
NHERF or GST alone as a control immobilized on GSH-Sepharose 4B
beads. For the peptide competition assay, peptides B1 (PQDTEADTAL)
and B2 (EFYPRDSAKH) were dissolved in distilled water, and 300 mg
of peptide were preincubated with the GST-NHE-RF beads for 1 h at
4 °C. Cytosol containing 300 mg of peptide was then added to the beads,
and the mixture was incubated overnight at 4 °C. The beads were then
washed extensively with phosphate-buffered saline containing Pefabloc
and resuspended in Laemmli sample buffer for SDS-PAGE.
Immunoprecipitation Assay—Rat kidney cytosol was prepared as for
the pull-down assay, except that cytosol from the entire cortex and
outer medulla was used to ensure that adequate amounts of NHE-RF
were present in the preparation. NHE-RF was immunoprecipitated
from 500 ml (2.8 mg of total protein) of precleared (by preincubation
with protein A-agarose beads alone) cytosol using 10 ml of anti-NHE-RF
antiserum (IC270 serum or IC270 preimmune serum) and 50 ml of
protein A-agarose beads (Roche Molecular Biochemicals). Immunopre-
cipitates were washed extensively with PBS and eluted by boiling in
SDS sample buffer (as for the pull-down assay). The immunoprecipi-
tates were run on SDS-PAGE and blotted using a monoclonal anti-E
subunit antibody (E11) as described below.
SDS-PAGE and Western Blot Analysis—Electrophoresis was per-
formed using 12% SDS-Tris-glycine-PAGE gels. Proteins were trans-
ferred to polyvinylidene difluoride membranes and analyzed by West-
ern blotting. The following antibodies were used as detailed in the
figure legends: affinity-purified chicken polyclonal anti-E H1ATPase
subunit (1:1,000) and affinity-purified rabbit polyclonal anti-B1
H1ATPase subunit (1:1,000), raised against the bovine subunits, and a
monoclonal anti-E subunit antibody (E11) kindly provided by Dr.
Steven Gluck (University of Florida, Gainesville). Images were scanned
and analyzed with NIH Image (version 1.62) software.
RESULTS
Localization of NHE-RF in the Kidney—NHE-RF was local-
ized in the kidney on PLP-fixed cryostat sections that had been
treated with SDS. As expected from the reported distribution of
NHE-3 (29), by far the greatest amount of NHE-RF was found
in proximal tubules. The entire brush border was strongly
stained in all proximal tubule segments (Fig. 1, A and C). In
addition, however, staining was seen in some cells of the cor-
tical collecting ducts and connecting segments (Fig. 1, A and C).
The extent and intracellular location of this staining was vari-
able, with some cells showing distinct basolateral staining (Fig.
1A), others showing a more diffuse cytoplasmic staining (Fig.
1C), and yet others showing apical staining (Fig. 1C). These
cells were identified as intercalated cells by double incubations
1 The abbreviations used are: PBS, phosphate-buffered saline; GST,
glutathione S-transferase; FITC, fluorescein isothiocyanate; PAGE,
polyacrylamide gel electrophoresis.
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using a chicken polyclonal antibody against the 31-kDa (E)
subunit of the H1ATPase (Fig. 1, B and D). We have previously
shown that the three major subunits of the cytoplasmic domain
of this enzyme colocalize in intercalated cells (30). Thus, the E
subunit is a reliable marker for the entire cytoplasmic domain
of the H1ATPase, which also contains the 56 B kDa subunit. In
these double-stained sections, the NHE-RF staining colocalized
with the H1ATPase staining in intercalated cells, whereas
connecting tubule cells that also contain the H1ATPase do not
express detectable levels of NHE-RF (Fig. 1, C and D). How-
ever, in some intercalated cells, apical H1ATPase staining was
seen with no detectable NHE-RF staining (Fig. 1A). Principal
cells in some tubule segments showed a faint, finely granular
staining in the cytoplasm that was much less intense than in
the adjacent intercalated cells.
To distinguish between A- and B-intercalated cells, anti-AE1
antibodies, which label only A-cells (21), were used in conjunc-
tion with anti-NHE-RF antibodies. All cells with distinct api-
cal, diffuse, or basolateral NHE-RF staining were negative for
AE1 (Fig. 2). Furthermore, only A-intercalated cells are found
in the inner stripe of the outer medulla, and these cells showed
no detectable staining with the NHE-RF antibody (not shown).
Thus, NHE-RF is most highly expressed in B-intercalated cells,
and its variable intracellular localization pattern overlaps with
that of the H1ATPase in each individual B-cell in the cortical
collecting duct and connecting segment.
In proximal tubules, NHE-RF was present in the brush bor-
der (Fig. 3), as predicted from previous studies that showed
abundant NHE-3 in this location (11, 29). However, the
H1ATPase staining was, as we have previously described (30),
the most concentrated in a tight subapical band at the base of
the brush border. This subapical domain, showing intense
FIG. 2. Double staining of rat kidney cortex collecting ducts
with antibodies against NHE-RF (green) and AE1 (red). The red
AE1 staining is basolateral in all A-intercalated cells. These cells do not
stain for NHE-RF. In A, two cells with apical NHE-RF staining are
found alongside an A-intercalated cell with basolateral AE1 staining. In
B, two cells with basolateral NHE-RF staining are found in the same
tubule as A-intercalated cells with basolateral AE1. Other cells are
negative for both antigens. C shows a collecting duct with a mixture of
AE1 positive/NHE-RF negative A-intercalated cells and NHE-RF-posi-
tive/AE1-negative B-intercalated cells. A small amount of punctate
NHE-RF staining is seen in cells that are probably principal cells. In
these merged digital images, CY3 staining is pseudocolored red to allow
it to be more readily distinguished from the adjacent green FITC stain-
ing. Bar, 10 mm.
FIG. 1. Sections of rat kidney cortex double stained for NHE-RF (A and C) and the 31-kDa subunit of the H1ATPase (B and D). The
brush border is strongly stained in all proximal tubules. Some cells of the collecting ducts (CD) and connecting segments (CNT) are also stained.
Different patterns of NHE-RF staining are detected, and the staining overlaps with that of the H1ATPase in intercalated cells. Some cells have
basolateral staining (1), some have diffuse cytoplasmic staining (2), some have apical staining (3), and others have little or no NHE-RF staining
but show apical H1ATPase staining (4). In connecting segments (CNT), all cells have strong H1ATPase staining, as described previously (30), but
only a few of these are clearly NHE-RF-positive. The staining in A and C, which represent single exposures of the NHE-RF staining, appears yellow
because of the use of a highly specific filter combination used for the CY3 fluorophore. Cy3 emission is yellow when the correct filter combination
is used. Bar, 15 mm.
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H1ATPase staining in the S3 segment, did not contain detect-
able levels of NHE-RF (Fig. 3). This is consistent with the
known expression of the C-terminally truncated B2 isoform of
the 56-kDa subunit in these cells, which lacks the DTAL PDZ-
binding motif (16). NHE-RF was not detected in the basolateral
domain of proximal tubules.
To determine the specificity of labeling with anti-NHE-RF
antibodies in kidney cortex, parallel incubations were per-
formed with normal anti-NHE-RF antibody and with antibody
that had been preincubated with 0.2 mg/ml of the GST-
NHE-RF fusion protein that was used as an immunogen. The
results show that the proximal tubule staining, as well as the
apical, basolateral, and bipolar intercalated cell staining were
completely abolished by preincubation with the immunizing
fusion protein (Fig. 4).
Binding of Soluble H1ATPase Complexes to a GST-NHE-RF
Affinity Matrix—Sepharose beads to which a GST-NHE-RF
fusion protein was bound were used as an affinity matrix to
extract potential binding proteins from renal medullary cy-
tosol. A cytosolic preparation from the inner medulla was used
for these experiments because (a) kidney cytosol contains large
amounts of free cytosolic H1ATPase subunits (Fig. 5A, Cy-
tosol), (b) this kidney region contains high levels of the B1-
H1ATPase isoform, located in A-type intercalated cells, and (c)
this region contains no proximal tubules, which express abun-
dant endogenous NHE-RF that could potentially compete with
protein binding to the affinity matrix. Under these conditions,
Western blots of the affinity-purified material bound to the
beads showed that both the B1 and the E subunits of the
H1ATPase were present (Fig. 5A). Control experiments using
the matrix with GST alone showed little or no H1ATPase
subunit antigenicity associated with the beads in the absence of
NHE-RF, indicating the specificity of the association. The bind-
ing of H1ATPase to the NHE-RF-GST affinity matrix was
completely inhibited by incubation of the beads with an 11-
amino acid C-terminal peptide derived from the B1 H1ATPase
subunit, which contains the C-terminal motif DTAL (PQD-
TEADTAL). However, binding was not inhibited by preincuba-
tion with a peptide containing the 11 C-terminal amino acids of
the B2 56-kDa subunit isoform (EFYPRDSAKH), which does
not contain the PDZ-binding motif (Fig. 5B).
Co-immunoprecipitation of NHE-RF and the H1ATPase—to
strengthen the evidence for an in vivo interaction between
NHE-RF and the H1ATPase, evidence for co-immunoprecipi-
tation of the two proteins from rat kidney cytosol was sought.
As shown in Fig. 5C, the E subunit of the H1ATPase was
co-immunoprecipitated from kidney cytosol by the anti-
NHE-RF antibody but not by preimmune serum.
DISCUSSION
The present data show that the 56-kDa B1 subunit isoform of
the H1ATPase is a PDZ-binding protein that allows association
of the cytosolic (V1) portion of the H1ATPase with NHE-RF, a
PDZ protein that is expressed in the kidney. Immunolocaliza-
tion indicates that in the collecting duct and connecting seg-
ment, this association occurs in a specialized subtype of inter-
calated cell, the B-cell, which has a highly variable pattern of
intracellular localization of the H1ATPase (19–21, 23). Other
FIG. 3. Proximal tubule from rat kidney cortex showing the
distribution of NHE-RF (red) on the brush border microvilli,
and the H1ATPase (31-kDa subunit; green) on submicrovillar
vesicles and invaginations. The two proteins are not co-localized in
this S3 tubule segment. A differential interference contrast image is
shown in the lower panel for orientation purposes. Bar, 10 mm.
FIG. 4. Control for the specificity of NHE-RF staining in rat
renal cortex. Under normal incubation conditions (A), NHE-RF stains
the brush border of proximal tubules, as well as intercalated cells in
variable patterns (apical, basolateral, and bipolar). This staining is
completely inhibited by preincubation of the NHE-RF antibody with the
immunizing GST-NHE-RF fusion protein (B). Bar, 10 mm.
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collecting duct cell types, including principal cells and A-inter-
calated cells, showed a very low level of staining. The greatest
amount of NHE-RF staining was observed, as expected in prox-
imal tubules, but some thin limbs of Henle in the medulla were
also strongly stained (not shown).
Especially intriguing is the failure to detect NHE-RF in
A-type intercalated cells, which also contain high levels of the
B1-H1ATPase subunit but which always have an apical stain-
ing for this protein, either on the plasma membrane or on
numerous subapical vesicles. Thus, NHE-RF expression is am-
plified in the AE1-negative B-cell population, in which the
pattern of H1ATPase localization is widely variable. This re-
sult suggests that the B-cell represents a distinct cell type with
respect to NHE-RF expression and that NHE-RF could be
involved in generating and/or maintaining apical and basolat-
eral H1ATPase polarity in B-cells. Because A-cells, which in-
sert H1ATPase uniquely into the apical domain, contain little
or no detectable NHE-RF, we conclude that NHE-RF is in some
way involved in the ability of B-cells to display plasticity of
membrane H1ATPase insertion. This could occur via the asso-
ciation of NHE-RF with merlin and/or ezrin, members of the
ERM (ezrin, radixin, moesin) family of actin binding proteins,
which bind to the C-terminal of NHE-RF (27, 31). Other fac-
tors, including an extracellular matrix protein named hensin,
have also been implicated in generating the plasticity of the
intercalated cell phenotype at least in vitro (19, 32). An addi-
tional interesting finding is that both the B1 and B2 subunits
of the H1ATPase are capable of binding actin directly via their
N-terminal domains (33). Thus, it is possible that the
H1ATPase interacts with the actin cytoskeleton both directly
and indirectly (via NHE-RF). The respective roles and the
regulation of these two mechanisms of interaction now need to
be evaluated in different cell types. Indeed, phosphorylation of
NHE-RF has been shown to disrupt the indirect interaction of
the b2-adrenegric receptor with the actin cytoskeleton and to
affect the endocytic sorting of this receptor (34).
Although antibodies against all of the H1ATPase subunits
were not utilized in this study, at least two major cytosolic
subunits associated with the NHE-RF-GST beads in an affinity
binding assay, and the E (31 kDa) subunit of the H1ATPase
was co-immunoprecipitated from rat kidney cytosol by anti-
NHE-RF antibodies. Because of interference from the rabbit-
derived polyclonal NHE-RF IgG used for immunoprecipitation,
we were unable to determine whether the 56-kDa H1ATPase
subunit was also co-immunoprecipitated from these samples.
In addition, our data show that a peptide derived from the C
terminus of the B1 56-kDa subunit isoform, but not from the B2
isoform, inhibits interaction of the H1ATPase with NHE-RF.
Coupled with previous data showing that preassembled
H1ATPase cytoplasmic domains exist in the cytosol (18), our
data suggest that the cytosolic portion of the H1ATPase can
bind NHE-RF via a specific interaction with the C-terminal
DTAL motif that is unique to the B1 subunit. Furthermore, our
data provide some evidence that the interaction occurs via the
C-terminal domain of the 56-kDa subunit, because the rest of
the protein sequence of these two isoforms is similar except for
a short N-terminal sequence difference (16, 35). It is likely that
when this 56-kDa subunit is assembled in a membrane to-
gether with the transmembrane portion of the H1ATPase (the
Vo sector), the entire H1ATPase assembly could thereby be
coupled to NHE-RF and thus be anchored into a selected mem-
brane domain. However, it is interesting that this domain can
be either the apical or the basolateral domain in the B-inter-
calated cell. It has been stated recently that NHE-RF expres-
sion is restricted to the apical domain of epithelial cells (36),
but this is clearly not the case in B-intercalated cells. Thus,
NHE-RF may not determine the polarity of H1ATPase expres-
sion per se, but NHE-RF might stabilize the complex once it has
reached its target membrane. In other cell types, NHE-RF
appears to stabilize the cystic fibrosis transmembrane conduct-
ance regulator in the apical plasma membrane (3), whereas in
Caenorhabditis elegans, PDZ proteins have been proposed to be
involved in basolateral anchoring and/or targeting of a TGF-b
homolog (37). Recently, a Drosophila PDZ protein, discs lost,
was also reported to have a dual role in maintaining apical and
basolateral epithelial cell polarity (38). However, the diffuse,
intracellular pattern of NHE-RF and H1ATPase localization
seen in some B-intercalated cells raises the possibility that
NHE-RF might participate in the trafficking or targeting of the
H1ATPase. Whether PDZ proteins are involved in anchoring,
targeting, or both processes remains to be determined, but our
results clearly indicate that this process is not unidirectional
(i.e. exclusively apical) in every cell type.
In the proximal tubule, NHE-RF is abundant and is colocal-
FIG. 5. Results of the GST-NHE-RF pull down assay and co-
immunoprecipitation. A shows that both the B1 and the E
H1ATPase subunits are pulled down by GST-NHERF beads, but not by
beads coupled to GST alone. B shows that the ability of the GST-
NHERF beads to pull down the H1ATPase (in this case the E subunit)
is completely inhibited by a peptide derived from the B1 H1ATPase
subunit (which contains the DTAL motif) but is not competed away by
the B2 subunit peptide. C shows that the E subunit of the H1ATPase is
co-immunoprecipitated by anti-NHE-RF antibodies but not by preim-
mune serum. In all of these blots, the E subunit runs slightly higher
than the predicted 31-kDa molecular mass for this subunit. IP,
immunoprecipitate.
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ized with NHE-3 in the apical brush border (data not shown).
This scaffolding interaction is probably responsible for main-
taining NHE-3 at a high concentration in the apical membrane
(29). The B subunit of the H1ATPase that is expressed in this
tubule segment lacks the C-terminal DTAL and should be
incapable of interacting with PDZ domain proteins (16). Immu-
nofluorescence shows that the H1ATPase is not colocalized
with NHE-RF at the apical pole of proximal tubules. Because
H1ATPase is involved in the extensive apical membrane endo-
cytosis and recycling that occurs in proximal tubules (1), it may
be advantageous for this cell type to express an isoform of
the H1ATPase B subunit that cannot interact with NHE-RF at
the apical membrane. Such an interaction would anchor the
H1ATPase in the plasma membrane by cross-linking to the
NHE-3/NHE-RF complex and might hinder the endocytotic
recycling of this protein, leading to failure of the endosomal
acidification process and defective recycling of apical mem-
brane proteins.
We have previously reported that the 56-kDa B1 subunit of
the H1ATPase is present on endosomes in the other collecting
duct cell type, the principal cell (39). These endosomes are
involved in recycling the water channel AQP2, they do not
acidify their lumen, and they lack other subunits of the
H1ATPase (39). We postulated that the 56-kDa subunit might
be a promiscuous subunit that could associate with the mem-
branes of these endosomes via another, as yet unidentified
mechanism. This mechanism can now be envisaged to occur via
the PDZ-binding domain, although principal cells were only
weakly stained with the anti-NHE-RF antibody. Thus, it is
possible that in principal cells, a different PDZ protein such as
the NHE-RF related NHE-RF2 (3) might be associated with the
56-kDa H1ATPase B1 subunit.
In summary, we have shown that the B1 subunit isoform of
the H1ATPase is a PDZ-binding protein that associates with
NHE-RF and may therefore be responsible for linking the
H1ATPase to the cytoskeleton in these cells. The two proteins
are colocalized in B-intercalated cells but not in A-cells, sug-
gesting a role in generating, maintaining, or modulating the
B-cell phenotype. NHE-RF and H1ATPase are not colocalized
in proximal tubules, which express a truncated B2 subunit
isoform of the H1ATPase that lacks the PDZ-binding domain.
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NHE-RF, a Merlin-Interacting Protein, Is Primarily
Expressed in Luminal Epithelia, Proliferative
Endometrium, and Estrogen Receptor-Positive
Breast Carcinomas
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NHE-RF, a regulatory cofactor for NHE (Na1-H1 ex-
changer) type 3, interacts with ion transporters and
receptors through its PDZ domains and with the
MERM proteins (merlin, ezrin, radixin and moesin)
via its carboxyl terminus. Thus, NHE-RF may act as a
multifunctional adaptor protein and play a role in the
assembly of signal transduction complexes, linking
ion channels and receptors to the actin cytoskeleton.
NHE-RF expression is up-regulated in response to es-
trogen in estrogen receptor-positive breast carcinoma
cell lines, suggesting that it may be involved in estro-
gen signaling. To further understand NHE-RF function
and its possible role in estrogen signaling, we ana-
lyzed NHE-RF expression in normal human tissues,
including cycling endometrium, and in breast carci-
nomas, tissues in which estrogen plays an important
role in regulating cell growth and proliferation.
NHE-RF is expressed in many epithelia, especially in
cells specialized in ion transport or absorption, and is
often localized to apical (luminal) membranes.
NHE-RF expression varies markedly in proliferative
versus secretory endometrium, with high expression
in proliferative (estrogen-stimulated) endometrium.
Furthermore, estrogen receptor status and NHE-RF
expression correlate closely in breast carcinoma
specimens. These findings support a role for NHE-RF
in estrogen signaling. (Am J Pathol 2001, 158:57–62)
NHE-RF (Na1-H1 exchanger regulatory factor), a cyto-
plasmic phosphoprotein, was originally identified in the
rabbit renal brush border as a cofactor required for
cAMP/protein kinase A-mediated inhibition of NHE
(Na1-H1 exchanger) type 3.1 The human homologue was
identified from human placenta and has also been re-
ferred to as EBP50 (ezrin binding protein).2 NHE-RF is a
358-amino-acid protein with two homologous PDZ do-
mains, which mediate protein-protein interactions. A re-
lated protein, NHE-RF2 (also known as E3KARP), was
isolated from small intestine and renal brush border and
shares 51% identity with NHE-RF, primarily in the PDZ
domains.3 PDZ-containing proteins are often localized at
the plasma membrane and appear to promote the as-
sembly of membrane-bound macromolecular complexes
(transduction complexes), into which target molecules
are recruited. Many PDZ domain-containing-proteins are
involved in cell signaling.4–6
NHE-RF interacts, via its PDZ domains, with a variety of
ion transport proteins such as the cystic fibrosis trans-
membrane regulator, the sodium bicarbonate cotrans-
porter, as well as with membrane receptors such as the
b2 adrenergic and the purinergic P2Y1. Recently, we and
others have shown that NHE-RF directly interacts with
merlin, the NF2 (neurofibromatosis 2)-encoded tumor
suppressor protein, and with ezrin, radixin, and moesin
(MERM proteins), which are involved in cytoskeletal reor-
ganization and signal transduction.7 The MERM binding
region is a non-PDZ site in the C-terminus.8 Thus,
NHE-RF may also be involved in the assembly of trans-
duction complexes that link membrane receptors and
transporters with intracellular signaling components.
Interestingly, NHE-RF expression is up-regulated in
response to estrogen in estrogen receptor (ER)-positive
breast carcinoma cell lines (see Ref. 9 and unpublished
data). NHE-RF expression in these cells is mediated by
the estrogen receptor and suppressed by antiestro-
gens.9 These findings suggest a role for NHE-RF in the
estrogen signal transduction cascade in estrogen-re-
sponsive tissues. To gain more insight into the physiolog-
ical relevance of NHE-RF, we performed a comprehen-
sive expression study of the protein in normal adult
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human tissues. To evaluate the relationship between es-
trogen and NHE-RF expression in normal and malignant
estrogen-responsive tissues, we also examined NHE-RF
expression in cycling endometrium, as well as in ER-
positive and ER-negative breast carcinomas.
Materials and Methods
Tissues
Formalin-fixed, paraffin-embedded sections of normal
adult human organs from surgical specimens and autop-
sies were obtained from the Department of Pathology at
Massachusetts General Hospital. We examined two to
five samples from each paraffin-embedded organ. Or-
gans examined included: brain and spinal cord, periph-
eral nerve, pituitary gland, placenta, kidney, skin, muscle,
endometrium, breast, esophagus, stomach, small and
large intestines, liver, spleen, pancreas, salivary glands,
thyroid, tonsils, heart, and lungs. To evaluate the possible
association between estrogen and NHE-RF expression in
normal tissues, we examined multiple samples of prolif-
erative and secretory endometrium. To assess the pos-
sible association between estrogen receptor status and
NHE-RF expression in breast carcinomas, we studied
eighteen invasive breast carcinomas for which estrogen
receptor status has been previously determined by im-
munohistochemistry.
Cell Lines
Breast cancer cell lines MCF-7, ZR-75-B, T-47D, MCF-7-
ADR, and MDA-MB-231 were obtained from the Massa-
chusetts General Hospital Cancer Center, and normal
breast epithelial cell lines HBL-100 and MCF-12-F were
obtained from ATCC. Cell lines were maintained in DMEM
with 10% fetal calf serum.
Antibodies
The polyclonal IC270 antibody is directed at the GST-
NHE-RF fusion protein and has been characterized else-
where.10,11 A commercial antibody (Estrogen Receptor,
Clone 1D5, DAKO, Carpinteria, CA) was used to evaluate
estrogen receptor status; this antibody recognizes both
the a and b forms of the receptor.
Western Blot Analysis
Protein lysates were prepared from cells in phosphate
buffered saline (PBS) containing 2% sodium dodecyl
sulfate (SDS) and a cocktail of protease inhibitors (Boehr-
inger Mannheim, Indianapolis, IN). Protein concentra-
tions were measured using the DC protein assay system
(Bio-Rad, Melville, NY). Three hundred mg of total cellular
protein were subjected to SDS-polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose membranes
(Bio-Rad). Blots were then probed with the NHE-RF anti-
body IC270 (affinity eluted 1:50. Proteins were visualized
with anti-rabbit horseradish peroxidase-conjugated sec-
ondary antibody and the ECL chemiluminescence sys-
tem (Amersham Inc, Arlington Heights, IL). Signal inten-
sity was quantified by densitometric scanning of
autoradiographs using transmittance analysis (Fluor-S,
Multiimager, Bio-Rad).
Immunohistochemistry
Immunohistochemistry for NHE-RF was performed using
IC270. Formalin-fixed, paraffin-embedded, 8-mm-thick
sections were deparaffinized, rehydrated, immersed in
0.5% H2O2/methanol for 20 minutes, and rehydrated in
graded ethanols. For antigen retrieval, sections were mi-
crowaved in 0.01 mol/L sodium citrate buffer (pH 6.0) for
15 minutes. Sections were then blocked in 10% normal
goat serum and 5% milk in 1% bovine serum albumin
(BSA) in PBS, followed by incubation with primary anti-
body overnight at 4°C. Incubation with biotinylated goat
anti-rabbit antibody (Vector Laboratories, Burlingame,
CA) for 30 minutes at room temperature was followed by
the standard avidin-biotin-complex (ABC) process (Vec-
tastain Elite ABC kit, Vector). Diaminobenzidine (DAB)
was used as a chromogen, followed by counterstaining
with hematoxylin. Positive controls included paraffin-em-
bedded human placenta sections as well as formalin
fixed, paraffin-embedded cell pellets from MCF-7 and
MCF-7-ADR cell lines, which express high levels or low
levels of NHE-RF, respectively, as shown in Western blot
analysis (see below). For negative controls, the primary
antibody was omitted and prior immunostaining with pre-
absorbed serum did not reveal any specific reactivity.12
To control for possible effects of fixation and antigen
retrieval, frozen sections of human placenta were also
immunostained.
Immunohistochemistry for estrogen receptors was per-
formed according to standard procedures. Briefly, anti-
gen retrieval was achieved by microwaving the sections
in Tris buffer (pH 10) for 10 minutes. Sections were blocked
with 10% normal horse serum and incubated with ER antibod-
ies (1:100 dilution) overnight at 4°C. Sections were incubated
with secondary antibodies at room temperature for 45 minutes
followed by the ABC reaction, visualization with DAB and
counterstaining with hematoxylin.
Results
Western Blotting and Immunohistochemistry for
NHE-RF in Cell Lines
Quantitative Western blot analysis, performed three
times, confirmed that three estrogen receptor-positive
breast cancer cell lines, MCF-7, ZR-75-B, and T-47D, had
9.50 6 2.20-fold higher levels of NHE-RF when compared
to the normal mammary lines HBL-100 and MCF-12-F
(Figure 1). Expression of NHE-RF was expressed at only
low levels in the estrogen receptor-negative breast can-
cer lines MCF-7-ADR and MDA-MB-231 and was not
detectable in the breast cancer cell line DU4475. Immuno-
cytotochemical staining of cell pellets from MCF-7 and
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MCF-7-ADR with the IC270 antibody showed strong ex-
pression only in MCF-7, the ER-positive cell line (Figure 2A).
Immunohistochemistry for NHE-RF Expression
in Normal Adult Tissues
NHE-RF is expressed in many tissues but has a highly
selective cellular and subcellular distribution. Intense
NHE-RF expression was seen in epithelial cells of many
organ systems, especially in cells that perform an ab-
sorptive function, possess microvilli, or are involved in ion
transport. Immunohistochemistry of paraffin-embedded
sections of placenta demonstrated a characteristic pat-
tern of NHE-RF expression, with prominent expression in
the syncytiotrophoblast, the outer cell layer of placental
villi, and its brush border, whereas the villous mesen-
chyme was immunonegative. Frozen sections of placenta
showed the same pattern of immunostaining. All negative
controls showed no staining.
As previously demonstrated using immunofluores-
cence,12 strong expression of NHE-RF was seen in the
renal proximal tubules with prominent staining of the lu-
minal cell membrane and the microvillous brush border
(Figure 2B). The parietal epithelium lining Bowman’s cap-
sule of the renal glomeruli also showed prominent posi-
tivity, while the mesangium and glomerular endothelium
were immunonegative and the distal tubules and collect-
ing tubules had only weak cytoplasmic staining.
A highly selective pattern of expression of NHE-RF was
also seen in the gastro-intestinal system. In the stomach,
fundic glands showed strong expression in parietal cells,
whereas chief cells, mucin-secreting cells, and surface
epithelium were immunonegative. In the small bowel, the
protein is abundant at the apical surface of absorptive
cells and in microvilli extending from the cell surface, but
is absent in intercalated goblet cells. Similarly, in the
large bowel, absorptive cells of the surface epithelium
and colonic crypts show strong membranous staining of
the luminal border, but adjacent intercalated goblet cells
were immunonegative (Figure 2C).
Stratified squamous epithelium in the esophagus, skin,
and tonsils showed only weak to moderate cytoplasmic
staining, more pronounced in the deep layers. Eccrine
glands in the skin, however, showed cytoplasmic immu-
nostaining with strong apical membranous expression,
highlighting intercalated canaliculi. In contrast, the un-
derlying myoepithelial cells were immunonegative. Other
skin adenexa, such as the pilar unit, showed weak diffuse
cytoplasmic staining. In the salivary glands, NHE-RF was
weakly expressed in the cytoplasm of serous acinar cells,
but there was prominent linear luminal membranous im-
munostaining. The mucinous acinar cells of the salivary
glands were immunonegative. Similarly, acinar cells of
the pancreas showed weak cytoplasmic staining and
luminal linear immunopositivity, while cells of the islands
of Langerhans were immunonegative. In the anterior pi-
tuitary, selected cells were moderately immunopositive.
The posterior pituitary was immunonegative, as was the
thyroid gland. In the breast, ductal and acinar epithelia
were immunopositive, with apical membranous staining
of the acinar epithelial cells (Figure 2D).
Skeletal muscle and myocardium were immunonega-
tive for NHE-RF, while smooth muscle, particularly vas-
cular smooth muscle, showed moderate immunopositivity
in most tissues. In the lung, bronchial epithelium was only
weakly positive and alveolar pneumocytes were immu-
nonegative. In the liver, hepatocytes and Kupffer cells
showed no expression of NHE-RF and only weak to mod-
erate expression was seen in ductal epithelium. Focal,
moderate positivity was seen in the white pulp of the
spleen and in scattered lymphocytes in germinal centers
of lymph nodes.
In the brain and spinal cord, neurons and resting glia
did not express NHE-RF. Strong expression of NHE-RF,
however, was observed in glial processes in areas of
chronic reactive gliosis, such as subpial region, or in
proliferating Bergmann glia in the cerebellum. Marked
NHE-RF expression was also observed at the apical
membranes of ependymal cells. Interestingly, this pattern
of expression was altered in buried ependymal cells
found just below the ventricular surface, in which NHE-RF
was seen as an area of strong cytoplasmic immunopos-
Figure 1. Western blot analysis, using affinity eluted IC270 antibody at 1:50
dilution, of mammary epithelial and breast cancer cell lines showing high
NHE-RF expression in the ER-positive cell lines T-47D, ZR-75-B, and MCF-7.
The arrow indicates NHE-RF at 50 kd.
NHE-RF Expression in Normal and Neoplastic Tissues 59
AJP January 2001, Vol. 158, No. 1
60 Stemmer-Rachamimov et al
AJP January 2001, Vol. 158, No. 1
itivity without polarized apical or membranous staining.
Arachnoid cells were immunonegative, as were Schwann
cells in peripheral nerves.
Immunohistochemistry for NHE-RF Expression
in Endometrium
Proliferative endometrium showed strong expression of
NHE-RF in the cytoplasm and luminal membrane of glan-
dular epithelium as well as in scattered stromal cells
(Figure 2F). NHE-RF was expressed in essentially all
epithelial cells in the proliferative endometrium samples.
In contrast, there was only weak expression of NHE-RF in
the glandular epithelium of secretory endometrium and
adjacent stroma (Figure 2E).
Immunohistochemistry for NHE-RF Expression
in Primary Breast Tumors
Examination of sections from 18 infiltrating breast adeno-
carcinomas showed strong correlation between positive
immunostaining for ER and high expression of the
NHE-RF protein: 10 of 11 (.90%) of the ER-positive
tumors strongly expressed NHE-RF. On the contrary, 5 of
7 ER-negative tumors did not express NHE-RF (Figure 2,
G–H, and Table 1). In those tumors that were NHE-RF
immunopositive, staining was observed in nearly all tu-
mor cells, contrasting with the adjacent immunonegative
stroma. NHE-RF positivity was present as membranous
staining, especially at the luminal aspects of cells, and as
diffuse cytoplasmic staining.
Discussion
NHE-RF is highly expressed in epithelia of many tissues,
particularly in cells with numerous microvilli, and is often
concentrated at the luminal membrane. Prominent
NHE-RF expression is seen in cells specialized in ion
transport: renal proximal tubules, eccrine glands, colonic
absorptive cells, parietal cells in gastric glands and
ependymal cells. These findings support the proposed
role of NHE-RF as a regulator of membrane protein trans-
porters, and confirm Northern blot data showing high
NHE-RF mRNA levels in human tissues containing polar-
ized epithelia such as the mammary gland, kidney, small
intestines and salivary gland.9
The association between estrogen stimulation and
NHE-RF expression in normal endometrium and in breast
carcinomas suggests that NHE-RF must be a multifunc-
tional protein, with additional roles to those of ion trans-
port. Specific and early induction of NHE-RF mRNA by
estrogen has been observed in breast carcinoma cells.9
The present observations extend the correlation between
ER status and NHE-RF expression in breast cancer to
primary human tumors, and raise the possibility that
NHE-RF may play a role in estrogen-mediated cell
growth. The proliferative effects of the estrogen are me-
diated through ER, an intracellular nuclear receptor that,
when bound to estrogen, is transformed into an active
transcription factor and regulates the expression of a
variety of genes. Antiestrogens may therefore be thera-
peutically effective in ER-positive breast cancers. ER-
negative tumors, however, are more aggressive tumors,
associated with early recurrence and poor patient sur-
vival, and do not generally respond to antiestrogen treat-
ment. However, about 40% of patients with ER-positive
cancer do not respond to endocrine manipulations, and
about 10% of ER-negative tumors respond.13,14 The fac-
tors that lead to the conversion of an ER-positive, respon-
sive breast cancer into a hormone-refractory tumor are
poorly understood, and encourage further study of mech-
anisms of ER-mediated cell growth.
Estrogens induce cytoskeletal changes in ER-positive
breast cancer cells that include an increase in the num-
ber and size of microvilli,15,16 as well as increased ex-
pression of cytokeratins associated with the nuclear matrix-
intermediate filament system.17 Interestingly, alterations of
the nuclear matrix-intermediate filament system, an exten-
sive network that connects the plasma membrane and cy-
toskeleton with the nuclear membrane and nuclear matrix,
can mediate changes in gene expression.18,19 NHE-RF, an
early response gene to estrogen stimulation, may therefore
play a role in the assembly of an estrogen transduction
complex by linking the actin cytoskeleton to an anchored
membrane protein. NHE-RF could bind a transduction com-
plex via interaction with MERM proteins at a C-terminal,
non-PDZ site, and to a membrane protein via one of the PDZ
Figure 2. NHE-RF expression in normal and neoplastic tissues immunostained with IC270 antibody. A: NHE-RF expression in breast carcinoma cell lines: low
expression in estrogen receptor (ER) negative MCF-7-ADR (left); strong expression in ER positive MCF-7 cells (right). B-F: NHE-RF expression in normal tissues.
B, strong membranous expression of NHE-RF in proximal tubular epithelium and parietal epithelial cells of Bowman’s capsule; C, NHE-RF expression in apical
surface of absorptive cells in colonic glands; goblet cells are immunonegative; D, strong expression of NHE-RF in luminal membrane of ducts and acini in the
breast; E, low NHE-RF expression in secretory endometrium; F, high expression of NHE-RF in proliferative endometrium. G-H: Expression of NHE-RF in breast
carcinomas. G, high expression of NHE-RF in ER-positive breast carcinoma; H, ER-negative breast carcinoma immunonegative for NHE-RF.
Table 1. NHE-RF and ER Expression in 18 Primary Breast
Carcinomas
Tumor sample NHE-RF IHC ER status
BC1 111 Positive
BC3 111 Positive
BC5 111 Positive
BC9 111 Positive
BC10 111 Positive
BC11 111 Positive
BC4 11 Positive
BC7 11 Positive
BC12 11 Positive
BC14 11 Positive
BC8 - Positive
BC6 11 Negative
BC15 11 Negative
BC2 - Negative
BC13 - Negative
BC16 - Negative
BC17 - Negative
BC18 - Negative
NHE-RF immunostaining intensity: 111, strong staining; 11,
moderate staining; -, no or minimal staining. When positive, nearly all
cells were positive.
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domains. NHE-RF may also be involved in cross-talk among
signal transduction pathways. Several signaling cascades,
including epidermal growth factor and tyrosine kinase/MAP-
kinase pathways, are involved in estrogen signaling;20–23
such overlapping pathways may partly explain how breast
cancer cells adapt to and bypass estrogen receptors
blocked by antiestrogen therapy. It is possible that an alter-
native pathway for estrogen signaling in ER-negative breast
carcinomas might involve NHE-RF expression, via ER-inde-
pendent up-regulation, which could explain the 30% of
ER-negative tumors expressing NHE-RF in our series.
These studies suggest that NHE-RF acts as a multi-
functional protein and has potential roles in the apical
surfaces of ion transporting epithelium as well as in es-
trogen-mediated growth control. The data encourage fur-
ther study of NHE-RF in breast carcinomas to increase
understanding of the growth control mechanisms in these
hormonally-regulated tumors, and to develop novel means
to interfere therapeutically in such growth pathways.
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